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ABSTRACT 
Tissue factor pathway inhibitor (TFPI) is a principal inhibitor of the initiation of coagulation 
through inhibition of factor (F) Xa and tissue factor (TF)/FVIIa. While TFPI on its own is a 
poor inhibitor of FXa, protein S acts as cofactor for TFPI through interaction with TFPI Kunitz 
3 domain, greatly enhancing FXa inhibition (~10-fold). The aim of my thesis was to further 
characterise the molecular basis underlying the TFPI cofactor function of protein S by 
identifying the complementary functional interaction site on protein S required for TFPI 
enhancement. I have screened over 40 protein S variants comprising substitutions spanning 
the whole protein S molecule and have identified the C-terminal sex hormone-binding 
globulin (SHBG)-like domain to be important for the enhancement of TFPI-mediated 
inhibition of thrombin generation in plasma. This was demonstrated using a protein 
S/growth arrest-specific 6 (Gas6) chimera, in which the SHBG-like domain was replaced with 
the corresponding domain in Gas6. Further examination of this chimera using FXa inhibition 
assays together with direct binding studies confirmed that the protein S SHBG-like domain is 
essential for the interaction with TFPI and the enhancement of TFPI-mediated inhibition of 
FXa. TFPI has also been reported to bind to FV in circulation. In my thesis I have aimed to 
evaluate the effects of FV interaction with TFPI upon its inhibition of FXa. While FV did not 
enhance TFPI on its own, it further enhanced the inhibition of FXa by TFPI in the presence of 
protein S (~32-fold by comparison to TFPI alone), suggesting that FV acts together with 
protein S as a synergistic cofactor for TFPI. Co-immunoprecipitation experiments revealed a 
direct interaction between TFPI and FV which was augmented by the presence of protein S. I 
propose that FV, in cooperation with protein S localise TFPI to the activated membrane 
surface in a position favourable for the efficient inhibition of FXa. Collectively, my findings 
shed light on the molecular mechanisms of TFPI enhancement by its cofactors protein S and 
FV. 
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1. INTRODUCTION
1.1 Haemostasis 
The cardiovascular system permits blood circulation to distribute vital nutrients, oxygen and 
hormones, remove toxic metabolites and to homeostatically maintain body temperature, 
blood pressure and pH. The integrity of the cardiovascular system is maintained by a highly 
regulated mechanism called haemostasis, which essentially serves to retain blood fluidity 
and whilst also protecting against extensive blood loss upon injury. Under normal 
physiological circumstances, the lack of procoagulant stimuli and the presence of 
physiological anticoagulants on endothelial surfaces, allow blood to circulate freely within 
the vasculature. Following blood vessel injury, blood loss and vessel repair are mutually 
controlled by three mechanistic processes comprising primary haemostasis (platelet plug 
formation), secondary haemostasis (coagulation) and fibrinolysis (clot clearance). 
Haemostasis is a normal physiological response and balanced haemostasis triggers 
responses rapidly to prevent excessive bleeding and blocking pathogen invasion through 
damaged tissue.1 Haemostatic processes are tightly regulated by blood vessels, platelets, 
coagulation factors as well as anticoagulant proteins which cooperate so that blood clotting 
is enabled only until the injured vasculature becomes repaired. Haemostasis represents a 
fine balance with respect to procoagulant and anticoagulant responses and abnormalities in 
this system can result in coagulation disorders leading to either haemorrhage or thrombosis. 
The most common bleeding disorders, resulting from inherited deficiencies in procoagulant 
factors, are Von Willebrand disease caused by Von Willebrand factor (VWF) deficiency, 
haemophilia A (FVIII deficiency) and haemophilia B (FIX deficiency).2,3 Conversely, inherited 
or acquired deficiencies in anticoagulant factors, such as antithrombin (AT), protein C and 
protein S deficiencies as well as FV Leiden (FV resistance to inactivation), are linked to an 
increased risk of occurrence of thrombotic events.4 Anticoagulant processes are the primary 
focus of my thesis. 
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1.1.1 Primary haemostasis 
Upon injury, an immediate reflex of vasoconstriction occurs to diminish the bleeding. 
Primary haemostasis involves the formation of a platelet plug at the site of the damage 
(Figure 1.1). Due to damage to the endothelial cell layer, the subendothelial extracellular 
matrix (ECM) and its content become exposed to the bloodstream. The exposure of the 
adhesive macromolecules, comprising collagen, laminin, fibroconectin, thrombospondin and 
vitronectin, together with disruption of the anticoagulant stimuli on the endothelial 
surfaces, trigger the process of primary haemostasis. Initially, exposed extravascular 
collagen recruits circulating platelets to the injury site (Stage 1 in Figure 1.1). While platelets 
are able to interact directly with collagen, this interaction is greatly improved by VWF.5 VWF 
is a large multimeric adhesive plasma glycoprotein secreted by endothelial cells and 
activated platelets.6-8 Upon collagen exposure to the blood stream, plasma VWF is recruited 
to these surfaces. The shear stress of the blood flow induces unravelling of the globular 
platelet-bound VWF. This way the VWF A1 domain becomes accessible and VWF multimers 
can act as an intermediary between a specific glycoprotein receptor complex (GPIb/V/IX) on 
the platelet surface and the exposed collagen fibrils.9,10 This allows more circulating 
platelets to adhere to the subendothelium and bind collagen through their GPVI receptors. 
Platelet binding to collagen induces their shape change (Stage 2 in Figure 1.1) and triggers 
intracellular signalling which potentiates the affinity of cell surface receptors subsequently 
leading to further adherence, activation and aggregation of platelets.9,11-13 In detail, 
following activation, platelets undergo degranulation and chemical messengers such as 
adenosine diphosphate (ADP) and thromboxane A2 (TXA2) are released (Stage 3 in Figure 
1.1).14 These platelet aggregating agonists further promote activation of platelets. Platelet 
activation can also be induced by thrombin. This occurs through GPIb and protease 
activated receptors (PARs).15 Activated platelets release additional VWF molecules 
producing a positive feedback and further platelet recruitment (Stage 4 in Figure 1.1). 
Platelet activation also promotes activation of their surface integrins. Active platelet 
integrins bind collagen, fibrinogen and fibrin, inducing substantial platelet aggregation.14 All 
above processes occur in a coordinated manner, ultimately leading to the formation of a 
primary platelet plug.  
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Importantly, during activation, the platelet membrane composition is altered causing 
presentation of negatively charged phospholipids, such as phosphatidylserine, that are 
normally confined within the inner phospholipid layer of the unactivated cell. The presence 
of the negatively charged surfaces facilitates the activation and assembly of coagulation 
cascade components.16 
Figure 1.1 Overview of platelet activation in primary haemostasis. 
Upon the injury of endothelium, collagen becomes exposed to the blood flow. Circulating platelets bind 
collagen through VWF/Gplb receptors complexes (1). Collagen-bound platelets undergo shape change (2), 
become activated and aggregation agonists, ADP and TXA2, are released (3) leading to further platelet 
recruitment and aggregation (4). As a result, haemostatic platelet plug is formed. 
1.1.2 Secondary haemostasis 
Secondary haemostasis, also referred as coagulation, involves proteolytic activation of 
numerous zymogens to serine proteases, as well as activation of coagulation cofactors. 
These processes occur in a highly coordinated manner, promoting thrombin generation 
eventually leading to fibrin formation, as visualised in Figure 1.2. Subsequently, fibrin 
strengthens the loose primary platelet plug (formed as a response to primary haemostasis) 
to form a stabilised haemostatic plug. 
The coagulation cascade comprises a series of sequential enzymatic conversions which can 
be initiated through two distinct ways comprising contact activation pathway (intrinsic) and 
the TF pathway (extrinsic). While the physiological relevance of the contact activation is still 
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debated, the currently accepted model of in vivo coagulation recognises TF as the major 
physiological initiator of blood clotting. Briefly, following the injury, coagulation is initiated 
by TF (Stage 1 in Figure 1.2), leading to production of trace amounts of thrombin. This 
induces positive feedback activation of further coagulation proteins (Stage 2 in Figure 1.2), 
resulting in the generation of large amounts of thrombin (Stage 3 in Figure 1.2), and 
formation of a stable fibrin clot (Stage 4 in Figure 1.2).17,18 
 
Figure 1.2 Overview of coagulation. 
Upon the injury, TF becomes exposed to the blood stream (1) and initiate coagulation cascade (2) comprising 
activation of multiple components on negatively-charged surfaces, leading to thrombin (FIIa) formation (3). 
Once sufficient amounts of thrombin are produced, stable fibrin clot forms (4), preventing blood loss and 
pathogen invasion. 
 
1.1.2.1 Initiation of coagulation 
The process of coagulation is initiated (Figure 1.3) after injury to the vasculature which 
breaks the endothelial barrier. This allows coagulation proteins circulating in blood to gain 
access to TF which acts as the major initiator of the coagulation cascade.17 TF is a 
transmembrane protein usually expressed on the surface of cells in extravascular sites, not 
normally exposed to the blood stream. Under the physiological conditions, coagulation 
factors circulate in their inactive zymogen forms, with a small proportion (1%) of FVII 
circulating in its active form, FVIIa.19 Due to vessel damage TF becomes exposed to the 
blood where it gains access to and binds circulating FVIIa. The TF/FVIIa complex catalyses 
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the proteolytic activation of FX zymogen to its protease form, FXa, which converts 
prothrombin to thrombin.19,20  
The other pathway that leads to thrombin formation is the contact activation pathway, 
named after the process of FXII auto-activation triggered by the contact with a surface 
interface. The contact activation system is regulated by three plasma proteins comprising 
FXII, prekallikrein (PK) and high molecular weight kininogen (HMWK).21 The pathway is 
initiated as FXII binds to a surface and undergoes spontaneous cleavage leading to its full 
activation. Polyphosphate anions released by activated platelets, lipopolysaccharides found 
on the surface of bacteria, and exposed collagen, have all been proposed as endogenous 
activators of FXII. The activated FXII subsequently converts FXI to FXIa and PK to kallikrein. 
HMWK acts as a cofactor for the activation of kallikrein and FXII, as well as facilitates the 
activation of FXI by FXIIa. FXIIa-activated kallikrein promotes HMWK conversion into 
bradykinin which in turn results in local vasodilatation.22 In the downstream of intrinsic 
pathway activation FIX becomes activated (also by TF/FVIIa), which has an important 
function in further phase of coagulation. The role of the contact activation pathway in 
initiating coagulation has been questioned due to lack of bleeding in patients with severe 
deficiencies of FXII, HMWK or PK. Then again, deficiencies in intrinsic factors VIII, IX and XI 
have been linked to bleeding disorders, while people with high levels of FVIII are at 
increased risk for deep vein thrombosis and pulmonary embolism.23 Additionally, 
importance of the contact activation system has been demonstrated for the process of 
inflammation.24,25  
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Figure 1.3 Initiation of the coagulation cascade. 
Circulating FVIIa binds to TF exposed to the bloodstream on the site of the injury. The TF/FVIIa complex 
activates FIX and FX. Subsequently, FXa generates trace amounts of thrombin (FIIa). During the contact 
activation, FXII is activated to FXIIa. Following this, FXI becomes activated (also through thrombin) leading to 
further formation of FIXa. 
1.1.2.2 Propagation of coagulation 
Thrombin acts a central serine protease in the coagulation cascade involved in the 
deposition of fibrin. As a coagulation enzyme, thrombin converts fibrinogen into fibrin. This 
is achieved through proteolytic removal of two pairs of precursor fibrinogen molecules, 
fibrinopeptide A (FpA) and fibrinopeptide B (FpB), resulting in formation of a fibrin 
monomer. Once polymerised, fibrin monomers are covalently cross-linked by thrombin-
activated FXIII. These γ-glutamyl-Є-lysyl amide cross links generated between fibrin 
molecules lead to a fibrin meshwork formation, which ultimately stabilises platelet 
aggregates at the site of vascular injury.18 Apart from activating FXIII and platelets, thrombin 
also mediates activation of anticoagulant protein C.26 
As previously mentioned, during the initiation process of coagulation, the TF/FVIIa complex 
catalyses the activation of FIX and FX, from which thrombin is generated. However, FXa on 
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its own converts only small amounts of thrombin. In the propagation step, the small 
quantities of thrombin formed during the initial stage of coagulation enable feedback 
mechanism involving activation of FV and FVIII (Figure 1.4). These activated components act 
as cofactors for FXa and FIXa, respectively. Activation of FX mediated by FIXa and FVIIIa links 
the intrinsic and extrinsic pathways into one, described as the common pathway. Formation 
of intrinsic tenase (FIXa/FVIIIa complex) and the prothrombinase complex (FXa/FVa) on 
phospholipid surfaces, results in augmented conversion of prothrombin leading to increased 
thrombin generation at the site of injury.18 This bypasses the requirement for TF/FVIIa 
activity. The prothrombinase complex has been reported to convert prothrombin into 
thrombin much more efficiently that FXa alone.1,27 For this reason, the extrinsic pathway has 
been proposed to be essential for the initiation of the coagulation cascade, whereas the 
intrinsic pathway is important for the growth and maintenance of the formed clot.14 FXIIIa-
cross-linked insoluble fibrin clot can now effectively prevent blood loos and entry of 
pathogens, as well as allows repair of the damaged endothelium.28 
Figure 1.4 Feedback activation. 
Traces of thrombin (FIIa) generated during the initiation step of coagulation produce a feedback mechanism 
leading to activation of FV and FVIII. FVa and FVIIIa serve as cofactors for FXa and FIXa, respectively. As a 
result, substantial amounts of thrombin are generated, ultimately converting fibrinogen into fibrin. 
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1.1.3 Regulation of coagulation by anticoagulant pathways 
Excessive thrombin formation and fibrin deposition can compromise vascular integrity and 
lead to thrombotic events. Therefore, the process of coagulation is strictly managed by 
three distinct anticoagulant pathways comprising TFPI, the protein C pathway and AT, each 
targeting different components of the coagulation cascade (Figure 1.5).29 These are able to 
regulate as well as localise the formation and activity of thrombin, controlling haemostasis 
both temporally and spatially.1,29  
As previously described, the process of coagulation is triggered by TF exposure and binding 
to FVIIa. TFPI inhibits the extrinsic coagulation pathway by blocking TF/FVIIa and FXa on the 
subendothelial cells and on the growing platelet plug.27,30 The anticoagulant activity of TFPI 
upon FXa is enhanced by protein S,31 which is the main subject of this thesis. Since TFPI 
targets the initiation phase of coagulation, it only controls generation of the trace amounts 
of thrombin (mediated by the activity of TF/FVIIa and initial FXa). Once more thrombin is 
formed in the propagation stage, TFPI is not able to efficiently influence coagulation.27,32 
Following the positive feedback activation, thrombin generation becomes TF-independent. 
From this moment, the protein C pathway serves as the main mechanism regulating 
generation of thrombin. Thrombin generated during the initial stage of coagulation escapes 
from the site of damage and binds to the TM expressed on adjacent intact endothelial cells. 
The thrombin/TM complex activates protein C, which in turn downregulates thrombin 
generation through inactivation of FVa and FVIIIa, eventually inhibiting expansion of fibrin 
deposition. This anticoagulant activity of APC is also potentiated by its cofactor, protein S.33 
AT, a serine protease inhibitor, circulates in plasma and can inhibit multiple free 
procoagulation serine proteases in the coagulation cascade. These include thrombin, FVIIa, 
FIXa, FXa, FXIa and FXIIa. The inhibition occurs via formation of a stable 1:1 stoichiometric 
complex, blocking the access of substrates to their active site.34,35 However, when targeted 
proteases are within a complex such as tenase or prothrombinase, AT is less effective in 
inactivating them.36 The inhibitory activities of AT are greatly enhanced by its interaction 
with heparin and heparin-like molecules (heparan sulphates) present on the surface of 
endothelial cells surrounding the damaged tissue. This direct binding induces a 
conformational change within the AT, potentiating the interaction and thereby the rate of 
25 
inactivation of the targeted proteases.36-38 Overall, the AT system limits coagulation by 
inhibiting free proteases that escaped the immediate proximity to the plug formed, 
preventing uncontrolled expansion of the clot and assuring targeted haemostatic 
response.36 
To preserve normal haemostasis, equilibrium between levels of procoagulant and 
anticoagulant components and their activities, needs to be maintained. Any disruption of 
this balance can lead to increased risk of bleeding or thrombosis. 
Figure 1.5 Regulation of coagulation by the anticoagulant pathways. 
The coagulation cascade is strictly regulated by the three established anticoagulant pathways comprising APC, 
AT and TFPI. APC in the presence of its cofactor protein S inactivates FVa and FVIIIa. AT inhibits multiple serine 
proteases, but to simplify, only inhibition of thrombin (FIIa) has been demonstrated in this chart. TFPI with its 
cofactor protein S inhibit TF/FVIIa and FXa. 
1.1.4 Fibrinolysis 
Fibrinolysis involves a proteolytic system that serves to degrade the fibrin clot once the 
vessel damage has been repaired. This process has been separated into primary and 
secondary fibrinolysis. The primary type encompasses usual physiological response 
following the coagulation (Figure 1.6), while the secondary mechanism comprises dissolving 
of clot either due to medical disorder or through therapeutic intervention.17,18 The following 
paragraphs focus on the primary fibrinolysis. 
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Plasmin is the key proteolytic enzyme involved in breaking down the fibrin mesh into 
soluble fibrin degradation products. Plasmin is produced in the liver in an inactive 
form, plasminogen. Although plasminogen is unable to cleave fibrin, it is incorporated into 
the fibrin clot once it is formed.39 The formation of plasmin from plasminogen is 
accomplished through proteolytic cleavage mediated by tissue-type plasminogen activator 
(t-PA) and urokinase-type plasminogen activator (u-PA) released by the damaged 
endothelial cells. Fibrin itself acts as a cofactor for t-PA and brings plasminogen to the site, 
accelerating activation of plasminogen by approximately 1000-fold. The activities of t-PA 
and u-PA are controlled by plasminogen activator inhibitors (PAI1 and PAI2), while fibrin 
degradation is counterbalanced by Thrombin Activatable Fibrinolysis Inhibitor (TAFI), which 
when activated diminishes plasminogen binding to fibrin by cleaving the C-terminal Lysine 
residues of fibrin.40-42 Additionally, α 2-antiplasmin and α 2-macroglobulin form a complex 
with and inactivate plasmin in order to increase fibrin resistance to the degradation to 
ensure sufficient clot formation.43,44 
Several hereditary and acquired disorders of the fibrinolytic system have been documented. 
Increased activities of PAI and α 2-antiplasmin have been implicated in the metabolic 
syndrome, whereas excessive activation of TF leading to hyperfibrinolysis is often reported 
in trauma patients. In addition to the key role in the final coagulation stage, the fibrinolytic 
system has an impact on inflammatory processes. While the fibrin degradation products 
increase vascular permeability, plasmin cleaves the complement system component C3 
leading to its activation.43,44 
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Figure 1.6 Process of primary fibrinolysis. 
Once the damage has been repaired, plasminogen activators, u-PA and t-PA, are released from the endothelial 
cells (1) and activate plasminogen. Following the formation of plasmin (2), fibrin becomes degraded (3) and 
clot is eventually removed. 
1.1.5 The role of membrane surfaces 
The majority of interactions in the blood clotting cascade and its regulation by anticoagulant 
processes require proteins to bind to suitable membrane surfaces, usually comprising 
activated platelets or endothelial cells. In general, membrane-bound clotting reactions are 
in the order of thousands of times more efficient than the same reactions occurring within 
solution. Cell membranes are composed of a double layer of phospholipids, in which 
hydrophilic heads face extracellular matrix or intracellular cytoplasmic surface. The major 
component of membrane is a phospholipid bilayer mostly comprising phosphatidylcholine, 
sphingomyelin, phosphatidylethanolamine and phosphatidylserine, variably distributed 
between the outer and inner surfaces of the cell.45 In detail, within the resting cell, the outer 
surface contains large amounts of phosphatidylcholine and sphingomyelin with trace 
amounts of phosphatidylserine, while the inner leaflet is enriched with phosphatidylserine, 
phosphatidylethanolamine and also phosphatidic acid. Membrane phospholipid asymmetry 
is considered to define functional properties of the membrane.46 In a response to triggers 
that activate the cell, such as in platelet activation, Ca2+ influx induces exposure of 
negatively charged phosphatidylserine to the outer side of the cell membrane. This change 
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in phospholipid layer symmetry due to exposure of phosphatidylserine is believed to 
encompass an optimum surface for blood clotting as well as anticoagulant reactions. 
In a typical step in the blood coagulation cascade, a soluble plasma serine protease 
assembles with its protein cofactor in order to activate it substrates. These processes are 
highly dependent on the presence of negatively-charged membranes containing available 
phosphatidylserine moieties.45 The most common phosphatidylserine-binding motifs in the 
blood clotting system are γ-carboxylated glutamic acid (Gla) domains, capable of 
coordinating divalent metal ions such as Ca2+ or Mg2+. These ions are able to form a complex 
with the phosphate groups of phosphatidylserine. Additionally, the Gla domain N-terminal 
hydrophobic chains have been suggested to penetrate inside the membrane, strengthening 
the Gla domain binding to the cell surface.45 Assembly with the phospholipid layer can be 
provided by the Gla domain of prothrombin, FVII, FIX, and FX as well as the C domains of FV 
and FVIII. Formation of such tight complexes with the cell membrane results in accelerated 
formation of the proteases FXa and thrombin, ultimately leading to increased thrombus 
growth.47-50 On the other hand, the ability of protein S to enhance APC and TFPI 
anticoagulant activities is also dependent on the phospholipid binding properties of the 
protein S Gla domain.50,51 
Phosphatidylserine in the outer side of plasma membrane is the primary regulator of the TF 
procoagulant activity on cell surfaces. However, phosphatidylserine requirement for the 
activation of FX by the TF/FVIIa complex is greatly decreased in the presence of 
phosphatidylethanolamine. It appears that the phospho-L-serine specific interactions 
provided by phosphatidylethanolamine synergise strongly with the small amounts of 
phosphatidylserine present on the membrane to promote efficient FX activation.46,52 The 
existence of two populations of TF on cell surfaces has been proposed. These include a 
minor population of 'active' TF that rapidly binds to FVIIa and a major 'cryptic' TF population 
that despite binding to FVIIa, fails to activate FXa.46 The mechanism underlying the 
phenomena of TF decryption has not been fully elucidated but cellular perturbations 
resulting in the exposed phosphatidylserine together with damage-induced translation of 
platelet TF messenger ribonucleic acid (mRNA) have been proposed. It may also involve de-
dimerisation of inactive TF, which exposes its FVII/FVIIa binding site. Recent studies have 
suggested that protein disulphide isomerase (PDI)-dependent thiol regulation of TF’s 
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allosteric Cys186–Cys209 disulphide bond may also be important in regulating TF 
procoagulant activity on cell surfaces.53 Once formed in response to stimuli, such as tissue 
damage or calcium influx, the disulphide bond maintains the conformation. Additionally, 
recruitment of encrypted TF microvesicles to the activated platelet surfaces may occur.  
Microvesicles are formed by platelets, endothelial cells, monocytes, granulocytes and 
erythrocytes, induced by cell activation, stress or apoptosis. Since microvesicles are 
enriched with exposed phosphatidylserine, they are fully capable of coordinating the 
assembly of coagulation components. Interestingly, the surface of the platelet-derived 
microvesicles can be up to ~100-times more procoagulant when compared to the platelet 
surface. In addition to TF, microvesicles expose P-selectin glycoprotein ligand-1 (PSGL-1), 
mediating interactions with P-selectin found on the surface of activated platelets. As a 
result, more platelets becomes recruited and bound. Once the damaged tissue and 
subendothelial cells start to be covered by the platelet plug, TF is decrypted, adheres to the 
surface of activated platelets and can function in the spread of a thrombus. In this way, 
microvesicle-associated TF enhances the propagation of both primary and secondary 
haemostasis, leading to rapid accumulation the haemostatic plug.54,55 
An increased content of microvesicles, even in normal blood conditions, has been 
demonstrated to enhance platelet deposition and thrombus formation. Circulating 
microvesicles have been associated with numerous vascular diseases. Elevated numbers of 
platelet microvesicles are often found in patients with coronary disease, and raised levels of 
blood microvesicles have been linked to functional effects in cardiovascular 
atherothrombotic disease.56-58 Nevertheless, no evident role of microvesicles in maintaining 
normal haemostasis has been presented to date. 
1.2 TFPI 
1.2.1 TFPI gene 
The human TFPI gene is located on the long arm of chromosome 2, q32. It consists of 9 
exons and 8 introns that span approximately 70 kilobase (kb). TFPI is produced in several, 
alternatively-spliced forms. To date, TFPIα, TFPIβ and TFPIδ, with different domain 
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organisation, have been identified in humans. TFPIα comprises the most abundant 
transcript and it is the most well-characterised form of TFPI with respect to its anticoagulant 
functions. TFPIα is translated into an unprocessed precursor of 304 amino acids with a 
predicted molecular weight of 35 kilodaltons (kDa). Following the post-translational 
modifications, the full-length TFPI protein derived from TFPIα transcript is composed of 273 
amino acids, and the molecular weight of the protein is 41kDa.27,59  
1.2.2 TFPI structure 
TFPIα, comprises an acidic (negatively-charged) N-terminal sequence, 3 tandem Kunitz-type 
domains separated by two linker regions and a basic (positively-charged) C-terminal tail60, 
visualised in Figure 1.7. TFPIα contains N-linked glycosylations at Asn117 (Kunitz 2 domain) 
and at Asn167 (linking region between Kunitz domains 2 and 3), and O-linked glycosylations 
at Ser174 and Thr175 (both within the linking region between Kunitz domains 2 and 3).27 
Additionally, a possible N-linked glycosylation site has been predicted for Asn228 (Kunitz 3 
domain).61 TFPI truncated forms, lacking C-terminal tail and often also part of the Kunitz 3 
domain, are commonly present in plasma.62 Although these TFPI forms are derived from the 
TFPIα transcript, their physiological origin has not been fully established. In vitro-based 
findings showed TFPIα cleavage by various proteases. Proteolysis by thrombin, plasmin, 
neutrophil elastase and some matrix metalloproteinases upon TFPI have been suggested.63-
67 The mRNA for the δ form of TFPI containing an alternatively spliced C-terminus has been 
detected in human lungs, but its physiological importance remains to be elucidated.62,68 The 
β isoform of TFPI comprises the N-terminal sequence and the first two Kunitz domains but 
lacks Kunitz 3 domain and contains an alternative C-terminus that has a 
glycosylphosphatidylinositol (GPI)-anchor attachment.69 TFPIβ was originally identified in 
mice,70,71 and importantly, it is also abundantly expressed on the surface of human 
endothelial cells.72 Despite the lack of Kunitz 3 domain and C-terminus, TFPIβ has been 
shown to exert very effective anticoagulant function of FXa and TF/FVIIa inhibition.73 
Moreover, in 2013, Maroney and co-workers suggested that surface-associated TFPIβ is a 
more potent inhibitor of TF procoagulant activity than full-length TFPI alone.74 Nevertheless, 
the most recent reports demonstrate that since TFPIβ lacks Kunitz 3 domain  and differs in 
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the C-terminal tail structure, this diminishes the enhancement by protein S,75-77 see further 
discussion in section 1.3.3.2. My project is focused on the anticoagulant properties of TFPIα, 
hence term 'TFPI' throughout the thesis refers to the TFPIα form, unless stated otherwise. 
Figure 1.7 Domain organisation of TFPIα and TFPIβ. 
TFPIα is a full-length protein and comprises an N-terminal tail, followed by three Kunitz domains and a C-
terminal tail. An alternatively-spliced TFPIβ contains an N-terminus, followed by two Kunitz domains and the 
GPI linkage. The model of the TFPI Kunitz 1-3 domains was adapted from Agrawal et al.
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1.2.3 TFPI expression 
TFPI is constitutively expressed and secreted mainly by the microvascular endothelium, with 
the highest TFPI mRNA levels detected in placenta and lungs, and the lowest in brain. 
Additionally, vascular smooth muscle cells, mesangial cells, megakaryocytes/platelets, 
monocytes/macrophages, fibroblasts, microglia, mesothelial cells as well as cardiomyocytes 
have been found to express TFPI. It has also been detected in T cells within atherosclerotic 
lesions.59,64,69,79-81 In plasma, TFPI circulates at concentration of 1.6nM,82 whereas the 
majority of TFPI is associated with the endothelial cell surface (Figure 1.8). Approximately 
25% of this TFPI pool has been suggested to comprise the α isoform which binds directly to 
cell surface glycosaminoglycans (GAG). This interaction is mediated by the TFPI C-terminal 
tail.83 The remaining endothelial TFPI is indirectly bound to GPI in the caveole. Of this, the 
vast majority comprises TFPIβ and only a small fraction is believed to be the α form.72 Since 
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TFPIα lacks any GPI anchor sequences, it has also been hypothesised that GPI binding 
protein serves as a link between TFPI and the cell surface.69,84-86 Treatment with 
phosphatidylinositol-specific phospholipase C (PIPLC) was shown to release most of the 
endothelial TFPI.69,72,87 The endothelial reservoirs of TFPI are also released upon the addition 
of heparin, at least doubling amount of circulating full-length TFPI.88-92 The majority of 
plasma TFPI (~80%) is bound to lipoproteins.93-95 This interaction occurs through the TFPI C-
terminal end of the truncated TFPI lacking Kunitz 3 domain and the C-terminus, and 
therefore its anticoagulant functions are compromised. Approximately 10% of the remaining 
plasma TFPI comprises a full-length free protein, whereas 5% circulates in a truncated form 
and 5% is full-length but stored within platelets (not within α-granules).94,96 Platelet TFPI can 
be released upon the platelet activation following dual stimulation with collagen and 
thrombin.97-99 Since platelets accumulate at the site of injury, TFPI released from platelets, 
together with the free full-length pool of TFPI in plasma, play an important role in regulating 
TF activity within a growing clot, thereby counterbalancing the procoagulant responses to 
prevent formation of an occlusive clot. Recently, Maroney et al. demonstrated diminished 
bleeding in mice expressing combined platelet TFPI and FVIII deficiency, suggesting that the 
platelet TFPI pool, but not endothelial TFPI, is the main regulator of haemostasis and/or 
thrombosis.100 
Figure 1.8 Distribution of TFPI. 
Schematic representation of the distribution of TFPI in plasma and on the endothelial cell surface. 
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Distinct mechanisms of TFPI clearance has been established for different forms of TFPI. 
Plasma TFPI binds low-density lipoprotein receptor-related protein (LRP) and its internalised 
via clathrin-coated vesicles for its degradation.101 TFPI complexed with FXa, on the other 
hand, is internalised by endothelial cells and then degraded.102 Studies comprising cultured 
endothelial cells revealed that following injury repair, inactive TFPI/FXa/TF/FVIIa complex is 
sequestered into caveole and further endocytosed for removal.85 
1.2.4 TFPI function 
TFPI directly binds to and inhibits FXa. This interaction produces a FXa-dependent negative 
feedback inhibition of TF/FVIIa. A quaternary TFPI/FXa/TF/FVIIa complex is formed which 
has no catalytic activity towards FX, effectively limiting its activation.30,103,104 This TFPI 
anticoagulant effect occurs only during the initiation step of coagulation. Following the 
generation of initial amounts of thrombin, feedback activation of FVIIIa and FVa escape the 
requirement for TF/FVIIa to produce FXa, and consequently, coagulation becomes 
principally controlled by the APC pathway.27,105 Recent studies have revealed an additional 
function of TFPI comprising inhibition of the prothrombinase complex through binding and 
inhibiting FXa-activated FV (FVa*) occurring during the initial procoagulant response.106 
1.2.4.1 Inhibition of FXa 
FX is one of the key proteins within the coagulation cascade. It comprises of a phospholipid-
binding Gla domain, two EGF-like domains which are involved in protein-protein 
interactions, and a serine protease domain (SP) containing the active site essential for the 
enzymatic activity of FXa. As previously mentioned, FX circulates in plasma as an inactive 
zymogen, at concentration of ~136nM. Once coagulation is initiated by TF exposure, FX 
undergoes proteolytic cleavage by the TF/FVIIa complex or FVIIIa/FIXa, leading to its full 
activation.107 The inhibitory activity of TFPI upon TF-initiated coagulation is conferred by the 
Kunitz domains which mimic the substrates of the targeted coagulation cascade protease. 
TFPI mediates slow, tight binding and thereby competitive inhibition of FXa via formation of 
a 1:1 stoichiometric complex. As a result, the active site within the FXa SP domain becomes 
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occupied, leading to decreased activity of FXa, and subsequently reducing formation of 
thrombin. The initial TFPI interaction with FXa is reversible and mediated through a P1 
residue, Arg107, in the Kunitz 2 domain of TFPI.30 The kinetic mechanism of FXa inhibition by 
TFPI is described as a two-step reaction (Eq.1): an association phase and formation of a 
loose FXa/TFPI complex (a rate-limiting step), followed by a slow isomerisation resulting in a 
tight binding of the enzyme to the inhibitor (FXa/TFPI*).108 The first step is described by the 
inhibition constant, Ki, where Ki=[FXa]*[TFPI]/[FXa/TFPI]. Tight binding characterises 
inhibition taking place at similar concentrations of the inhibitor and the enzyme. The overall 
reaction is expressed by the final inhibition constant, Ki*, where 
Ki*=[FXa]*[TFPI]/([FXa/TFPI]+[FXa/TFPI*]). 
The acceleration effect of the phospholipid membranes upon the TFPI-mediated inhibition 
of FXa has been reported.108,109 The interaction of FXa with membranes occurs through its 
Gla domain, whereas TFPI has been suggested to bind cell surfaces through the positively-
charged C-terminus. Hence, it is very likely that phospholipids co-localise FXa and TFPI on its 
surface, facilitating FXa interaction with and inhibition by TFPI.110-112 On the other hand, 
when FXa is in complex with FVa, the TFPI-mediated inhibition becomes ineffective. It has 
been suggested that under these conditions, prothrombin competes for the active site of 
FXa, leading to reduced TFPI ability to bind and therefore inhibit FXa.109,113
Several studies have demonstrated reduced FXa inhibition of truncated forms of TFPI, either 
lacking its C-terminus or C-terminus together with the Kunitz 3 domain, when compared to 
the anticoagulant activity of the full-length TFPI.114-116 This decreased ability to inhibit FXa 
was initially explained by a possible loss of or severe reduction in interactions with 
phospholipid surfaces.110-112 Furthermore, lack of the C-terminal tail is expected to result in 
TFPI inability to bind to the Gla domain of FXa, also leading to reduced inhibition.115,116 
Originally, it was reported that, in the presence of phospholipids, the rate of association 
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phase of FXa with full-length TFPI is ~10-fold faster comparing to the activity of the C-
terminus truncated TFPI.114,115 Subsequently, it was shown that this enhancement is also 
highly dependent on calcium.112 On the other hand, recent experiments performed by 
Peraramelli et al. demonstrated that interactions between the TFPI C-terminus and the FXa 
Gla domain promote efficient inhibition of FXa in the absence of calcium ions. They also 
confirmed the importance of the Kunitz 3 domain and the C-terminal tail for effective FXa 
inhibition through enhancing the formation of the encounter complex, whereas Kunitz 
domain 1 contributes to the isomerisation step.76 Exactly how these domains fulfil this 
mechanistically, is unclear. 
1.2.4.2 Inhibition of TF/FVIIa 
TFPI inhibits TF/FVIIa in a FXa-dependent way by reversibly binding and inhibiting the active 
site of FVIIa through its P1 residue, Lys36 within the Kunitz 1 domain.30,103,104 The 
importance of the Kunitz 3 domain together with the C-terminus of TFPI for more efficient 
inhibition of TF/FVIIa, was initially demonstrated.114,115 However, more recent results 
revealed equivalent inhibition of FXa generation by full-length TFPI and its forms lacking 
Kunitz domain 3 and the C-terminal tail, but only in the presence of saturated amounts of 
phospholipids.77 The Gla and EGF1 domains of FXa mediate interactions with the TF/FVIIa 
complex, which may be potentially significant for effective inhibitory activity of TFPI. Unlike 
the binding and inhibition of FXa, this step is Ca2+-dependent due to the phospholipid-
binding function of the Gla domain of FXa.95,112,117-119 
Two distinct models of the mechanism of TFPI inhibitory activity upon the TF/FVIIa complex 
have been proposed, illustrated in Figure 1.9. According to the first model (A), TFPI slowly 
binds and inhibits free or membrane-bound FXa, producing a negative feedback inactivation 
of FVIIa/TF by directly binding to FVIIa in a FXa-dependent manner. This results in the 
formation of a TFPI/FXa/TF/FVIIa complex, lacking catalytic activity towards FX or FIX, and 
markedly reduced thrombin generation. Recent results indicate that the binary TFPI/FXa 
complex formation is the limiting step in inhibition of TF/FVIIa.77 In the second proposed 
model (B), TFPI binds and inhibits FXa that is already bound to TF/FVIIa. As a result, the 
formation of the catalytically inactive quaternary complex takes place. The two-stage 
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process is illustrated more frequently in the literature, even though kinetic studies favour a 
mechanism where TFPI directly binds and inhibits the tertiary complex. In both scenarios, 
TFPI diminishes thrombin formation through direct FXa inhibition as well as reduction of 
TF/FVIIa-mediated activation of FX.104 Because of the relatively slow inhibitory function, TFPI 
is only effective when the coagulation is induced by low concentrations of TF, ranging up to 
1pM. At high TF concentrations (~14pM), FXa is generated at much faster rate therefore 
greatly increasing the rate of thrombin formation. Under these conditions, TFPI is simply to 
slow to effectively inhibit the TF/FVIIa/FXa complex.31 
Figure 1.9 FXa-dependent inhibition of TF/FVIIa by TFPI. 
Two distinct ways of TF/FVIIa inhibition have been proposed. It is frequently described as a two-stage process 
in which TFPI first binds and inhibits FXa, following by the binding and inhibition of the TF/FVIIa (A). 
Alternatively, a process favoured kinetically, where TFPI directly binds FXa/TF/FVIIa complex, may occur (B). In 
any case, ultimately inactive quaternary complex comprising TFPI/FXa/TF/FVIIa is formed. 
1.2.4.3 Inhibition of prothrombinase 
The C-terminal tail of TFPI contains a nearly identical amino acid sequence to that of a 
portion of the FV B domain which is required for maintaining its inactive conformation.120,121 
It appears that the TFPI basic C-terminal tail directly interacts with an acidic region of the FV 
following its partial activation by FXa. As mentioned previously, TFPI is not effective in 
inhibiting prothrombinase complex during the propagation of coagulation. This is because 
under these circumstances, B domain has been entirely removed from FV by proteolytic 
cleavage by thrombin therefore eliminating the interaction site conferred by the acidic 
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region. New findings by Wood and co-workers suggest that TFPI is able to inhibit 
prothrombinase complex, but only at the early stages of its assembly during the initial 
propagation response when FVa* still retains the acidic part of its B domain. Interestingly, 
this function of TFPI is not mediated by TFPIβ, suggesting an isoform-specific activity of TFPI 
that is achieved through unique mechanisms. It appears that while TFPIβ reduces TF 
function on the surface of vascular cells, TFPIα decreases amounts of initial prothrombinase 
formed on the activated platelets surfaces.106 
More details regarding activation of FV and inactivation of thrombin-activated FV (FVa), and 
the functions of particular FV forms will be discussed in section 1.4. 
Figure 1.10 Prothrombinase inhibition by TFPI. 
TFPI binds to and inhibits FVa* assembled in complex with FXa during the propagation phase of coagulation. As 
a result, the prothrombinase activity is decreased, leading to reduction in thrombin formation. 
1.2.5 The role of TFPI in disease 
TFPI is the primary inhibitor of the extrinsic pathway of coagulation, thereby playing an 
essential role in controlling the effects of TF.62 The actions of TFPI have been shown to be 
relevant in the pathology of atherosclerosis. In the murine apolipoprotein E (apoE)-deficient 
model of atherosclerosis, heterozygous deficiency in TFPI results in moderately reduced 
occlusion time in atherosclerotic carotid arteries.122 On the other hand, overexpression of 
platelet TFPI in the apoE knockout mice lowers atherosclerotic plaque development.123 
Alternatively, overexpression of mouse hematopoietic TFPI alone leads to reduction of 
smooth muscle cell proliferation and pulmonary vascular remodelling induced by chronic 
hypoxia.124 TFPI was suggested to regulate angiogenesis in mice by attenuating the 
migratory capacity of endothelial cells via its C-terminal.125 Surprisingly, the majority of 
38 
clinical research reveals increased instead of decreased TFPI antigen and activity levels in 
atherothrombotic disease. For example, levels of heparin-induced-releasable TFPI were 
found to be raised in first time ever lacunar stroke patient.126 This reinforced the idea that 
compensatory mechanisms for the increased procoagulant state are taking place.127 
Results of numerous studies, mainly comprising animal models, suggest that TFPI deficiency 
may contribute to the pathogenesis of thrombotic disorders. Work conducted on various 
rabbit models demonstrated that administration of recombinant TFPI increases the TF 
activity threshold and exerts protective functions against venous thrombosis. On the other 
hand, reduction of TFPI amounts by immunodepletion, results in an increased threshold for 
TF activity, was also shown.128-131 The physiological requirement of TFPI is clearly 
demonstrated by the lethal phenotype exhibited by homozygous TFPI gene deletion in mice, 
resulting in severe coagulopathy as early as during the embryonic stage of development.132 
Lethality of the TFPI Kunitz 1 domain knockout mice phenotype can be rescued by 
concomitant FVII or TF deficiency, most likely due to the counterbalancing effects.133,134 
Heterozygous Kunitz domain 1-deficient mice do not present an obvious phenotype but 
have lethal thrombotic predispositions when combined with FV Leiden or thrombomodulin 
deficiency.98,135 Finally, studies performed in animal models of haemophilia comprising FVIII-
deficient rabbits, dogs, and monkeys have revealed decreased injury-induced blood loss 
resulted from the TFPI inhibition.136 
Since genetic TFPI deficiencies are exceptionally rare, it is difficult to study its association 
with thrombosis in humans. Furthermore, the low levels of free full-length TFPI (~0.16nM)82 
and the inability to assay cellular TFPI levels in patients presents obstacles to fully define the 
role of TFPI. Regardless these difficulties, very low total plasma TFPI levels were found to be 
a weak risk factor for deep vein thrombosis.27,82 Additionally, decreased levels of both 
plasma and monocyte cell surface TFPI has been noted in patients that experienced 
thrombolytic therapy.137 Oral oestrogen therapy was shown cause a ~25% reduction in total 
plasma TFPI concentration and activity, although it is uncertain whether this is associated 
with a procoagulant state.138 
As a natural inhibitor of initial phase of coagulation, recombinant (r)TFPI is an attractive 
therapeutic candidate to control thrombosis. In fact, a number of basic animal-based 
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research, as well as clinical trials comprising phase I and II studies, showed effectiveness of 
rTFPI, comparable to heparin administration. However, following more detailed data 
analysis and repetition of studies assessing its efficacy in humans, no benefit of rTFPI 
therapy was found. Hence, whether rTFPI will become an accepted therapeutic agent in 
routine clinical practice remains unclear.139 Fortunately, evidence suggests potential 
benefits of blocking TFPI activity to treat haemophilia. Studies of human plasma clotting 
assays initiated with dilute TF demonstrated that antibodies directed against TFPI shorten 
the clotting time of haemophilia plasma more than normal plasma. Maroney et al. suggests 
that targeting platelet TFPI but not endothelial pool may specifically aid controlling bleeding, 
while the risk of thrombosis that could occur due to inhibition of all TFPI pools would be 
minimised. However, differences in TFPI expression between mice and humans, should be 
carefully considered. Nevertheless, pharmaceutical agents that block platelet TFPI are 
currently under development.100,136 For example, small peptides blocking inhibition of FXa 
and TF/FVIIa by TFPI, are being tested.140 Standard treatment of haemophilia A and B 
involves a replacement therapy with FVIII and FIX, respectively. Medicines designed for 
subcutaneous and less frequent administration, as well as with a reduced risk of inhibitor 
formation are highly desirable. For example, monoclonal antibody 2021 directed against 
Kunitz 2 domain that effectively prevented TFPI-mediated inhibition of FXa/FVIIa/TF and 
improved clot formation in a haemophilia rat model, may constitute novel therapy for 
haemophilia in the near future.141 
Collectively, despite the large amounts of research performed using animal studies, the 
clinical relevance of the antithrombotic and atheroprotective effects of TFPI remains 
uncertain. Although considerable knowledge of molecular mechanisms behind the TFPI 
activities has been obtained, additional studies are still needed for better understanding of 
the pathophysiological importance of TFPI function to enable development of improved 
therapeutics treating thrombosis and/or haemophilia. 
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1.3 Protein S 
1.3.1 PROS1 and protein S expression 
Protein S is encoded by the PROS1 gene on chromosome 3q11.2, comprised of 15 exons and 
14 introns spanning over 100kb. It gives rise to an mRNA of 3292 bases.142,143 The transcript 
yields a 676 amino acid-long protein with a hydrophobic N-terminal signal peptide directing 
it to the endoplasmic reticulum (ER). Within the ER, protein S undergoes several post-
transcriptional modifications, including γ-carboxylation of glutamate residues, β-
hydroxylation of several asparagines and aspartic acid residues and addition of N-linked 
glycosylations. Prior to secretion, both the signal peptide and propeptide are proteolytically 
removed, resulting in generation of a mature protein comprising 635 amino acids with a 
molecular weight of 73kDa (70.6kDa excluding glycosylations).144,145 Protein S is expressed 
by hepatocytes, endothelial cells, megakaryocytes and vascular smooth muscle cells.146-148 
Following protein S synthesis and secretion into the blood stream, the total plasma 
concentrations of protein S is around 0.35µM,149 of which the majority (up to 70%) forms a 
complex with a complement pathway component, C4b binding protein (C4BP) and the 
remaining amount circulates freely.150 The half-life of protein S in plasma has been reported 
to be approximately 42 hours.151 
1.3.2 Protein S structure 
The mature protein S comprises an N-terminal Gla domain, a thrombin sensitive region 
(TSR), 4 epidermal growth factor-like (EGF) domains and a C-terminal SHBG-like domain 
composed of two laminin G (LG)-type subunits (Figure 1.11).152,153 Protein S has not been 
crystallised to date, but significant progress has been made in understanding structures of 
the individual domains. Homology models of Gla-TSR-EGF1,154,155 EGF3-4156 and the SHBG-
like domain157,158 are available. 
Over the past few years much information has been obtained concerning the specific 
functions of protein S domains. The N-terminal Gla domain of protein S contains one 
disulphide bond between Cys17 and Cys22, and 11 γ-carboxylated glutamic acid residues 
comprising Glu 6, 7, 14, 16, 19, 20, 25, 26, 29, 32 and 36.159 The Gla domain coordinates 
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seven calcium ions required for the conformational change which allows binding to 
phospholipids surfaces. This occurs through an incorporation of protein S hydrophobic ω-
loop into the membrane layer resulting in ionic interactions between positively-charged Ca2+ 
and the negatively-charged phospholipids.50,51,159 Binding of protein S to phospholipid 
surfaces, comprising either activated platelets or endothelial cells, is essential for its 
anticoagulant functions as well as the activities unrelated to coagulation. For example, the 
natural protein S variant Gly11Asp exerts reduced affinity for the membranes leading to an 
impaired APC-cofactor function.160 Additionally, the Gla36 has been demonstrated to be 
necessary for the APC-cofactor function of protein S. Mutation of this residue results in 
severely reduced ability to bind and enhance APC both in plasma and in purified systems, 
but this is not due to an impaired affinity for phospholipids.161 
The TSR domain is unique to protein S. It is composed of 29 amino acids forming two α-
helixes brought in close contact through a disulphide bridge between Cys47 and Cys72.162 
Several in vitro studies suggest that the cleavage of the TSR can inhibit the APC-dependent 
as well as APC-independent cofactor functions of protein S.163,164 Protein S cleavage by 
thrombin at Arg49 and Arg70, and by FXa at Arg60 within the TSR region have been 
reported.162,165,166 While cleavages by thrombin occur only in the absence of calcium ions 
and phospholipids, cleavage by FXa is dependent on the presence of both Ca2+ and 
phospholipid surfaces.162 From 10% to 14% of circulating protein S appears to be cleaved at 
Arg60 in vivo, whereas occurrence of the cleavages by thrombin under the physiological 
conditions is currently uncertain.167  
Each EGF-like domain is composed of ~40 amino acids and three disulphide bonds linking 
cysteine to a cysteine in a 1 to 3, 2 to 4 and 5 to 6 patterns. These four domains all undergo 
posttranslational modifications leading to a single β-hydroxylasparatic acid (Hya 95) in EGF1 
and one β-hydroxylaparagine (Hyn 136, Hyn 178 and Hyn 217) within EGF2,3 and 4.168,169 
Non-hydroxylated protein S manifests diminished cofactor activity towards APC.169 The 
EGF2-4 domains each contain a high affinity Ca2+ binding site important for the protein S 
functions.170-172 Interestingly, no evidence of calcium ions binding to EGF1 has been 
reported to date, and its β-hydroxylation might be dispensable for protein S activities.169 
EGF1, EGF2 and TSR have been implicated to be key in the APC cofactor function of protein 
S.173,174 This was confirmed in a recent study by my lab when a critical role of Asp95 within 
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the EGF1 for the APC enhancement was discovered.175 EGF3 as well as EGF4 are essential for 
protein S interaction with FXa.176 Interestingly, alterations in binding of calcium ions to EGF4 
induces conformational changes within the EGF1,172 while a naturally occurring deletion 
mutation in EGF4, I203D204, results in modified structure and functionality of the Gla 
domain.177  
The C-terminal part of protein S consists of 392 amino acids that together form the SHBG-
like domain which comprises two individual LG subunits. The SHBG domain of protein S has 
been reported to confer protein S interaction with C4BP178,179 and with FVa.180 It is kept in its 
globular state through three disulphide bonds, Cys408-Cys434 within LG1 and Cys598-
Cys625 in the LG2, and an additional bridge connecting the two LG subunits. It also contains 
N-linked glycans at Asn458, Asn468 and Asn489, and a high affinity Ca2+ binding site.178,181 
While binding of calcium ions is essential for protein S binding to C4BP, no functional 
importance of the glycosylations has been reported.163,178 The LG domains have been 
suggested to have a role in the APC cofactor function182 and may encompass protein S 
interaction with Tyro3, Axl and Mer (TAM) receptors.183,184 More details regarding the 
importance of the SHBG domain in protein S activities are discussed in section 1.3.3. 
Substantial evidence has been accumulated demonstrating protein S multimerisation 
resulting from in vitro manipulation, especially during protein purification procedures.185,186 
Although it is commonly considered that protein S circulates in plasma in its monomeric 
form, presence of its multimeric forms in circulation also has been reported.187,188 
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Figure 1.11 Domain organisation of protein S. 
Protein S comprises an N-terminal Gla domain, TSR followed by four EGF-like domains and a C-terminal SHBG-
like domain containing two LG subunits. The boxes show the representative domain models adapted from 
Villoutreix et al./Giri et al., Drakenberg et al., and Villoutreix et al.
154-156,158
 Calcium ions mediating binding of 
the Gla domain to phospholipids are presented as pink spheres. 
1.3.3 Protein S function 
Protein S is a vitamin K-dependent, multifunctional protein playing an essential role in 
coagulation. Its value has also been implicated in the classical complement pathway and 
apoptotic clearance.189-191 Protein S is mostly known for its cofactor function towards 
anticoagulant activities mediated by APC.192 Protein S was also suggested to exert 
anticoagulant properties independently of APC,193 which was later explained by protein S 
competing for binding to the limited amounts of phospholipids.194 When protein S retained 
its APC independent anticoagulant properties despite of the presence of saturated amounts 
of phospholipids, but at low concentrations of TF, the TFPI cofactor function of protein S 
became evident.31 
44 
1.3.3.1 APC cofactor function 
Following the amplification stage of coagulation, APC mediates the downregulation of 
thrombin generation through inactivation of two procoagulant components, activated FV 
and activated FVIII. FV and FVIII both comprise three A domains, a single B domain and two 
C domains (A1-A2-B-A3-C1-C2). Both proteins are activated by thrombin-mediated 
cleavages resulting in the release of the B domain. Activation of FV will be discussed in detail 
in section 1.4.3. APC mediates the kinetically favourable proteolytic cleavage of FVa at 
Arg506 within the A2 domain, followed the slower cleavage at Arg306 within the A1 domain 
and finally the cleavage at Arg679 within the A2 domain. The APC-mediated cleavage of 
FVIIIa occurs at Arg336 and Arg562 resulting in dissociation of the A2 domain and a 
complete loss of FVIIIa function.195,196 
Protein S is a well-established cofactor for APC, effectively potentiating its anticoagulant 
effects through inactivation of both FVa and FVIIIa in a phospholipid-dependent 
manner.192,197-199 Protein S specifically enhances the slow cleavage at Arg306 of FVa by 
approximately 20-fold.200,201 It has been also suggested that protein S can slightly facilitate 
the APC-mediated cleavage at Arg506 of FVa.200 Interestingly, a study by Maurissen et al. 
revealed that protein S bound to C4BP is also able to enhance APC-mediated cleavage of 
FVa. It is however 6-8-fold less effective than free protein S.202 Protein S does not affect 
binding between APC and FVa itself.203 Three distinct mechanisms by which protein S 
potentiates APC activity in inactivating FVa, have been proposed. Protein S may augment 
APC activities through potentiating its binding to phospholipid surfaces onto which FVa is 
bound.198,204,205 Consequently, the low affinity of APC for the membranes (Kd(app)=2-
7µM)198,206 is increased by activity of protein S, which binds stronger to phospholipids 
(Kd(app)=4-15nM).
160,177,207,208 As a result, APC can effectively inactivate FVa within the range
of its physiological concentrations (~65nM). It has also been suggested that protein S might 
modify the orientation of the active site of APC.209,210 Fluorescence resonance energy 
transfer (FRET) experiments performed by Yegneswaran et al. revealed the allosteric 
conformational changes induced within the APC upon the presence of protein S, which may 
facilitate FVa cleavages at Arg506 and Arg306 positions.210 Alternatively, protein S binding to 
APC may overcome the resistance of FVa when bound to FXa to cleavage by APC. This could 
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be achieved either through protein S competition with FXa for FVa binding, or protein S-
induced dissociation of FVa from the FXa/FVa complex.201,211
While the physiological relevance of protein S enhancement of FVa inactivation by APC is 
commonly accepted, its importance in the inactivation of FVIIIa is less well established. 
Protein S stimulates degradation of FVIIIa mediated by APC by augmenting the FVIIIa 
cleavage at Arg336 only ~2-fold and cleavage at Arg562 only ~3-fold.212,213 FV and protein S 
function as synergistic cofactors for APC-mediated degradation of FVIIIa. While protein S 
enhances APC alone, FV has little cofactor function for APC in the absence of protein S.213-215 
Interestingly, full efficiency is achieved by synergistic effects of protein S and inactivated FV 
(cleaved at Arg506), resulting in ultimate ~10-fold enhancement. While both free and C4BP-
bound protein S are cofactors for APC in FVIIIa inactivation, only free protein S is able to act 
in synergy with FV in this process.216 The mechanism underlying the protein S effects upon 
FVIIIa degradation remain to be fully elucidated, but it is believed that, apart from increasing 
APC binding to phospholipids, protein S may compete with FIXa for binding to FVIIIa, thus 
overcoming the protective action exerted by the tenase complex.217 
Figure 1.12 Protein S enhancement of inactivation of FVa and FVIIIa by APC. 
APC binds and inhibits FVa by its proteolytic cleavage at Arg506, Arg306 and Arg679. The cleavage at Arg306 is 
greatly enhanced by protein S. FVIIIa is inactivated by the APC-mediated cleavages at Arg336 and Arg562. 
Protein S moderately enhances the cleavages at Arg336 and Arg562. Consequently, assembly and activity of 
the prothrombinase complex is reduced, effectively limiting generation of thrombin and thus fibrin formation. 
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Significant amount of research has been conducted to understand the roles of individual 
protein S domains in its enhancement of APC. Several investigators have suggested 
important contributions of Gla, TSR, EGF1 and EGF2 in interaction and/or enhancement of 
APC by protein S.171,173,218,219 The TSR and EGF1 domain of protein S have additionally been 
described to account for the APC species specificity.220 A cluster of residues Leu21, Asn23, 
Lys24, Arg28, Asp34, Tyr41, Leu45 (termed Face2) within the Gla domain has been proposed 
to form an APC interaction site.207 In a subsequent work, the essential roles of Asp95 in the 
EGF1 and Gla36 in the Gla domain in the APC cofactor function were demonstrated by the 
members of my lab.161,175 Additionally, also work from my lab, revealed the importance of 
Asp36, Leu38, Ala39 within APC Gla domain for its interaction with protein S.221 The SHBG-
like domain may also have a role in the APC cofactor function of protein S. Examination of 
mini protein S lacking the entire SHBG domain by Wijnen et al., demonstrated that this 
domain is indispensable for the expression of optimal APC cofactor function by protein S in 
plasma. In purified assays on the other hand, the SHBG-like domain was not essential for the 
enhancement of APC-mediated degradation of FVa and FVIIIa.179 Subsequently, a protein 
S/Gas6 chimera in which the protein S SHBG domain was substituted with the 
corresponding domain from the structurally homologous Gas6, lacking anticoagulant 
properties, has been constructed. Interestingly, this chimera expressed only 40-50% of the 
APC cofactor function in plasma compared to WT protein S. Using purified assays, the 
chimera exerted nearly normal ability to enhance degradation of FVa by APC, whereas it lost 
entire APC cofactor function for the FV-dependent enhancement of FVIIIa inactivation.222 In 
a subsequent study, additional protein S/Gas6 chimeras, comprising replacements of the 
individual SHBG LG subunits, were generated. Evenas et al. identified the LG2 domain to be 
indispensable for an efficient inactivation of FVa as well as FVIIIa, while LG1 domain 
appeared partially important for the enhancement of FVIIIa (but not of FVa) inactivation by 
APC.182 
1.3.3.2 TFPI cofactor function 
In 2006, Hackeng et al. discovered that protein S enhances TFPI-mediated inhibition of FXa 
by 10-fold in a phospholipid-dependent manner.31 They reported increased thrombin 
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generation in normal plasma incubated with antibodies against protein S in the presence of 
polyclonal antibodies against APC. This effect only occurred at low concentration of TF. It 
was not observed in TFPI-depleted plasma, indicating the TFPI-dependent anticoagulant 
activity of protein S. Indeed, when this plasma was supplemented with TFPI, the 
potentiating effect of protein S returned. Further kinetic studies using pure component FXa 
inhibition assays where the inhibition of FXa by TFPI could be followed in real time were 
performed. The results suggested that protein S facilitates TFPI inhibitory function by 
reducing the inhibition constant of the initial TFPI/FXa complex to below the plasma 
concentration of TFPI (Figure 1.13). Little effect was seen on the transition from the loose 
FXa/TFPI complex to the tightly bound FXa/TFPI* complex. It was also suggested that 
protein S bound to C4BP only exerts 60% of the cofactor function of free protein.31 The 
molecular mechanisms by which protein S enhances TFPI-mediated inhibition of FXa are still 
under investigation. It was originally proposed that protein S enhances TFPI direct inhibition 
of FXa as well as TFPI-mediated TF/FVIIa activation of FX.31 Subsequent studies carried out 
by Ndonwi et al. highlighted that whereas the presence of protein S enhances the TFPI 
association with FXa (the rate limiting step), the rates of FXa inactivation and TF/FVIIa 
inhibition, are unaffected.223 Ndonwi and colleagues suggested that TFPI mainly binds to FXa 
already bound to TF/FVIIa. Consequently, a model in which the major role of protein S 
enhancement of TFPI is to downregulate any FXa that escapes TF/FVIIa/FXa inhibition by 
TFPI, has been proposed.223 These mechanisms have been recently re-evaluated by 
Peraramelli and co-workers.77,224,225 Their work have demonstrated that apart from the well-
established enhancement of FXa inhibition by TFPI, protein S also decreases the Ki of 
relipidated TF/FVIIa inhibition of TFPI by about 6-7-fold. As expected, the enhancement of 
both FXa as well as TF/FVIIa inhibition by TFPI were lost in the presence of truncated forms 
of TFPI lacking Kunitz domain 3 and the C-terminus.225 These results, together with their 
newest data77, confirmed protein S enhancement of inhibition of TF/FVIIa-catalysed FX 
activation by full-length TFPI. 
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Figure 1.13 Kinetics of the protein S enhancement of FXa inhibition by TFPI. 
Protein S mainly reduces the inhibition constant of the initial TFPI/FXa complex (Ki), with a small effect on the 
transition from the loose FXa/TFPI complex to the tightly bound FXa/TFPI*. Constants reported by Hackeng et 
al.
31
 
In 2008, Dahm and colleagues noted that increased plasma concentrations of protein S were 
associated with an increased TFPI anticoagulant function.226 Furthermore, it was suggested 
that impaired protein S enhancement of TFPI activities may account for defects within the 
anticoagulant processes observed in patients with protein S deficiency.227 Shortly after this, 
protein S binding to TFPI in plasma was reported, providing an explanation for the observed 
reduction in TFPI antigen levels in protein S-deficient patients.228 These results were also 
followed up by reports showing a direct interaction between TFPI and protein S using 
surface plasmon resonance (SPR).228-230 According to co-immunoprecipitation experiments 
performed by Castoldi et al., protein S bound to C4BP is no longer able to interact with 
TFPI.228 After these publications, identifying a direct interaction between protein S and TFPI, 
the search for interaction sites in both proteins began. In 2010 Ndonwi and co-workers 
showed that the Kunitz 3 domain of TFPI and in particular its Arg199 residue was necessary 
for protein S cofactor activity towards TFPI.229 Following this, my lab have indentified 
additional residues involved in the TFPI cofactor function comprising Asp194, Arg199, 
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Glu226, Glu234 and Arg237. Substitution of Glu226 in particular resulted in a minimal 
protein S enhancement, as was shown by plasma-based thrombin generation and 
experiments using purified systems. Almost no binding between TFPI E226Q and protein S 
could be observed using SPR.230 
The molecular mechanisms underlying the TFPI cofactor activity of protein S, has not been 
fully characterised. Only recently, work performed by Wood et al. revealed that the activity 
of TFPI/protein S complex is limited to plasma or platelet-releasable TFPIα isoform that is 
localised by protein S to the negatively-charged surfaces for efficient inhibition of 
membrane-bound FXa.75 Nevertheless, the roles of particular protein S domains in TFPI 
interaction and enhancement have not been characterised to date. Hence, my work focused 
on identifying a TFPI functional interaction site on protein S in order to further elucidate the 
molecular mechanisms of protein S cofactor function towards TFPI. 
1.3.3.3 Direct anticoagulant functions of protein S 
Protein S has also been shown to have direct anticoagulant functions independent of APC or 
TFPI. Initially it was suggested that protein S can bind to FVa, FXa, and FVIIIa and inhibit both 
the tenase and prothrombinase complexes, in the presence of limited concentrations of 
phospholipid surfaces.166,176,180,231-235 However, this was later shown to arise due to a 
competition of protein S multimers for binding to limiting phospholipid surfaces.185,186,194,236 
Amongst several publications reporting direct anticoagulant properties of protein S, key 
findings point out protein S multimerisation during purification. Therefore, the physiological 
importance of direct interactions have been questioned. While Sere et al. have suggested 
that the APC- and TFPI-independent anticoagulant activities of protein S are attributed only 
to its multimeric form,185 Heeb and colleagues claim that both monomers and multimers 
exert these direct effects.188 In 2009, Heeb et al. demonstrated that immunopurified protein 
S preparation containing Zn2+ expresses ~10-times higher direct anticoagulant properties in 
comparison to conventionally-purified samples.237 Increased binding to FXa was noted, 
whereas the APC and TFPI cofactor functions were unaffected by the presence of zinc ions. 
In a subsequent study by Fernandes and co-workers, Zn2+-containing protein S inhibited 
tenase formation independently of TFPI but likely through a direct interaction with TF.238 
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Recently data showing direct anticoagulant effects of platelet-derived protein S upon FXa 
generation and thrombin formation on the surfaces of activated platelets have been 
presented.239 
1.3.3.4 Protein S functions unrelated to coagulation 
Functions of protein S unrelated to coagulation have been extensively explored. Protein S is 
involved in apoptotic clearance through direct binding to apoptotic cells that expose 
phosphatidylserine, and stimulating their macrophage engulfment.240 Moreover, it is 
believed that protein S is able to stimulate vascular injury repair241,242 and studies in mice 
have demonstrated its neuroprotective effects during ischemic brain injury.243 Protein S was 
also shown to impair formation of capillary-like structure and vascular endothelial growth 
factor (VEGF)-mediated migration, proliferation and signalling in human endothelial cells.244 
Additionally, protein S has been shown to be structurally similar (44% homology) to Gas6 
which is involved in cell growth and has no known anticoagulant properties.245 
As previously mentioned, ~60% of protein S circulates as a non-covalent, high affinity 
complex with C4BP. C4BP regulates complement activation and serves as an inhibitor of the 
classic and the alternative pathways.246 In detail, C4BP is a cofactor for serine protease 
factor I in degradation of C4b, leading to downregulation of C3-convertase formation. This is 
also achieved through C4BP binding C4b and thereby blocking its assembly into a complex 
with C2a. Additionally, C4BP acts as a cofactor to factor I in cleavage of C3b.247,248 C4BP is a 
570kDa multimeric protein existing in three distinct isoforms comprising different α and β 
chain compositions: α7β1, α6β1 or α7β0. The chains are held together covalently by 
disulphide bonds at the C-terminus.249,250 α chains confer binding site for C4b,251,252 whereas 
β chain contains the interaction site for protein S (Figure 1.14).178,253,254 The total 
concentration of C4BP is approximately 260nM, of which ~80% comprises the β chain-
containing form capable of binding protein S with a 1:1 stoichiometry. During acute phase, 
the proportion of C4BP containing only α chains increases due to differential regulation of 
C4BP genes,255 while the levels of C4BP form able to bind protein S are retained. Hackeng et 
al. suggested that only free protein S fully enhances TFPI, while protein S bound to C4BP 
exerts significantly reduced TFPI cofactor function.31 Protein S binding to C4BP was not 
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initially considered to interfere with the complement regulatory activities of C4BP.256-258 
More recent data however suggests protein S role in localising C4BP on the membrane 
surfaces of apoptotic cells resulting in inhibition of phagocytosis, thereby downregulation of 
inflammation.191,259,260 
Within C4BP, four amino acids in the complement control protein 1 domain including Ile16, 
Val18, Val31 and Ile33 have been identified to confer the interaction site with protein S.261 
On protein S, it is the SHBG-like domain that is responsible for the binding to C4BP. 
Considerable efforts has been made to identify the exact interaction site and collectively 
significance of residues 423-429, 447-460, 453-460, 583-635 and 605-614, spanning both LG 
subunits, has been suggested.262-267 The most recent computational analysis indicated that 
indeed the interface between LG1 and LG2 forms an extended binding site for C4BP.158
Figure 1.14 Schematic representation of C4b and protein S binding to C4BP. 
The majority of plasma C4BP contains seven α chains into which C4b proteins can bind, and a single β chain 
exclusively interacting with protein S. 
1.3.4 The role of protein S in disease 
Protein S has an important role in vivo, as shown clinically by the association of protein S 
deficiency with venous thromboembolism (VTE) in 1984.268 While protein S deficiency only 
occurs in 0.03-0.13% of the normal population,269 ~2% of thrombophilic patients were found 
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to suffer from this condition.270 The pathophysiological importance or protein S was also 
reflected by complete protein S deficiency reported in infants suffering from purpura 
fulminas despite treatment with supplementary anticoagulants. Individuals with inherited 
heterozygous (due to PROS1 gene deletions or point mutations) or acquired protein S 
deficiencies  are at higher risk of developing thrombotic disease.271 Studies using murine 
models revealed a prothrombotic phenotype when expressing heterozygous protein S 
deficiency,272 while complete knockouts appear to develop coagulopathy and vascular 
dysgenesis and die during early development.273  
Genetic protein S deficiency is an uncommon autosomal dominant disorder, but over 200 
hereditary protein S variants have been identified.274,275 They are classified into type I, type 
II and type III deficiencies. Type I is a quantitative deficiency of total protein S, type II is a 
quantitative deficiency of free protein S, and type III comprises a qualitative protein S 
deficiency. Type I and II deficiencies account for ~96% of all protein S deficiencies found in 
the human population, whereas the remaining ~4% are represented by type III 
deficiencies.275 One example of genetic variation within protein S is protein S Heerlen. This 
natural variant comprises a polymorphism of Ser460 substitution to Pro resulting in the loss 
of Asn458 N-linked glycosylation276 and has been identified in 0.5% of the healthy 
population. This genetic variation has been linked to mildly reduced levels of free protein S 
as well as total protein S, most likely due to an increased protein S clearance rate.277 
Acquired protein S deficiencies are more common and usually result as a consequence of 
oral anticoagulant therapy such as warfarin, oral contraception, pregnancy, liver disease, 
nephritic syndrome or chronic infections such as human immunodeficiency virus 
(HIV).271,275,278 Additionally, transient acquired protein S deficiencies due to development of 
autoantibodies following infection with varicela virus or human herpes virus-6 have been 
reported.279,280 
When Castoldi et al. demonstrated that free protein S forms a complex with full-length TFPI 
in plasma, they linked reduced levels of full-length TFPI with genetic or acquired protein S 
deficiencies. This finding reinforced the idea that the prothrombotic phenotype 
demonstrated in these individuals likely occurs due to combined reduction of protein S and 
TFPI plasma levels.228 
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To summarise, the anticoagulant properties of protein S are critical for controlling 
haemostasis, and hereditary or acquired protein S deficiency is a well-known risk factor for 
the development of thrombotic disorders. Yet, there is still more to understand regarding 
association between protein S and TFPI deficiencies. 
1.4 FV 
1.4.1 FV gene and expression 
The human FV gene is located on chromosome 1q21-21 and spans over 80kb comprising 24 
introns and 25 exons. The isolated complimentary deoxyribonucleic acid (cDNA) has a length 
of 6672bp and encodes a preprotein of 2224 amino acids resulting in formation of a post-
transcriptional mRNA of 6.8kb.281,282 Human FV biosynthesis occurs the liver, where it 
undergoes extensive posttranslational modifications prior to the secretion.283,284 It circulates 
in plasma as a large single-chain glycoprotein of a molecular weight of 330kDa at a 
concentration of ~20nM.285 FV has also been reported to be present within platelet α-
granules, comprising 20-25% of the total FV content in human blood. Platelet FV appears to 
be partially fragmented and stored in association with multimerin which serves as a carrier 
molecule for FV in platelets as well as within endothelial cells.286-289 The platelet pool of FV is 
released upon the platelet activation during coagulation while it simultaneously dissociates 
from multimerin.285,290 Interestingly, a fraction of the platelet FV pool appears to be taken 
up from circulation through megakaryocyte-mediated endocytosis and then sequestered in 
the α-granules.291,292 Consequently, it remains rather unclear whether the presence of FV in 
platelets results from absorbing exogenous FV from plasma, or actual FV synthesis.291,293,294 
1.4.2 FV structure 
The mature FV molecule is composed of 2196 amino acids forming a mosaic-like structure 
comprising three A domains, a B domain and two C domains. FV shares significant homology 
with FVIII except the B domain region.295 FV A domains are also structurally similar to the 
copper-binding plasma protein ceruloplasmin, while the C domains are homologous to a 
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slime mold protein termed discoidin.281,282,296 Structural studies using electron microscopy 
by Fowler et al. suggest a model in which A and C domains constitute a globular head and 
the connecting B domain is substantially folded (contained in a two-stranded tail).297 Due to 
the homology between the A domains of FV and ceruloplasmin, a molecular model 
suggesting a triangular arrangement of the A domains within the FV molecule has been 
developed.298 Molecular models were also determined for the C domains of FV,299 while the 
3D structure of the C2 domain was resolved using x-ray crystallography.300 The factor V 
molecule undergoes multiple posttranslational alterations including sulphation, 
phosphorylation, and glycosylations.301-306 Tyrosine sulphation is of particular importance 
for the FV activation by thrombin and therefore impacts the functional properties of 
activated form of FV.306 
An alternatively-spliced FV variant, FVshort has been recently described. An in-frame 
deletion of residues 757-1457 within the B domain results in formation of a partially 
truncated FV isoform of a molecular weight ~250kDa.307 Additionally, a recombinant partial 
B-domainless form of FV, FVdes811–1491 commonly called FVdt, has been produced mainly 
for the purposes of investigating importance of the B domain in FV activity.308 Both, FVshort 
and FVdt can undergo full activation through further proteolysis by thrombin, resulting in 
formation of a typical FVa. The domain structures of full-length FV, FVshort and FVdt are 
visualised in Figure 1.15. 
Figure 1.15 Domain organisation of FV, FVshort and FVdt. 
FV comprises three A domains with integrated B domain, followed by two C domains. In FVshort a single-point 
A to G mutation results in an alternative splicing within the B domain leading to removal of residues 757-1457, 
and FVdt lacks residues 811-1491. 
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1.4.3 Activation of FV 
FV circulates as a single-chain procofactor and is inefficient in binding FXa. It is therefore not 
able to assemble or function within the prothrombinase complex.309-313 Upon the 
stimulation of coagulation, FV can be activated by a number of proteases including 
thrombin, FXa, or a snake venom enzyme (RVV-V activator).312,314-317 FV activation by 
thrombin and FXa (Figure 1.16) are the most relevant for the coagulation cascade and hence 
these two processes have been studied extensively. Thrombin sequentially cleaves three 
peptide bonds within the B domain at Arg709, Arg1018 and Arg1545, generating a non-
covalently associated two-chain FVa molecule (Figure 1.16).281,312,314,318 In detail, the 
cleavage process pursues a kinetically preferred order in which cleavage at Arg709 is 
followed by cleavage at Arg1018, while formation of the light chain is associated by cleavage 
at Arg1545.311 The resulting FVa is a heterodimer composed of an N-terminal heavy chain of 
molecular weight of 105kDa and a C-terminal light chain of molecular weight of 74kDa. The 
heavy chain spans residues 1-709 and comprises two A domains (residues 1-303 and 317-
656), connected by a region rich in basic amino acids. The C-terminal end of the heavy chain 
comprises residues 657-709 and is rich in acidic amino acids. The light chain of FV spans 
residues 1546-2196 and contains one A domain (residues 1546-1877) followed by two C 
domains (residues 1878-2036 and 2037-2196).319 The two chains are associated through 
non-covalent interactions mediated by calcium ions.281,312,314,318 Initially it has been 
suggested that the divalent metal ions directly bridge the heavy and light chain resulting in a 
tight interaction with a dissociation constant (Kd) of ~6nM.
319 However, more recent crystal
structure studies demonstrated that Ca2+ was fully coordinated by a loop comprising 
residues Lys93-Asp112 from the A1 domain of the heavy chain.47 These findings showed 
that numerous non-covalent interactions between the A1 and A3 domains (requiring the 
presence of divalent metal ion) confer the chain-chain association.47  
Upon FV activation by thrombin, the large, heavily glycosylated central B domain, is released 
in the form of two fragments of molecular weight of 71kDa and 150kDa, spanning amino 
acids 710-1018 and 1019-1545, respectively.312,314,318,320 Available evidence reinforces the 
idea that variable FVa cofactor activity occurs depending on which region of the B domain is 
removed. For example, while only partial cofactor function of FV cleaved at Arg709 and 
Arg1018 has been reported,314,320-322 maximal FVa activity occurs with cleavage at 
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Arg1545.321-323 Supported by additional studies demonstrating RVV-V-mediated cleavage at 
Arg1545 leads to full FV activation, it has been suggested that this single cleavage is 
sufficient for activation of FV, while release of the B domain appears to be unnecessary. 
Further studies, however, clarified the importance of the B domain in maintaining an 
inactive form of FV. It has been suggested that the binding sites important for cofactor 
function of FV are present on heavy and light chains, and are in a conformational state that 
prevents FXa/prothrombin binding. Proteolytic removal of the B domain triggers key 
conformational shift exposing these essential binding sites and therefore enabling FVa 
assembly to the prothrombinase complex.324 The importance of the B domain in FV 
functions are discussed further in the following sections. Nevertheless, an alternative 
mechanism has been proposed in which B domain sequences serve an inhibitory function 
and cleavage by thrombin facilitates their dissociation resulting in formation of active FV. 
Toso and colleagues revealed that B-domainless FV (introduced in the section above) was 
equally functional to thrombin-cleaved FV, suggesting that proteolysis within the B domain, 
although necessary for its removal, is incidental for the activation of FV.308 This was 
supported by experiments by Zhu and co-workers showing that deletion of the B domain 
alone, without the proteolytic processing, led to formation of fully active FV.325 Conversely, 
the role of the B domain role in the anticoagulant function of FV has also been indicated. 
This domain appears to be involved in the APC-mediated inactivation of FVIIIa.326 
FV activation by FXa takes place following the initiation phase of coagulation and it occurs 
with a different sequence of events than cleavages mediated by thrombin. FXa 
preferentially cleaves the B domain at Arg1018 following by the cleavage at Arg709 resulting 
in the formation of a partially-activated FV isoform containing the acidic residues of the B 
domain (Figure 1.16). Eventually, cleavage at Arg1545 also occurs, leading to removal of the 
entire B domain.323 The resulting FV isoform, similar to thrombin-activated FV, is composed 
of two chains held together by calcium ions.  
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Figure 1.16 Schematic representation of FV activation processes. 
During the initial assembly of the prothrombinase complex, FXa cleaves FV mainly at positions R1018 and 
R709, which initially deletes large proportion of the B domain, partially activating FV (FVa*). The proteolytic 
cleavage of FV by thrombin at positions R709, R1018 and R1545 leads to the removal of the entire B domain 
resulting in complete activation of FV (FVa). 
1.4.4 FV/FVa functions 
In 1993, the existence of two forms of FV, named FV1 and FV2, differing in molecular 
weights and affinity for phospholipids, was noted within the human blood and platelets.327 
The following studies described the effects of the membrane-binding properties of these 
two forms upon their procoagulant and anticoagulant cofactor functions.213,328 FV1, 
containing an additional carbohydrate at the Asn2181 residue,329,330 facilitates an increased 
thrombin formation by about 7-fold, in comparison to FV2.328 Since then, a dual pathway 
determing the function of FV has been recognised. While complete FV activation leads to 
formation of its procoagulant form, the APC-mediated proteolysis of intact FV results in 
generation of a molecule lacking any procoagulant properties, and mostly serving as a 
cofactor for the anticoagulant activities of APC.331 Additionally, as mentioned in section 
1.2.3.3, FV partially activated by FXa has been shown to have a role in the TFPI-mediated 
inhibition of prothrombinase.106 There is a fine balance between the procoagulant and 
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anticoagulant properties of FV which is strictly dependent on the local availability of 
procoagulant and anticoagulant enzymes comprising thrombin, FXa and APC.331 
1.4.4.1 Procoagulant activities 
Thrombin-activated FV has been extensively characterised and is known to serve as a 
coagulation cofactor by participating in the rapid generation of thrombin under 
physiological conditions. As previously mentioned, during the propagation stage of 
coagulation, FVa together with FXa assemble into a complex facilitating binding to and 
conversion of prothrombin to thrombin. While the heavy chain of FVa contains binding sites 
for FXa and prothrombin, the light chain confers interactions with FXa and phospholipid 
membranes. Additionally, thrombin binding sites have been identified within the acidic C-
terminal region of the FVa heavy chain.332-335 In 2000, Nicholaes et al. suggested that 
mutations in a potential phospholipid binding loop in the C2 domain of FV affect assembly 
of the prothrombinase complex.336 Following this, the C1 domain of FVa comprising an 
interaction site for phosphatidylserine, has been shown to regulate assembly and activity of 
the prothrombinase complex.48 Recently it has been demonstrated that the basic and acidic 
regions of the FV B domain prevent its interaction with FXa, and the binding sites for FXa 
only become exposed following the proteolytic removal of the B domain.120  
FXa-dependent activation of FV, although slower and limited, has been proposed to be 
particularly important during the initiation phase of coagulation when traces of initial 
thrombin are restrained by fibrinogen and physiological thrombin inhibitors limiting 
thrombin-mediated FV activation. Following the initial prothrombinase complex formation, 
complete FV activation leads to amplified generation of thrombin observed during the 
propagation phase.324 
59 
1.4.4.2 Anticoagulant activities 
1.4.4.2.1 APC cofactor function 
The first reports of anticoagulant function of FV described its cofactor function for the APC-
mediated inactivation of FVIIIa in the presence of protein S.214,215 It was demonstrated that 
FV, in cooperation with protein S, stimulate the APC-mediated cleavage of FVIIIa at Arg336 
by ~3-fold and at Arg562 by ~8-fold,195,337 ultimately facilitating the overall inactivation rate 
by approximately 11-fold.213 Importantly, the cleavage at Arg506 has been shown to be key 
for the APC cofactor effects of FV in inactivating FVIIIa.213,338 Although the molecular 
mechanisms behind the anticoagulant function of FV are yet to be fully characterised, the 
involvement of the FV B domain has been generally accepted. Full procoagulant activation 
of FV, and the loss of the ability to enhance APC occurs following the proteolytic cleavages 
at Arg709 and Arg1545 by thrombin and the associated release of the B domain.213,339 The C-
terminal part of the B domain has been shown to be essential for the APC cofactor function 
of activated FV.326 Recent experiments comprising additions of FV in the presence of APC to 
FV-deficient plasma revealed the sensitivity of clotting to FVa inactivation but not to FVIIIa 
inactivation. These results indicate that anticoagulant FV also contributes to APC-mediated 
inactivation of FVa.340 Collectively, this suggests that FV anticoagulant function contributes 
significantly to the APC-dependent inactivation of both FVIIIa and of FVa. However, since 
inactivation of FVIIIa can also occur spontaneously, the physiological relevance the APC 
inactivation of FVIIIa has been questioned.215,341 This suggests a higher importance of FVa 
inactivation by APC and FV. Nevertheless, the occurrence of FV anticoagulant cofactor 
function for FVa inactivation by APC still requires further characterisation and confirmation 
using plasma-based assays. 
1.4.4.2.2 TFPI cofactor function 
It has been recently discovered that TFPI binds FV while circulating in plasma. First, Duckers 
et al. reported that TFPI levels are nearly 70% lower in the plasma of patients with severe FV 
deficiency, compared to normal plasma. Following this, they demonstrated a direct binding 
between TFPI and FV using immunoprecipitation experiments.342 Further studies by Ndonwi 
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et al. revealed that TFPI also binds FVa. The interactions between TFPI and FV or FVa are 
both independent of calcium, but strictly dependent on the presence of the TFPI C-
terminus.121 Binding affinity of ~9nM between FV and TFPI-2, a protein homologous to TFPI 
but regulating intrinsic coagulation and fibrinolysis, was recently derived.343 Whether similar 
affinity exists between FV and TFPI, remains undiscovered. Vincent and colleagues reported 
that TFPI also binds to FVshort which lacks a large portion of the B domain. FVshort is 
abundantly present in plasma in patients suffering from east Texas bleeding disorder and 
was recently shown to inhibit coagulation by forming a complex with TFPI, resulting in a 
dramatic increase in TFPI plasma levels. Since low levels of FVshort have also been found in 
normal plasma and TFPI was found to preferentially bind FVshort in comparison to 
interaction with full-length FV, FVshort was suggested to be the primary form of FV 
interacting with TFPI under physiological conditions.307 
The role of partially-activated FV has recently been investigated, leading to the discovery of 
anticoagulant properties of this form of FV. In 2013, Wood et al. showed that FVa* enables 
inhibition of prothrombinase by TFPI during the initial phase of coagulation. Prothrombinase 
inhibition by TFPI occurs early in the coagulation response during which the prothrombinase 
complex assembles with partially-activated FV (either generated through limited proteolysis 
by FXa or newly released from activated platelets). Such forms of FV retain the B domain 
acidic sequences which confers a direct interaction site for the basic region within the TFPI 
C-terminus. The procofactor conformation of FV is maintained by the intra-molecular 
interaction between its basic and acidic regions within the B domain. It has been 
hypothesised that TFPI is able to bind and inhibit prothrombinase by mimicking this 
interaction. The TFPI anticoagulant activity is therefore lost upon thrombin activation of FV 
during which the acidic region is removed.106 Moreover, the TFPI anticoagulant function can 
be blocked by addition of negatively-charged molecules such as heparin, polyphosphate or 
fucoidan, providing explanation for the procoagulant effects of heparin observed in the 
absence of AT.109,344  
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1.4.5 Inactivation of FVa 
As I mentioned previously in section 1.3.3.1, APC mediates cleavages of FVa initially at 
Arg506, followed by a slower cleavage at Arg306 and finally at Arg679 generating an 
inactive, disintegrated FV molecule often termed FVi (Figure 1.17). Additionally, in vitro 
studies comprising FVa variants, have identified further cleavage sites at Lys309, Arg313, 
Arg316, Arg317 and Arg505. While the physiological relevance of these additional cleavages 
as well the role of the Arg679 cleavage is still under debate, it has been generally accepted 
that the two cleavages at Arg506 and Arg306 are truly essential for a complete inactivation 
of FVa.345-347 The presence of the negatively-charged surface membranes, in particular 
phosphatidylserine and phosphatidylethanolamine, appears to facilitate the cleavages at 
Arg506 and Arg306.197,198,200,206,345 Cleavage at Arg506 occurs first and is kinetically most 
favoured leading to formation of an intermediate form of FVa. This form has been reported 
to exert approximately 40% of intact final FVa cofactor activity.345 Although the subsequent 
cleavage at Arg306 site is ~20-fold slower, it results in a significant reduction of FVa affinity 
for both FXa and prothrombin, when combined with the cleavage at Arg506.345,348,349 
Whether complete inactivation of FVa is achieved following Arg506 and Arg306 cleavages 
(while the A2 domain remains partially intact) or only after a complete dissociation of the A2 
domain, is still uncertain.348,350 Several studies have reported FVa protection from the APC-
mediated proteolytic inactivation when it is bound to FXa201,211,351,352 and prothrombin.353,354 
Interestingly, interaction with FXa specifically reduces FVa cleavage by APC at Arg506 site by 
about 20-fold, while at the same time it can stimulate APC cleavage at Arg306.201,211,355 
Direct binding of prothrombin to FVa prevents APC-mediated cleavages at Arg506 as well as 
at Arg306. Inactivation of FVIIIa, on the other hand, is not affected by prothrombin 
binding.354,355 
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Figure 1.17 Schematic representation of the APC-mediated inactivation of FVa. 
Upon the propagation stage of coagulation, APC cleaves FVa at positions R306, R506 and R679. Resulting FV 
molecule (FVi) becomes disintegrated and consequently losses its functions. 
1.4.6 The role of FV in disease 
The physiological significance of FV and its isoforms is indisputable. A single point missence 
R506Q in FV (FV Leiden) results in a phenotype known as APC resistance, comprising the 
most common hereditary risk factor of venous thrombosis.356-359 The mutation affects one 
of the key target sites for the APC-mediated inactivation of FVa, resulting in impaired 
efficiency in degradation of FVa and thus increasing thrombin formation. In addition, the FV 
cofactor function for the APC-catalysed inactivation of FVIIIa has been shown to be affected 
by FV Leiden.213,215,360 Surprisingly, in the presence of high concentrations of protein S and 
FXa, the APC-mediated inactivation of activated FV Leiden was comparable to normal 
FVa.201 Although the FV Leiden mutation confers only a mild to moderate risk of thrombosis, 
the APC resistance contributes to the hypercoagulable state in patients with thrombosis, 
predominantly in combination with other genetic or acquired risk factors. Thrombotic 
predispositions were noted in mice expressing FV Leiden combined with heterozygous TFPI 
deficiency.135 The importance of FV in blood clotting was also demonstrated in FV-deficient 
mice suffering from haemorrhage and death.361 
On the other hand, humans with reduced plasma FV levels and thus low FV clotting activity, 
usually resulting from missence mutations within the FV gene, often demonstrate relatively 
mild bleeding tendencies.362-365 For instance, a rare autosomal recessive bleeding disorder 
termed parahaemophilia characterises in the absence or very low FV function and/or 
antigen levels.366 Having nearly undetectable FV concentrations, patients express bleedings 
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described as occasional mild to severe.367 Mutations within genes LMAN1 and MCFD2 
encoding for proteins facilitating FV and FVIII expression have been linked to combined FV 
and FVIIIa deficiency.368 Also development of inhibitory antibodies against FV,369,370 
enhancing proteolysis of platelet FV in the Quebec platelet disorder and reducing platelet FV 
concentrations in the FV New York disorder,371 have been linked to moderate bleeding 
phenotypes. Furthermore, in 2001, a moderately severe autosomal dominant bleeding 
disorder was described in east Texas. The affected individuals exhibited decreased 
coagulation despite normal concentrations of the coagulation factors.372 This inherited 
bleeding tendency has been linked to an A2440G variant in exon 13 of the FV gene leading 
to an in-frame deletion of 702 amino acids of the B domain and ultimately resulting in 
formation of the alternatively-spliced FV termed FVshort, which I discussed in sections 1.4.2 
and 1.4.4.2.2.307,373 As explained in previous sections, this truncated isoform of FV was 
recently shown to form a complex with TFPI and increase plasma TFPI levels by about 10-
fold. The authors proposed alterations in TFPI clearance through stabilising effects of 
FVshort binding, thereby providing explanation for the bleeding phenotype observed in 
A2440G carriers.307 Interestingly, while FVIII and FIX mutations confer severe bleeding when 
the normal FV gene is present, haemophiliacs (type A or B) heterozygous for the FVR506Q 
mutation are more protected from bleeding episodes.374,375 Resulting prolonged activity of 
FVa most likely compensates for reduced concentrations and functions of the procoagulant 
FVIIIa.  
To sum up, recent observations lay the groundwork for understanding of the molecular 
mechanisms behind the formation and function of various forms of FV, potentially enabling 
their modification and control. Since FV exerts multiple pro- and anticoagulant motifs, it 
represents a prospective target for anticoagulant treatments as well as therapies preventing 
bleeding. 
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1.5 Aims of my thesis 
TFPI is crucial in regulating haemostasis. While TFPI on its own is a poor inhibitor of FXa, 
protein S greatly enhances its anticoagulant activities.31 Deficiencies in TFPI and protein S 
have been suggested to contribute to the pathogenesis of thrombotic disorders.228 Although 
considerable knowledge of the physiological and clinical relevance of protein S activities is 
available, there is still much to be discovered regarding the molecular mechanisms behind 
its TFPI cofactor function.  
Recently, glutamic acid 226 residue within the Kunitz 3 domain in TFPI was shown to be 
essential for the interaction and enhancement of TFPI by protein S.230 The primary aim of 
my thesis was to fully delineate the mechanism underlying the enhancement of TFPI 
anticoagulant activity in the initiation phase of coagulation by protein S, through defining 
the binding site on protein S for TFPI interaction and enhancement. To identify this 
complementary functional interaction site on protein S, I have screened 44 protein S 
variants for the enhancement of TFPI-mediated inhibition. Wild-type (WT) protein S and 
protein S variants were expressed in human embryonic kidney fibroblast (HEK) cells and 
purified, as required. The functional cofactor activity of protein S mutants towards TFPI 
anticoagulant activities was evaluated and compared to that of WT protein S in various 
functional assays including calibrated automated thrombography (CAT) and FXa inhibition 
assays. Direct binding studies using SPR were utilised to study protein S interaction with 
TFPI. 
TFPI has recently been shown to bind to FV,342 FVa,121 FVa*,106 and to an alternatively-
spliced FV variant, FVshort.307 The interaction between TFPI and FVshort has been linked to 
the augmented anticoagulant activity of TFPI, resulting in increased bleeding.307 TFPI also 
inhibits the prothrombinase complex by directly binding to FVa*.106 The effects of TFPI 
interactions with FV or FVa upon the anticoagulant activities of TFPI has not been 
characterised to date. Therefore, the second objective of my project was to further assess 
FV function in the TFPI pathway and to study whether it affects TFPI cofactor function of 
protein S. For this, TFPI and FV were expressed in HEK cells and baby hamster kidney (BHK) 
cells, respectively. I kinetically evaluated the effects of the presence of FV upon the TFPI-
65 
mediated and TFPI/protein S-mediated inhibition of FXa. Direct interactions between TFPI, 
protein S and FV were assessed using a co-immunoprecipitation approach. 
Ultimately, the goal of my work was to provide a detailed understanding of how three 
haemostatic proteins interact to regulate production of FXa. Such profound knowledge may 
enable more effective control of the initiation phase of coagulation. I believe that 
appreciation of these molecular mechanisms may indeed provide opportunities for 
improved regulation of thrombotic disorders or novel treatments of haemophilia. 
66 
2. METHODOLOGY
A schematic overview of the experimental methods employed during this project is shown 
in Figure 2.1. 
Figure 2.1 Overview of the methodology of this thesis. 
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2.1 Materials 
A pcDNA6/protein S vector containing the cDNA for the WT protein S sequence had 
previously been generated by Dr Suely Rezende.376 A panel of 37 protein S variants 
containing composite or single amino acid substitutions spanning the Gla-TSR-EGF1-EGF2-
EGF3-EGF4 domains were generated by my colleagues through site directed mutagenesis 
(KOD Hot Start DNA polymerase kit; Novagen) using the pcDNA6/WT protein S vector as a 
template and mutagenic oligonucleotide primers (Thermo Scientific).161,175 The cDNA for 
three previously described protein S/Gas6 chimeras were a kind gift from Prof Björn 
Dahlbäck. In these, either the whole SHBG-like domain (Val243-Ser635; chimera III), or its 
individual LG1 (Ser283-Val459; chimera I) or LG2 (Ser460-Ser635; chimera II) subunits, were 
replaced by the corresponding domains of the homologous Gas6.182,222 All mutations (Table 
2.1) were previously verified by DNA sequencing, and their locations within the protein S 
molecule are visualised in Figure 2.2. The vectors containing WT or mutant protein S were 
either transiently or stably transfected into HEK293T or HEK293 cells (ATCC), respectively, 
followed by expression in the presence of vitamin K as described in further sections. The 
Gla-TSR-EGF1-EGF2-EGF3-EGF4 protein S variants were expressed and quantified previously, 
whereas WT protein S, protein S/Gas6 chimeras were expressed and quantified during this 
study. 
A mammalian expression vector pcDNA3.1 containing WT TFPI cDNA was previously 
available.230 TFPI was transiently transfected into HEK293T cells. 
The pED expression vector containing WT TFPI cDNA was a kind gift from Dr Rodney 
Camire.308 BHK cell line stably expressing WT FV was created by my colleague Dr Helena 
Andersson. The vector expressing WT FV was also used as a template to generate FV 
R506Q/R679Q by Dr Josefin Ahnström, and stably expressed in BHK cells. 
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Table 2.1 Protein S variants investigated during this thesis. 
Protein S variants, containing mutations within Gla-EGF1-EGF2-EGF3-EGF4, were transiently expressed in 
HEK293T cells and quantified in media prior to this work. Protein S/Gas6 chimeras comprising substitutions 
within the protein S SHBG domain were stably expressed in HEK293 cells, purified and quantified during this 
project.  
Protein S domain Amino acid substitution(s) 
Gla 
Face1 (N33S/P35T/E36A/Y39V) 
Single point variants: N33S, P35T, E36A, Y39V  
GLA2 (L21T/N23S/K24Y/R28F/D34S/Y41W/L45T) 
TSR/EGF1 TSR1 (R49Q/R60Q/D68N/R70Q/D78N) 
TSR N74A 
Gla/TSR/EGF1 GLA1 (D38N/V46G/K97Q) 
EGF1 
NEDM (N86A/E87Q/D88A/M91A) 
KTK (K94A/T103A/K105A) 
Single point variants: D78A, Q79A, K94A, D95A, K97A, S99A, T101A, 
T103A, K105A, P106A, W108A, Q109A, E111A, K112A,  
EGF2 
Single point variants: D135A, T137A, Y141A, H142A, S144A, K146A, 
S153A, N154A, K155A, K156A, D157A  
EGF3 DEEE (D182N/E184Q/E186Q/E189Q) 
EGF3/4 REDD (R192Q/E201Q/D202N/D204N) 
EGF4 
DK (D227N/K233Q) 
KK (K229Q/K230Q) 
DKE (D237N/K239Q/E242Q) 
SHBG 
Chimera I (Protein S Ala1-Phe282; Gas6 Val272-Val451; Protein S 
Ser460-Ser635) 
Chimera II (Protein S Ala1-Val459; Gas6 Gly452-Ala630) 
Chimera III (Protein S Ala1-Glu242; Gas6 Asp231-Ala630) 
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Figure 2.2 Molecular visualisation of protein S variants studied during this thesis. 
Protein S variants comprising either point, composite or domain substitutions (highlighted in red) spanning the 
whole protein S, were evaluated for their TFPI cofactor function. The protein S Gla-TSR-EGF1, EGF3-EGF4 and 
the SHGB-like domain models are adapted from Villoutreix et al./Giri et al., Drakenberg et al., and Villoutreix et 
al., respectively.
154-156,158
 
2.2 Protein expression 
2.2.1 Transformation of competent cells and DNA MaxiPreps 
Competent cells (One shot TOP10; Invitrogen) were transformed with a mammalian 
expression vector pcDNA 3.1 containing WT TFPI cDNA or protein S/Gas6 chimeras I-II-III 
according to the manufacturer’s instructions. For this, 50μl of cells were thawed on ice and 
incubated with 1μl DNA for 20 minutes. Cells were then heat-pulsed in a water bath at 42°C 
for 30 seconds and placed on ice for an additional 2 minutes. Transformed bacteria were 
grown in 0.25-0.5ml of preheated S.O.C. medium at 37°C for 1 hour with shaking. 
Transformed bacteria were subsequently plated out on a 20ml Luria-Bertani medium (LB) 
agar (Invitrogen) plate containing 100 μg/ml ampicillin and incubated at 37°C overnight. 
Ampicillin-resistant clones were picked and grown initially in 5ml LB broth (Invitrogen) with 
100 μg/ml ampicillin for ~8 hours and then in 200mL over night at 37°C with shaking. The 
plasmid was extracted using the MaxiPrep kit (OMEGA Bio-Tek) according to the 
manufacturer’s instructions. DNA concentrations were determined by measuring the 
absorbance at 260nm using a NanoDrop spectrophotometer (Thermo Scientific). 
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2.2.2 Mammalian cell culture 
2.2.2.1 HEK293 and HEK293T cells 
HEK293 and HEK293T cells were cultured in the humidified incubators at 37°C, 5% CO2, in 
complete media containing minimum essential media (MEM; GIBCO or SIGMA) 
supplemented with 10% foetal bovine serum (FBS; Invitrogen), 1x non-essential amino acids 
(Invitrogen), 2mM L-glutamine (Invitrogen), 1U/mL penicillin and 0.1mg/mL streptomycin. 
Cells were grown in T175 flasks (VWR) and, when 70-80% confluent, washed with 10 
ml/T175 flask of phosphate buffered saline (PBS; 10mM phosphate buffer, 2.7mM 
potassium chloride, 137mM sodium chloride), then split 1:3 using 1.5ml 1x trypsin-EDTA 
solution (Sigma) per T175 flask. Once cells detached, trypsin was stopped by adding 5mL of 
complete MEM media.  
2.2.2.2 BHK cells 
BHK cells were cultured in the humidified incubators at 37°C, 5% CO2, in complete media 
containing DMEM/F12 with phenol-red (Invitrogen) supplemented with FBS, non-essential 
amino acids, L-glutamine, penicillin, streptomycin and 100 mg/L CaCl2. Cells were grown in 
T175 flasks until 70-80% confluent, washed with PBS, and split using Trypsin as described in 
section 2.2.2.1. 
2.2.2.3 Cryopreservation and revival of mammalian cells 
Cells were cryopreserved in liquid nitrogen. When confluent, cells were washed with PBS 
and trypsinised as usual and diluted in 10mL of complete media. Cells were centrifuged at 
1200 rpm at room temperature (RT) for 5 minutes, the supernatant was discarded and cells 
were resuspended in 3 ml of FBS supplemented with 10% dimethyl sulfoxide (DMSO). 
Instantly, cells were aliquoted in 1ml cryo-vials and stored in a cryo-freezing container 
(Nalgene) at -80°C for 3-12 hours prior to being transferred to liquid nitrogen. 
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To revive cryopreserved cells, vials were thawed at 37°C and cells were immediately added 
to 20mL complete media in T75 flask (VWR).  
2.2.3 Expression of protein S 
2.2.3.1 Stable transfection of HEK293 cells 
Heterogeneous stable HEK293 cell lines expressing WT protein S and the Gla-TSR-EGF1-
EGF2-EGF3-EGF4 protein S mutants have been generated prior to my studentship. 
Heterogeneous stable HEK293 cell lines expressing protein S/Gas6 chimeras were produced 
during this project. Cells were seeded in a 6-well plate in complete MEM medium and grown 
until reaching 85-95% confluence. For transfection, 10μL Lipofectamine 2000 (Invitrogen) 
and 4μg protein S DNA were individually diluted in 250μL MEM media. Following a 5-minute 
incubation, DNA mix was added drop-wise to the Lipofectamine mix and allow to further 
incubate for 5 minutes at room temperature. The resulting transfection mixture was 
dispensed in various volumes (50-500μL) over the cells covered with 2.5mL of MEM 
medium. Cells were then incubated at 37°, 5% CO2 for 4-6 hours, after which the medium 
was removed and replaced with complete medium supplemented with 10 μg/ml of Vitamin 
K (Roche). Following 24 hours cells were split 1:10 and seeded in complete MEM media 
containing 450μg/mL of selection reagent, G418 (CALBIOCHEM), and cultured for ~3 weeks. 
2.2.3.2 Protein S expression and harvesting 
Protein S was expressed in 10-12 T175 triple flasks (VWR) in OptiMEM reduced serum-
medium (GIBCO or Invitrogen) supplemented with penicillin/streptomycin, 10 μg/ml of 
Vitamin K and 100 mg/L CaCl2 for 60-72 hours. The conditioned medium containing protein 
S was collected after 60-72 hours of protein expression centrifuged and/or filtered through 
nitrocellulose 0.45µm membrane filters (Millpore) to remove remaining cell debris and 
concentrated to 50mL (15-18 times) using a tangential flow filtration system (TFF; Millipore) 
with a 10kDa cut-off membrane. Following this, protein S was directed for purification 
(section 2.3.1). 
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2.2.4 Expression of TFPI 
2.2.4.1 Transient transfection of HEK293T cells 
To express TFPI, HEK293T cells were cultured in complete MEM media in 10 T175 triple-
flasks until 70% confluent. For each flask, 385.2μl (1 mg/ml) of linear polyethylenimine (PEI) 
(Polysciences,Inc) were diluted in 3.36 ml of 0.15 M autoclaved NaCl and added to 3.48 ml of 
0.15 M autoclaved NaCl containing 107μg DNA and incubated for 20 minutes at RT. The 
resulting DNA-PEI solution was added to 75ml OptiMEM supplemented with 100 mg/L CaCl2. 
Cells were washed with PBS and the transfection mixture was added. 
2.2.4.2 TFPI expression and harvesting 
Media expressing TFPI was harvested after 60-72 hours and it was either dialysed and 
concentrated further, or directed for purification. For TFPI media samples, concentrated 
conditioned media was buffer-exchanged against 3L and 5L of 20mM Tris 
(tris(hydroxymethyl)aminomethane)-HCl pH 7.4, 150 mM NaCl for 1.5 hours at RT and 12 
hours at 4°C, respectively. Subsequently, TFPI in media was concentrated using Amicon 
Ultra centrifugal filter devices (Millipore) with a cut off of 10 kDa, aliquoted and stored at -
80°C. 
2.2.5 Expression of FV 
2.2.5.1 Stable transfection of BHK cells 
Stable BHK cell lines expressing WT FV have been generated prior to this thesis. Stable BHK 
cell line expressing FV R506Q/R679Q was produced as a part of this work. For this, BHK cells 
were cultured in a T75 flask in complete medium excluding calcium. When confluent, cells 
were split and mixed with 9mL of media. Different volumes (0.5-1.5 mL) of the slurry were 
added to the wells of a 6-well plate containing 5mL of media, and incubated at 37°, 5% CO2 
for 7-12 hours. For transfection, 10μL Lipofectamin and 4μg of FV DNA were individually 
diluted in 250μL DMEM/F12 supplemented with L-glutamine. Following a 5-minute 
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incubation, DNA mix was added drop-wise to the Lipofectamine mix and allow to further 
incubate for 5 minutes at room temperature. The resulting transfection mixture was gently 
dispensed over the cells of 40-50% confluence covered with 2.5mL of transfection media. 
Cells were then incubated at 37°, 5% CO2 for 4-12 hours. Next, cells were split and mixed 
with complete media supplemented with 450μg/mL G418, and 0.5-1mL of slurry was 
dispensed to 9.2cm Petri dishes, each containing additional 10mL of selection media. Media 
was changed twice every 3 days for ~2 weeks until colonies became visible. About 15 
colonies were picked and resuspended in 1mL of selection media, and distributed in a 48-
well plate. When confluent, media was harvested and assessed for the protein expression 
using dot blot (described in section 2.4.3). The colonies with the highest FV expression were 
maintained and expressed in a large scale. 
2.2.5.2 FV expression and harvesting 
FV was expressed in 15 T175 triple flasks in DMEM/F12 without phenol red supplemented 
with penicillin/streptomycin, 100 mg/L CaCl2, 1.5 mg/mL albumax, 4.2 mg/mL insulin, 3.8 
mg/mL transferrin and 5 μg/mL sodium selenite (ITS; Roche). FV conditioned media was 
harvested following a 60-72 hour expression and immediately supplemented with protease 
inhibitors: 50μM amidinophenylmethanesulfonyl fluoride hydrochloride (APMSF; Sigma-
Aldrich), 10mM benzamidine (Sigma-Aldrich). Also, 20mM Tris, pH 7.4 was added and the 
media was centrifuged to remove cell debris. The media was then directed for purification 
(section 2.3.4). Alternatively, FV-expressing media was concentrated on TFF, followed by a 
concentration using spin columns with a 100kDa cut-off. Following the first harvest, FV was 
re-expressed and media was harvested additional 2-4 times every 24 hours. 
74 
2.3 Protein purification 
2.3.1 Purification of protein S 
2.3.1.1 Barium citrate precipitation 
Protein S was partially purified by barium citrate precipitation. Media previously 
concentrated using TFF, was divided into two 50ml tubes, each containing 25ml media, and 
incubated on ice. 1.13ml of 0.5M trisodium citrate (C6H5Na3O7) was added to each sample 
and incubated on ice for 10 minutes. Following this, 1.13ml of 1M barium chloride dihydrate 
(BaCl2) was added to each sample, media was vortexed, incubated on ice for 1 hour and 
centrifuged at 5000 x g at 4°C for 15 minutes. The pellet was resuspended in 25ml of 0.1M 
BaCl2/0.1M NaCl, incubated on ice for 1 hour and centrifuged as before. The pellet was 
resuspended in 25mL of 0.15M sodium citrate, 20mM Tris-HCl pH 7.4 and 150mM NaCl. 
Precipitated protein was buffer-exchanged against 3L and 5L of 20mM Tris-HCl pH 7.4, 
150mM NaCl (TBS) for 1.5 hours at RT and 12 hours at 4°C, respectively. Small aliquots were 
collected from each step for further analysis. 
2.3.1.2 Weak anion exchange chromatography 
Barium citrate precipitated protein S was further purified on a 5ml HiTrap diethylaminoethyl 
(DEAE) cellulose Sepharose fast flow anion exchange column (GE Healthcare). All buffers 
were filtered through 0.45µm nitrocellulose membrane filters prior to the purification 
procedure. The column was equilibrated with TBS. The sample was loaded onto the column 
at 1-1.5 ml/minute and protein S was eluted with a 0-30mM CaCl2 gradient. Following 
elution, the column was stripped of remaining proteins with 20mM Tris-HCl pH 7.4, 1M 
NaCl, 50mM CaCl2 or 2M NaCl, cleaned with dH2O and stored in 20% ethanol at 4°C. Small 
aliquots were collected throughout the entire purification procedure and protein S purity 
was assessed by Western blotting and silver staining. Elution fractions containing pure 
protein S were pooled and concentrated further on a spin column with a 30 or 50kDa cut-
off, aliquoted and stored at -80°C. 
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2.3.2 Purification of C4BP 
Plasma purified C4BP (Complement Technologies, Inc.), was further purified to remove non-
covalently bound protein S using size exclusion chromatography. All buffers were filtered 
through 0.45µm nitrocellulose membrane filters prior to the purification procedure. Briefly, 
C4BP was incubated in 3M guanidine and 20mM Tris, pH 7.4 for 1 hour at room 
temperature and separated from protein S using a 120mL HiPrep 16/60 Sephacryl S-300 HR 
column (GE Healthcare) that was previously equilibrated with 1.5 column volumes (CVs) 
with the same buffer. Fractions containing C4BP were pooled and concentrated on a spin 
column with a 100kDa cut-off, aliquoted and stored at -80°C. The column was cleaned with 
deionised water and stored in 20% ethanol at 4°C. The purity of C4BP was assessed by 
evaluating the presence of protein S in the eluted peaks using western blotting (described in 
section 2.4.3). 
2.3.3 Purification of TFPI 
2.3.3.1 Heparin affinity chromatography 
TFPI was purified on a 5mL HiTrap Heparin HP column (GE Healthcare). All buffers were 
filtered through 0.45µm nitrocellulose membrane filters prior to the purification procedure. 
Following column equilibration with TBS, TFPI containing media, previously concentrated 
using TFF, was loaded onto the column at flow rate of 2mL/minute. After washing with TBS 
TFPI was eluted with a 15 CV linear NaCl gradient (0.15-2M) in 20mM Tris, pH 7.5. All elution 
fractions were collected and 2 TFPI ELISAs were used to determine the presence of full-
length and truncated TFPI (protocol in section 2.4.4.2). The column was cleaned with dH2O, 
and stored in 20% ethanol at 4°C. 
2.3.3.2 Antibody affinity chromatography 
The elution fractions from heparin affinity chromatography containing full-length TFPI and 
not cleaved forms, were pooled and purified further on a 1mL HiTrap TM NHS HP column 
(GE Healthcare) coupled with 2mg/mL of monoclonal antibody against human TFPI Kunitz 1 
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domain (Sanquin) according to the manufacturer’s instructions. Briefly, the antibody was 
dissolved in coupling buffer (0.2M NaHCO3 0.5M NaCl, pH8.3) and applied onto the column 
previously washed with ice-cold 1mM HCl, at a flow-rate of 1mL/min. The column was 
sealed and incubated at room temperature for 30 minutes. To remove non-specifically 
bound ligands and deactivate any excess of active groups which were not coupled to the 
ligand, the column was washed with the equilibration buffer and stored in TBS.  
All buffers were filtered through 0.45µm nitrocellulose membrane filters prior to the 
purification procedure. The column was equilibrated with TBS. Sample was loaded onto the 
column at flow rate of 0.5-1 ml/minute and following a wash with TBS, TFPI was eluted with 
0.1M Glycine, pH 2.7. Physiological pH of the eluate containing TFPI was immediately 
restored by addition of 1M unbuffered Tris. Due to the limited capacity of the column, the 
flow-through from the loading step was re-applied and purified until no elution peak could 
be observed. Once the purification was completed, the column was regenerated with 3M 
guanidine and re-equilibrated with TBS and stored in TBS supplemented with 0.2% sodium 
azide at 4°C. All elution fractions containing pure TFPI were pooled and dialysed against TBS 
for 12h at 4°C, then concentrated on a spin column with a 10kDa cut-off, aliquoted and 
stored at -80°C. 
2.3.4 Purification of FV 
2.3.4.1 Strong cation exchange chromatography 
FV was purified on a 5ml HiTrap SP Sepharose FF cation exchange column (GE Healthcare). 
All buffers were filtered through 0.45µm nitrocellulose membrane filters prior to the 
purification procedure. The column was equilibrated with 20mM Tris-HCl pH 7.4, 0.15M 
NaCl, 5mM CaCl2, 4mM benzamindine. The sample was loaded onto the column (both 
placed on ice) at a flow rate of 4 ml/minute. The column was washed with the equilibration 
buffer and FV was eluted with 20mM Tris-HCl pH 7.4, 0.3M NaCl, 5mM CaCl2, 4mM 
benzamindine. Elution fractions containing FV were collected and stored at -80°C for a 
further purification step. The column was stripped of remaining proteins with 20mM Tris-
HCl pH 7.4, 2M NaCl, cleaned with dH2O, and stored in 20% ethanol at 4°C. 
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2.3.4.2 Strong anion exchange chromatography 
The purification alone was repeated with 3-4 individual harvests. The elution fractions 
(containing FV) were pooled and purified further on a 5mL HiTrap Q Sepharose FF anion 
exchange column (GE Healthcare). All buffers were filtered through 0.45µm nitrocellulose 
membrane filters prior to the purification procedure. The column was equilibrated with 
20mM Tris-HCl pH 7.4, 0.2M NaCl, 5mM CaCl2. The sample was loaded onto the column 
(both placed on ice) at flow rate of 2.5 ml/minute. Following washing with the equilibration 
buffer, FV was eluted with a 10 CV linear gradient into 20mM Tris-HCl pH 7.4, 0.7M NaCl and 
5mM CaCl2. The column was regenerated, cleaned and stored as described above for the SP 
column. Small aliquots were collected throughout the entire purification procedure and 
assessed for FV content using dot blot followed by Western blotting and silver staining. 
Elution fractions containing pure FV were pooled and concentrated further on a spin column 
with a 100kDa cut-off, aliquoted and stored at -80°C. 
2.4 Protein characterisation and quantification 
2.4.1 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under non-
reducing or reducing (3% dithiothreitol; DTT) conditions was performed to assess the 
presence and/or purity of protein S, TFPI, C4BP and FV. Samples diluted in 25% Nu PAGE LDS 
sample buffer (Life Technologies) were heated at 96°C for 5 minutes. Protein S, TFPI and FV 
electrophoresis was performed on 10 and 12% polyacrylamide in-house cast gels (Table 2.2), 
whereas C4BP and C4BP-bound protein S electrophoresis were run on 4-12% pre-casted 
Mini-Protean TGX gradient gels (Bio-Rad). All gels were run in 400mM glycine, 5mM SDS in 
50mM Tris at 200V. Precision Plus (Bio-Rad) and HiMarkTM Protein Standards (Life 
Technologies) were run in parallel to the samples for small to medium-size and for large 
proteins, respectively, to provide a reference for molecular weights. 
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Table 2.2 In-house SDS gel composition. 
10% SDS gel for protein S and TFPI electrophoresis comprised: PROTOGEL (National Diagnostics), Tris pH8.8, 
tetramethylethylenediamine (TEMED; Sigma), 20% SDS, 60% Sucrose, dH2O and ammonium persulfate (APS; 
Sigma). APS was added just before use and gel mixtures polymerised at RT. 
Running gel (10%) Stacking gel (3.7%) 
PROTOGEL 3.3ml 1.2ml 
2M Tris pH8.8 2ml ― 
0.5M Tris pH6.4 ― 1.4ml 
TEMED 5µl 10µl 
20% SDS 25µl 25µl 
60% Sucrose 2ml 2ml 
dH2O 2.67ml 5.365ml 
APS 50µl 50µl 
2.4.2 Native PAGE 
Protein S samples in native state were diluted 1:2 in a sample buffer for Native PAGE and 
run on 4-12% pre-casted gels at 100-150 V in 400mM glycine and 50mM Tris for 
approximately 40 minutes. NativeMarkTM Protein Standard (Invitrogen) was used in parallel 
for referencing molecular weights. 
2.4.3 Silver staining 
2.4.3.1 Silver staining of in-house SDS-PAGE gels 
In-house SDS-PAGE gels were silver-stained using buffers reported in table 2.3. For all steps, 
volumes of 50 ml of solution per gel were used and incubations were performed at RT with 
gentle shaking. Proteins were fixed with 40% ethanol and 10% acetic acid (buffer A) for 30 
minutes. Afterwards, the gel was incubated with 30% ethanol, sodium thiosulfate, sodium 
acetate and glutaraldehyde (buffer B) for 30 minutes, followed by a 3x20 minutes wash with 
dH20. Next, the gel was silver-stained with silver nitrate (buffer C) for 40 minutes and 
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developed with sodium carbonate and formaldehyde (buffer D). When sufficient colour 
developed, the reaction was stopped with EDTA (buffer E).  
Table 2.3 Buffers used in silver staining of in-house casted gels. 
Protein S and TFPI were silver-stained by incubating the gel with 50ml of freshly prepared buffers. 
Glutaraldehyde solution (Fluka) and formaldehyde solution (Sigma) were added shortly before use. 
Buffer Composition 
A 40% C2H6O, 10% CH3COOH 
B 
30% CH3COOH, 8.1mM Na2S2O3 · 5H2O 
512mM C2H3NaO2 or 500mM CH3COONa · 3H2O 
260µl of 25% CH2(CH2CHO)2 
C 5.9mM AgNO3, 20µl of 37% HCOH 
D 235mM Na2CO3, 15µl of 37% HCOH 
E 50mM Na2EDTA 
2.4.3.2 Silver staining of pre-casted SDS-PAGE gels 
Following the Native PAGE or SDS-PAGE using pre-casted gradient gels, proteins were silver-
stained according to the appropriate protocol (details provided in table 2.4). Volumes of 
50ml of solution per gel were used in all steps and incubations were performed at RT with 
gentle shaking. First, the gel was fixed with 50% methanol, 10% acetic acid (buffer A) for 30 
minutes and additional incubation was performed with 5% methanol (buffer B) for 15 
minutes. Afterwards, the gel was washed 3x5 minutes with dH2O and then incubated with 
sodium thiosulphate (buffer C) for 2 minutes. Following 3x30 seconds wash with dH2O, the 
gel was silver-stained with silver nitrate (buffer D) for 25 minutes. Next, the gel was washed 
3x1 minute with dH2O and developed with sodium thiosulphate, sodium carbonate and 
formaldehyde (buffer E). When sufficient colour developed, the reaction was stopped with 
EDTA (buffer F). 
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Table 2.4 Buffers used in silver staining of pre-casted gels. 
FV was silver-stained by incubating the gel with 50ml of freshly prepared buffers. Formaldehyde solution was 
added shortly before use.  
Buffer Composition 
A 50% CH3OH, 10% CH3COOH 
B 5% CH3OH 
C 1.26mM Na2S2O3 · 5H2O 
D 11.8mM AgNO3 
E 283mM Na2CO3, 1 ml solution C, 25μl of 37% HCOH 
F 37.6mM Na2EDTA 
2.4.3 Western Blotting 
Proteins separated on polyacrylamide gels were transferred onto a Hybond-ECL 
nitrocellulose membrane (Amersham Biosciences) in a transfer buffer containing 25mM Tris, 
190mM glycine, 20% methanol. Protein S and TFPI transfers were run at either at 25V for 7 
minutes in the Trans-Blot Turbo transfer system (Bio-Rad) or at 35V for 1 hour in the XCell II 
Blot module (Invitrogen), whereas transfers of FV were run at 35V for 1.5-2 hours in the 
XCell II Blot module. Following the transfer, membranes were blocked with 3% bovine 
serum albumin (BSA; Sigma or Santa Cruz) diluted in suitable dilution buffer for 30-45 
minutes. Proteins of interest were specifically detected (Table 2.5) with a primary antibody 
diluted in a suitable dilution buffer supplemented with 0.5% BSA for 1 hour at RT or 
overnight in 4°C. Following a 3x 5 minutes wash with an appropriate dilution buffer 
substituted with 0.1% Tween 20, the membrane was incubated with a secondary HRP 
(horseradish peroxidise)-conjugated antibody diluted in a suitable dilution buffer 
supplemented with 0.5% BSA for 45-60 minutes at RT or overnight in 4°C. All incubations 
were performed with gentle shaking. Following the second wash, membranes were treated 
with the chemiluminescent HRP substrate Immobilon (Millipore) for 5 minutes and 
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developed either on an Amersham Hyperfilm ECL (GE Healthcare) in a darkroom emitting 
red safelight, or using a C-DiGit blot scanner (LI-COR). 
Table 2.5 Antibody dilutions used for Western blotting. 
Protein S, TFPI and FV were specifically detected with a primary antibody recognizing the protein of interest, 
followed by a secondary antibody conjugated with HRP (all diluted in suitable buffers supplemented with 0.5% 
BSA). TBSCa
2+
, TBS supplemented with 3mM CaCl2.
Protein 1° antibody 2° antibody Dilution buffer 
protein S 1:7000 polyclonal rabbit anti-
protein S (DAKO) 
1:10 000 goat anti-rabbit 
(DAKO) 
PBS 
TFPI 1:200 polyclonal rabbit anti-
TFPI (Santa Cruz) 
1:10 000 goat anti-rabbit 
(DAKO) 
PBS 
FV 1:500 polyclonal sheep anti-
FV (Cambridge Biosciences) 
1:160 000 monoclonal 
mouse anti-sheep (Sigma) 
TBSCa2+ 
2.4.4 Protein quantification using ELISA 
2.4.4.1 Protein S ELISA 
The molar concentration of purified protein S or protein S in concentrated conditioned 
media was determined using a previously optimised in-house enzyme-linked 
immunosorbent assay (ELISA). A 96-well Nunc Maxisorp microplate (Nunc TM) was coated 
with 100µL/well of 1 μg/ml of polyclonal rabbit anti-human protein S antibody in 50mM 
sodium carbonate buffer pH 9.6 at 4°C overnight. All subsequent incubations were carried 
out at RT and wells were washed 3 times with 250μl/well of TBSCa2+ supplemented with 
0.1% TWEEN 20 (TBSTCa2+) between each incubation step. Wells were blocked with 
200µL/well of TBSCa2+, 2% BSA for 2 hours. 100µL/well of protein S samples and a standard 
curve, 0-2nM plasma purified protein S (Enzyme Research Laboratories; ERL) were diluted in 
TBSCa2+, 0.5% BSA and incubated in wells for 1 hour. Bound protein S was detected with 100 
µL/well of 4nM monoclonal mouse anti-protein S antibody (HTI) followed by 100 µL/well of 
8nM polyclocnal goat anti-mouse HRP-conjugated antibody (DAKO), both diluted in the 
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sample buffer and incubated in wells for 1 hour. The plate was developed with 100 μl/well 
of chromogenic substrate o-phenylenediamine dihydrochloride (OPD; Sigma) diluted in 
dH2O. Once sufficient colour developed, the enzymatic reaction was stopped with 50 μl/well 
of 3.2M sulphuric acid and the absorbance was read at 492nm with μQuant microplate 
spectrophotometer (BioTek). Data was analysed with GraphPad Prism4 where data points 
were fitted to a sigmoidal dose response curve. The intra assay variability was determined 
from the coefficient of variation between 2 different dilutions of the same sample, whereas 
the inter assay variability was determined from the coefficient of variation obtained for the 
same sample in 3-5 different ELISAs. 
2.4.4.2 TFPI ELISA 
The molar concentration of purified TFPI or TFPI in concentrated conditioned media was 
determined using a previously optimised ELISA. A 96-well Nunc Maxisorp microplate was 
coated with 1µg/mL of anti-human Kunitz domain 2 antibody (Sanquin) or 5µg/mL of anti-
human TFPI C-terminus antibody (Sanquin), for detection of total TFPI and full-length TFPI, 
respectively. Wells were washed 3 times with PBS supplemented with 0.1% TWEEN 20 
(PBST) between each incubation step. Wells were blocked with PBS, 3% BSA for 2 hours. 
TFPI samples and a standard curve, 0-2nM of plasma purified TFPI (a kind gift from 
Chemoserotheraputic Institute Kaketsuken) were diluted in blocking solution and incubated 
in wells for 1 hour. Bound TFPI was detected with a biotinylated monoclonal anti-human 
Kunitz domain 1 antibody, 1 µg/mL and 5 µg/mL respectively, followed by 0.1 mg/L of HRP-
conjugated streptavidin 1:5000 (Thermo Scientific), all diluted in PBST, 0.5% BSA and 
incubated in wells for 1 hour. The plate was developed, the absorbance was read and the 
data was analysed as described previously for protein S ELISA. 
2.4.4.3 FV ELISA 
An in-house FV ELISA was developed to determine the molar concentration of FV in 
concentrated conditioned media. A 96-well Nunc Maxisorp microplate was coated with 
5μg/mL of polyclonal sheep anti-FV antibody. Wells were washed 3 times with TBSTCa2+ 
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between each incubation step. Wells were blocked with TBSCa2+, 3% BSA. FV samples and a 
standard curve comprising 0-10nM of plasma purified FV (HTI) were diluted in TBSCa2+, 0.5% 
BSA and incubated in wells for 1 hour. Bound FV was detected with 8nM of monoclonal 
mouse anti-FV antibody (HTI), followed by 16nM of polyclonal goat anti-mouse HRP-
conjugated antibody, both diluted in a sample buffer and incubated in wells for 1 hour. The 
plate was developed, the absorbance was read and the data was analysed as described 
previously for protein S ELISA. 
2.4.5 Protein quantification using A280 
The total protein concentrations of purified WT protein S and protein S/Gas6 chimeras and 
FV were quantified by measuring the absorbance at 280nm using a NanoDrop 
spectrophotometer. Beer-Lambert law for concentration c=A/ ε L with an extinction 
coefficient ε 1% 9.82 for WT protein S, ε 1% 10 for chimera I, ε 1% 9.51 for chimera II and ε 
1% 9.9 for chimera III were used. The ε values were derived based on the protein sequences 
using ProtParam Tool (ExPasy). Purified C4BP concentration was determined by absorption 
at 280nm using an extinction coefficient of 13.32.377 Purified WT FV concentration was 
determined by absorption at 280nm using an extinction coefficient of 9.6.309 
2.4.6 Quantification of C4BP containing a free β-chain using size-exclusion 
chromatography 
To assess the proportion of C4BP containing a β-chain, and thereby a protein S binding site, 
different nanomolar ratios of C4BP and WT protein S (33:20; 66:20 and 132:20) were mixed 
in TBSCa2+ supplemented with 0.1% BSA and incubated for 1 hour at room temperature. The 
protein S-C4BP samples and a sample containing only protein S were then loaded 
sequentially on a 24mL Superose 12 column GL (GE Healthcare) equilibrated with the 
sample dilution buffer. Elution fractions of 300μL were collected and the presence of free 
protein S was investigated using ELISA (protocol in section 2.4.4.1) and Western blotting 
(protocol in section 2.4.3). The % of C4BP containing free β-chain was calculated by 
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establishing the protein S-C4BP molar ratio where all protein S bound to C4BP and therefore 
was not detected by ELISA or Western blotting. 
2.4.7 Binding of protein S to domain-specific monoclonal antibodies 
To assess the integrity of the domain structure and folding of protein S/Gas 6 chimeras, 
their binding affinity to domain-specific monoclonal antibodies was assessed and compared 
to WT protein S in optimised ELISA-based assays. All incubation conditions and assay buffers 
were prepared and performed as previously described for protein S ELISA in section 2.4.4.1. 
A 96-well Nunc Maxisorp microplate was coated with 1μg/mL of domain-specific 
monoclonal antibodies recognising either Gla domain (MK21), EGF3/EGF4 (MK41), EGF1 
(MK54) or TSR (MK67). Following blocking, titrated protein S (0-15nM for MK41, 0-10nM for 
MK21 and MK54, and 0-1.5nM for MK67) was incubated in the plate for 1 hour. A 
monoclonal anti-protein S antibody (HTI) was biotinylated according to the manufacturer’s 
instructions and used for protein S detection. Following incubation with a HRP-conjugated 
streptavidin diluted 1:10 000, the plate was developed and the absorbance was read as 
described for protein S ELISA in section 2.4.4.1. Data was fitted to a one site binding 
hyperbola and the Kd(app) for protein S binding to the monoclonal antibodies were obtained. 
2.5 Functional assays 
2.5.1 Preparation of phospholipid vesicles 
Synthetic phospholipid vesicles (Avanti Polar Lipids Inc.) comprising 1,2-dioleoyl-sn-glycero-
3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPS), and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dissolved in chloroform were prepared 
in order to serve as a progoagulant surface in the functional assays.175 The phospholipid 
mixture composed of DOPC, DOPS and DOPE at a molar ratio of 60:20:20, respectively, was 
prepared and chloroform was removed under a nitrogen (N2) stream in a fume hood. 
Phospholipids were then resuspended in TBS and extruded by passage through a 0.1µm 
polycarbonate membrane (Whatman) 19≤ times to obtain a unilamellar composition. 
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Phospholipids of final concentration of 1.25mM were stored at 4°C for 3-5 days and used in 
functional coagulation assays. 
2.5.2 FXa generation assay 
2.5.2.1 Principle of FXa generation assay 
FXa generation assay was used to assess the protein S cofactor function towards TFPI in the 
inhibition of TF/FVIIa-mediated activation of FX.31,223 In this assay, FXa was generated by the 
TF/FVIIa-mediated activation of FX. After specific time points, the FXa generation was 
stopped by dilution in a buffer containing EDTA. To evaluate the concentration of FXa 
generated over time, the amount of FXa present in the samples was measured using a 
chromogenic substrate. The higher concentration of FXa, the faster cleavage of substrate 
occurs, leading to higher absorbance. The ability of TFPI and protein S to inhibit TF/FVIIa was 
determined by evaluating decrease in FXa generated. 
2.5.2.2 Enhancement of the TFPI-mediated inhibition of FXa generation by protein S 
The effect of TFPI and protein S on the inhibition of TF/FVIIa-mediated generation of FXa 
was assessed in a two-stage assay comprising purified components. 1pM TF (Dade Innovin, 
Dade Behring) was incubated with 5nM FVIIa (NovoSeven) and 25µM phospholipid vesicles 
in TBSCa2+ at 37°C. FXa generation was initiated by addition of 160nM FX (Haematologic 
Technologies Inc.) either in the presence or absence of 2nM TFPI, in the presence or absence 
of 100nM protein S, or in the presence of 2nM TFPI and titrated (0-100nM) protein S, or in 
the presence or absence of 2nM TFPI with addition of 100nM protein S supplemented with 
25µL of control media. At different time intervals (0, 30, 60 and 120 seconds), aliquots of 
the reaction were withdrawn and diluted 10-fold in ice-cold 20mM EDTA in TBS, 0.5% BSA. 
In the second stage, FXa concentrations were measured through determination of the 
cleavage of the chromogenic substrate S-2765 (Chromogenix; 400μM) at 405nm at one-
minute intervals for 20 minutes at room temperature. 
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2.5.3 CAT assay 
2.5.3.1 Principle of CAT assay 
The TFPI cofactor function of protein S was assessed by CAT using a Fluoroscan Ascent FL 
plate reader (Thermo Labsystem) and Thrombinoscope software (Synapse BV). CAT is a 
plasma-based assay that allows measurement of thrombin generation initiated by the 
addition of TF (Dade Innovoin). The amount of thrombin formed is determined by the 
measurement of the cleavage of a thrombin-sensitive fluorogenic substrate, Z-Gly-Gly-Arg-
AMC (Bachem) over time, which is quantified by reference to a standard thrombin calibrator 
(Diagnostics Stago UK Ltd). Based on the calibrated amount of thrombin activity, the 
concentration of thrombin generation over time can be calculated from the signal derived 
from the samples where thrombin generation occurs. A calibrator was used for each 
individual plasma to provide the correct reference. To ensure that the initiation of thrombin 
generation is specifically dependent on TF addition, contact activation is repressed by the 
addition of corn trypsin inhibitor (CTI), inhibiting FXIIa. The citrated plasma is supplemented 
with calcium to restore the functions of calcium-dependent coagulation factors, and 
phospholipids are added to the reaction to provide a surface for coagulation. Thrombin 
generation is described and quantified according to certain parameters such as lag time (the 
time to the burst of thrombin generation which usually approximates the clotting time), 
thrombin peak height (maximum velocity of thrombin generation), and the endogenous 
thrombin potential (ETP), which is the total amount of thrombin formation over time, 
represented by the area under the curve. 
Figure 2.3 Thrombin generation curve.  
A thrombin generation curve is displayed with the parameters including peak height, lag time and ETP. 
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2.5.3.2 TFPI cofactor function of protein S 
To assess the ability of protein S to act as cofactor for TFPI, thrombin generation was 
initiated in either normal plasma, in the in-house preparation of protein S-immunodepleted 
plasma described in section 2.5.3), in lypholised protein S-depleted plasma from Affinity 
Biological and Hyphen Biomed, or in frozen protein S-depleted plasma from Enzyme 
Research Laboratories, with 1pM TF, 50μM phospholipid vesicles and 16.6mM CaCl2. The 
amount of thrombin formed was monitored using 0.42mM of Z-Gly-Gly-Arg-AMC in the 
presence or absence of TFPI (0-5nM) and protein S (0-100nM). Protein S was added either as 
concentrated and dialysed conditioned media or as a purified protein. To inhibit contact 
activation, 30µg/ml or 65µg/ml of CTI was added per ml plasma in the screening 
experiments and in protein S titrations, respectively. A polyclonal antibody against protein S 
(2.8μM) and a mixture of 120nM of monoclonal antibodies against Kunitz 1 domain, Kunitz 2 
domain and C-terminus of TFPI (Sanquin) were used to assess the efficiency of the protein S 
immunodepletion and show that any effects from addition of protein S and TFPI were 
specific. Thrombin generation was evaluated as described in section 2.5.3.1 and all assays 
were performed at least two times. To compare the cofactor activity of WT protein S and 
protein S variants towards TFPI, the changes in peak height were measured.  
2.5.4 FXa inhibition assay 
2.5.4.1 Principle of FXa inhibition assay 
FXa inhibition assay was used to assess the protein S cofactor activity towards TFPI-
mediated inhibition of FXa activity.229,230 In this assay, the ability of TFPI to inhibit FXa and 
the enhancement of the TFPI anticoagulant activity by protein S is determined as a change 
in FXa activity measured through the FXa-specific substrate cleavage in time. The substrate 
hydrolysis is followed over time by measuring the absorbance at 405nm at one-minute 
intervals for 40-90 minutes at RT.  
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2.5.4.2 Enhancement of the TFPI-mediated inhibition of FXa by protein S, C4BP-bound 
protein S and FV  
To evaluate the protein S, C4BP-bound proteins or FV enhancement of the TFPI-mediated 
inhibition of FXa, FXa (0.5nM; Hyphen Biomed) activity was monitored by the cleavage of 
200μM of chromogenic substrate S-2765 (Chromogenix), in the presence or absence of TFPI, 
protein S, C4BP-bound protein S or FV, in the presence of 25μM phospholipids and 5mM 
CaCl2. Details regarding concentrations of the proteins and the conditions of their addition 
are provided in the Results section. 
2.5.4.3 Kinetic data analysis of the TFPI-mediated inhibition of FXa 
To assess the kinetics of the TFPI-mediated FXa inhibition, the progress curves of mA405 
were fitted according to the integrated rate equation:  
At = A0 + Vst + (V0 – VS)(1-exp(-kobst))/kobs 
where t represents time, At represents the absorbance at time point t, A0 the absorbance at 
time zero, V0 the initial velocity, VS the final steady state velocity of S-2765 conversion and 
kobs the apparent rate constant for the transition from V0 to VS. The V0 was determined using 
non-linear regression as previously described.31,229 To derive the concentration of protein S 
required to reach 50% of the maximal enhancement of TFPI-mediated inhibition of FXa 
(EC50), the initial velocity of the S-2765 cleavage was plotted against the protein S 
concentration and the EC50 values were derived by a one-phase exponential decay nonlinear 
curve fit.229,230  
The maximum initial velocity, Vmax, representing FXa conversion of S-2765 in the absence of 
TFPI, was obtained and divided by the initial velocities at each time point. The resulting 
Vmax/V0 values were then plotted against the TFPI concentration. The x intercept was 
determined by a linear regression fit and subsequently used to calculate the Ki value 
according to the following equation:  
Ki = -xintercept/(1+[S]/Km) 
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where [S] represent the concentration of the chromogenic substrate and Km, the Michaelis-
Menten constant, the concentration of substrate required to reach 50% of the maximal 
cleavage by FXa. 
Alternatively, Vmax was divided by the final velocities at each time point and the resulting 
Vmax/Vs values were plotted against the TFPI concentration, the intercept was obtained and 
used to derive the final inhibitory constant (Ki*). 
Details regarding concentrations of the proteins added into the particular assays are 
provided in the Results section. 
2.5.5 FVa inactivation assay 
2.5.5.1 Principle of FVa inactivation assay 
A FVa inactivation assay was used during this project to assess the enhancement of the APC-
mediated inactivation of FVa by protein S/Gas6 chimeras. Overall, FVa inactivation by APC is 
indirectly determined using a prothrombinase assay which relies on the amount of FVa that 
escaped inactivation by APC and its ability to form a complex with FXa in order to activate 
prothrombin required for thrombin formation. The amount of thrombin generated is 
measured by the rate at which it cleaves its chromogenic substrate S-2238 (Chromogenix).  
2.5.5.2 Activation of FV 
FV (1.336nM) was first activated by 0.5 U/mL of human thrombin (Enzyme Research 
Laboratories) in TBSCa2+ supplemented with 0.5% BSA at 37°C for 10 minutes to obtain FVa. 
The reaction was stopped by the addition of 1.5 U/mL of hirudin. To confirm the activation 
by thrombin, the cofactor activity towards FXa of FV and FVa was assessed using a 
prothrombinase assay as described in section 2.5.5.4. A FVa variant, R506Q/R679Q, was 
used to evaluate protein S-enhanced APC-mediated cleavage at Arg306. Mutations in FVa at 
Arg506 and Arg679 prevent their cleavage by APC, allowing evaluation of the cleavage at 
Arg306 specifically which is the main site enhanced by protein S. FV R506Q/R679Q was 
activated according to the same procedure as described for FV above. The activated FV 
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R506Q/R679Q served as a substrate for APC to evaluate the ability of protein S to enhance 
the APC-mediated cleavage of Arg306 of FVa (section 2.5.6.3). 
2.5.5.3 Inactivation of FVa 
In the FVa inactivation step, the activity of APC (enhanced by protein S) was evaluated. For 
this, protein S was incubated with APC, 25μM phospholipids and 0.8nM FVa R506Q/R679Q, 
5mM CaCl2, 5 mg/ml BSA in total volume of 50μL. The mixture was incubated at 37°C for 10 
minutes and the reaction was terminated by a 20-fold dilution in ice-cold TBSCa2+ 
supplemented with 0.5% BSA. The remaining FVa activity was measured in a 
prothrombinase assay described in section 2.5.5.4. The FVa inactivation was implemented 
to evaluate either the titrated (0-4nM) APC activity in the presence or absence of fixed 
amount of WT protein S (100nM), or to assess the APC (0.25nM) cofactor function of 
increasing amounts of protein S (0-100nM).  
2.5.5.4 Prothrombinase assay 
The prothrombinase assay was used to quantify the amount of FVa through its cofactor 
function of FXa in the activation of prothrombin to thrombin. FVa or FVa R506Q/R679Q was 
diluted 33 times, either straight after activation or after inactivation by APC and protein S 
resulting in a maximum concentration of 8pM. In detail, 50μl of the WT FVa or FVa 
R506Q/R679Q was incubated with 5nM FXa in the presence of 2mM CaCl2 and 50μM 
phospholipid vesicles at 37°C for 15 seconds. Following this, the reaction was initiated by 
the addition of 0.5μM prothrombin in a final volume of 125μl in TBS supplemented with 0.5 
mg/ml of ovalbumin, and incubated at 37°C for 2 minutes. All concentrations are final. The 
reaction was then stopped by a 5-fold dilution in ice-cold 50mM Tris-HCl pH 7.4, 100mM 
NaCl, 20mM EDTA, 1% PEG 6000. The samples were then diluted further (1 in 4) in the stop 
buffer. The amount of thrombin generated was measured by the cleavage of the 
chromogenic substrate, S-2338 (Chromogenix; 125μM), at 405nm for 20 minutes with 1-
minute intervals. The data was plotted with a linear regression fit and the slope value was 
obtained. To determine the enhancement of APC activity by protein S, the percentage of the 
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derived slope was plotted against the protein S concentration, where the activity of APC in 
the absence of protein S represents 100%. From the progress curves, the concentration of 
protein S required to reach 50% of the maximal enhancement of APC-mediated inhibition of 
FXa, EC50 values, were determined. To ensure that the FVa concentration used in the FVa 
inactivation assays lies within a linear range and the thrombin formation is fully dependent 
on this FVa, FVa was titrated (0-10pM), and its activity was assessed using a prothrombinase 
assay.  
2.6 Binding studies 
2.6.1 Co-immunoprecipitation 
2.6.1.1 Principle of co-immunoprecipitation 
Co-immunoprecipitation was used during this project to study direct protein-protein 
interactions in solution. For this, magnetic beads are coated with a covalently-attached 
antibody directed against the ligand of interest. Conjugated beads are incubated with the 
ligand, and based on the protein-antibody affinity, the ligand binds to the antibody on the 
beads (immunoprecipitation). Any additional protein present in the sample able to form a 
complex with the ligand, will co-immunoprecipitate. All proteins bound to the beads can be 
eluted by low pH or change of ionic strength resulting in protein unfolding and breakage of 
the non-covalent bonds. After restoring the physiological pH with addition of unbuffered 
Tris, the antibody re-folds and the conjugated beads can be reused. 
2.6.1.2 Protein S binding to TFPI 
To evaluate the ability of protein S variants to interact with TFPI in media, tosylactivated 
magnetic beads (Invitrogen) were coated with a monoclonal anti-human Kunitz 1 antibody 
according to the manufacturer’s instructions. The beads were blocked with 2% BSA in 
concentrated control media. The mixture was stirred gently for 30 minutes at RT on a 
rotating unit (Clifton). 50nM TFPI and 40nM protein S, both in concentrated media were 
diluted further in 150µL concentrated control media and pre-incubated at RT for 25 
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minutes. Subsequently, the beads were incubated with the samples for 20 minutes. 
Following two washes (600μL) with TBSCa2+ supplemented with 2% BSA, beads were eluted 
with 50µL 0.1M glycine, pH 2.7. The physiological pH of the eluate was restored with 2.5µL 
1M unbuffered Tris. Subsequently, the sample analysis was carried out using SDS-PAGE 
followed by western blotting by detecting protein S and TFPI with polyclonal antibodies as 
described in section 2.4.3. The ability of protein S variants to co-immunoprecipitate with 
TFPI was assessed and compared to WT protein S using above approach. Following two 
series of independent screenings of all available protein S mutants, the intensity of the 
bands on western blots were analysed with MacBiophotonics ImageJ software and plotted 
as a percentage of co-immunoprecipitation with TFPI, where co-immunoprecipitated WT 
protein S represents 100%.  
2.6.1.3 Protein S and FV binding to TFPI 
To evaluate the ability of protein S and FV to interact with TFPI, the co-immunoprecipitation 
assay was further optimised. Tosylactivated magnetic beads coated with a monoclonal anti-
human Kunitz 1 antibody were blocked with 3% BSA in TBSCa2+ for 30 minutes. 20nM TFPI, 
40nM protein S and 40nM FV diluted in blocking buffer were pre-incubated at RT for 25 
minutes. The beads were incubated with the samples, washed and eluted as described 
previously in section 2.6.1.2. Subsequently, the sample analysis was carried out using SDS-
PAGE followed by Western blotting by detecting TFPI, protein S and FV with polyclonal 
antibodies as described in sections 2.4.3. 
2.6.2 SPR 
2.6.2.1 Principle of SPR 
To investigate direct protein-protein interactions in a highly-purified environment, one of 
the proteins of interest is immobilised on a gold sensor surface prepared prior to the 
measurements. A sample containing a potential interacting partner is perfused over the 
surface through a series of flow cells. The interaction is measured in real time by directing 
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polarized light towards the sensor surface. The angle of reflected light changes as molecules 
bind and dissociate, and is proportional to the mass of bound material. The response is 
recorded by a sensogram which displays increasing response while molecules interact, and 
decreased response during the dissociation phase when sample is replaced by a buffer. 
2.6.2.2 Protein S binding to TFPI 
SPR was implemented to investigate the direct interaction between protein S and TFPI.228-230 
The measurements were carried out on a Biacore T100 (GE Healthcare). Purified 
recombinant WT TFPI covalently immobilised on a carboxymethyldextran-modified gold 
surface (CM5) chip (GE Healthcare) was available prior to this study. The immobilisation 
(approximately 2500 resonance units; RU) was performed by Dr Josefin Ahnström using 
amine coupling according to the previously described protocol. In the assay, after 
stabilization of the baseline signal, purified WT protein S and protein S/Gas6 chimeras (0-
1000nM) in TBS, 5mM CaCl2, 0.005% Tween 20 were perfused over immobilised TFPI for 500 
seconds at a flow rate of 30μL/min at 25°C. Following a 1000-seconds dissociation, the chip 
was regenerated with two 30-seconds pulses of 1M NaCl in running buffer. Binding was 
expressed in RU and a non-coated flow cell (coupled only with etholamine) served as a 
reference surface to correct for non-specific binding. 
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3. RESULTS
3.1 Purification and quantification of protein S, C4BP, TFPI and FV 
3.1.1 Purification and quantification of protein S 
3.1.1.1 Purification of protein S using BCP and a DEAE column 
In order to characterise the interaction site on protein S important for its cofactor function 
upon TFPI, I aimed to evaluate protein S variants for their enhancement of TFPI-mediated 
inhibition. The majority of the functional assays used in this thesis required purified 
components. Protein S was expressed by stably transfected of HEK293 cells. Harvested 
protein S media was either concentrated and assayed directly, or purified using previously 
optimised methods.161 For purification, concentrated media was first partially purified by 
BCP allowing isolation of γ-carboxylated protein S. This was achieved by addition of sodium 
citrate which binds calcium ions present in the protein S Gla domain. With the subsequent 
addition of barium chloride, a barium precipitate complex was formed which pulled down 
protein S containing γ-carboxylated Gla domain. Following overnight dialysis against TBS, 
protein S was further purified using anion exchange chromatography. A representative 
chromatogram from purification of WT protein S on a DEAE column displaying milli 
absorbance unit (mAU) at 280nm plotted against the volume of liquid flowing through the 
column is shown in Figure 3.1A. Protein S was eluted with a linear gradient of 0-30mM 
CaCl2. Elution fractions A3-A7 containing pure protein S were pooled and concentrated 
further. Samples from the different purification steps were assessed using SDS-PAGE under 
non-reducing conditions. The stained SDS-PAGE in Figure 3.1B shows a band corresponding 
to the molecular weight of full-length protein S (73kDa) present in barium precipitated 
fraction and IEX elution pool. The presence of protein S in these samples was confirmed 
using Western blotting (Figure 3.1C). Following the two-step purification, the yield from 
0.75L expression media was 0.25-0.05 mg for WT protein S and 0.1-0.2 mg for protein 
S/Gas6 chimeras, respectively. 
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Figure 3.1 Purification of WT protein S by BCP followed by an anion exchange DEAE column and analysis of 
the purification steps fractions using silver staining and Western blotting.  
WT protein S was expressed in stably transfected HEK293 cells. Conditioned media expressing the protein was 
harvested, concentrated and purified through BCP followed by anion exchange chromatography using a 5ml 
DEAE column. (A) The chromatogram shows the mAU at 280nm (black line) plotted against the elution volume. 
The green line represents a change of buffer. Protein S bound to the column was eluted with a gradient of 0-
30mM CaCl2. The samples from each purification step were subjected to a 10% SDS-PAGE under the non-
reducing conditions. The result of the purification was assessed by silver staining 500ng/lane (B) or using 
Western blotting where protein S (40ng/lane) was detected with a polyclonal anti-protein S antibody followed 
by a HRP-conjugated antibody (C). The samples assessed comprised: conditioned media (CM), first and second 
supernatants form BCP (S1 and S2), precipitant from BCP (P), flow-through from IEX (FT), elution from IEX (E) 
and IEX regeneration (R). 
3.1.1.2 Quantification of protein S using ELISA and A280 
The concentration of purified WT protein S was determined by ELISA. A standard curve of 0-
2nM of commercial plasma purified protein S was fitted to a sigmoidal dose-response curve 
(Figure 3.2) and samples were diluted to ensure they fell in the unsaturated part of the 
curve. The mean inter-assay coefficient variation was below 5% for a minimum of three 
ELISAs, indicating that the protein S concentration obtained using this method was accurate.  
A 
B C 
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ELISA is optimal for determing concentrations of pure WT protein S or protein S variants 
containing point substitutions. However, a polyclonal antibody containing an epitope for the 
SHBG-like domain is not efficient in detecting the protein S/Gas6 chimeras comprising large 
substitutions within this particular domain. For this reason, protein S ELISA using polyclonal 
anti-protein S antibodies was not a suitable method for quantification of these variants. 
Hence, I used A280 for quantification of the chimeras where I applied Beer-Lambert law for 
concentration c=A/ ε L (extinction coefficient provided in the Methods section). Predicted 
molecular weights used for the quantification were 73kDa for WT protein S, 71kDa for 
chimera I, 67kDa for chimera II and 69kDa for chimera III. When my quantified recombinant 
protein S preparations were analysed by SDS-PAGE silver staining (described in section 
3.2.2.1), bands of equal intensity were obtained, suggesting that A280 is a reliable method 
for concentration determination.  
Figure 3.2 Standard curve of WT protein S assessed using ELISA. 
Protein S was captured using a polyclonal anti-protein S antibody. Commercially available plasma purified 
protein S was used as a standard curve (0-2nM). Protein S detection was performed with 4nM of a monoclonal 
anti-protein S antibody, followed by a polyclonal HRP-conjugated antibody, all diluted in TBSCa
2+
 
supplemented with 0.5% BSA. 
3.1.2 Purification and quantification of C4BP 
3.1.2.1 Purification of C4BP on a Sephacryl column 
One of my objectives during this thesis was to evaluate the effects of protein S interaction 
with C4BP upon the TFPI cofactor function of protein S. In human plasma ~70% of total 
protein S circulates in complex with C4BP. Under normal circumstances, ~80% of C4BP is 
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able to bind protein S.255 C4BP purified from human plasma using procedures commonly 
used by manufacturers has been reported to contain 2-5% non-covalently bound protein 
S.378 In this project, pure, protein S-free C4BP was required to study the effects of its binding 
upon the anticoagulant functions of protein S (assessed in section 3.2.4). Western blotting 
using polyclonal anti-protein S antibodies suggested that the commercially available C4BP 
preparation contained trace amounts of protein S (results not shown). The C4BP 
preparation was therefore purified further to remove non-covalently bound protein S. For 
this, C4BP was denatured using guanidine followed by size exclusion chromatography. As 
shown in a chromatogram in Figure 3.3A, C4BP eluted as a symmetrical peak, well separated 
from protein S. Both protein pools were concentrated further and the protein concentration 
was determined by absorption at 280nm. Analysis by Western blotting with polyclonal anti-
protein S antibodies (Figure 3.3B) illustrated successful removal of protein S. The successful 
separation of protein S from C4BP was also confirmed with silver-stained SDS-PAGE (results 
not shown). 
Figure 3.3 Separation of C4BP from protein S using size exclusion chromatography on a HiPrep Sepharcyl 
column and analysis of the purification elution fractions using Western blotting. 
(A) Plasma purified C4BP was incubated in 3M guanidine and 20mM Tris, pH 7.4 for 1 hour at room 
temperature and separated from protein S using a HiPrep 16/60 Sephacryl S-300 column. (B) 500ng of the 
starting product (C4BP-PS), and the elution peaks containing C4BP and protein S were subjected to a 10% SDS-
PAGE under the non-reducing conditions and assessed using Western blotting where protein S was detected 
with a polyclonal anti-protein S antibody followed by a HRP-conjugated antibody. PS, protein S. 
A B 
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3.1.2.2 Quantification of C4BP free β-chains using gel filtration followed by protein S ELISA 
and Western blotting 
I intended to study the effects of C4BP binding to protein S upon the enhancement of TFPI-
mediated FXa inhabitation. For this, the concentration of C4BP containing a β-chain in the 
pure C4BP preparation needed to be estimated to recognise the amount of protein S that 
can bind C4BP. This was achieved by establishing the optimal C4BP/protein S ratio resulting 
in complete binding of protein S. Different molar concentrations of C4BP and WT protein S 
were mixed in TBSCa2+ supplemented with 0.1% BSA and incubated for 1 hour at room 
temperature. The presence of free and C4BP-bound protein S was investigated using size-
exclusion chromatography. The elution samples were assessed by protein S ELISA and 
Western blotting to establish at what C4BP/protein S ratio all protein S was bound to C4BP. 
Figure 3.4A shows protein S ELISA results visualising the elution profile for free protein S and 
C4BP-bound protein S in a 33:20 nanomolar ratio. While unbound protein S gave a high and 
symmetrical peak eluting approximately at 10mL, no free protein S could be detected in the 
C4BP-protein S sample. Protein S bound to C4BP was poorly detected by the antibodies 
against protein S, most likely due to C4BP covering the antibody binding sites. Furthermore, 
C4BP-bound protein S in 66:20 and 120:20 nanomolar ratios were also assessed using 
protein S ELISA showing virtually identical elution patterns (results not shown). The C4BP-
protein S (33:20) elution fractions were assessed using Western blotting and are presented 
in Figure 3.4B. Protein S was readily detected in the elution volume indicating it was C4BP-
bound. No protein S bands could be seen in the elution volume expected for free protein S. 
To summarise, even when a molar ratio of 33:20 of C4BP and protein S were mixed, no free 
protein S was detected, suggesting that at least 60% of C4BP preparation contains β-chains 
that are able to bind protein S. In further experiments, described in section 3.2.4, C4BP was 
used to evaluate its effects upon the anticoagulant functions of protein S. 
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Figure 3.4 Quantification of C4BP free β-chains using gel filtration, protein S ELISA and Western blotting. 
C4BP (33nM) and WT protein S (20nM) were mixed in TBSCa
2+
 supplemented with 0.1% BSA and incubated for 
1 hour at room temperature. The presence of free protein S was investigated using size-exclusion 
chromatography. The elution fractions containing C4BP-bound or free protein S were assessed using protein S 
ELISA (A) and subjected to a 10% SDS-PAGE under non-reducing conditions and assessed using Western 
blotting (B), where protein S was detected with a polyclonal anti-protein S antibody and a HRP-conjugated 
antibody. 10ng protein S not incubated with C4BP was loaded on the SDS-PAGE as a positive control (+ve Ctrl). 
PS, protein S. 
3.1.3 Purification and quantification of TFPI 
3.1.3.1 Purification of TFPI using a Heparin column and antibody affinity chromatography 
WT TFPI and TFPI variants, pure or in concentrated conditioned media, were required for my 
work. TFPI was expressed by transient transfection of HEK293T cells. Harvested TFPI media 
was either concentrated and assayed directly, or purified using previously optimised 
methods.230 For purification, TFPI was initially purified using heparin affinity 
chromatography. A representative chromatogram from purification of WT TFPI on a HiTrap 
heparin HP column displaying mAU at 280nm plotted against the volume of liquid flowing 
through the column is shown in Figure 3.5A. TFPI was eluted with a linear gradient of 0.15-
2M NaCl and appeared as a broad peak. Fractions after the first purification step were 
assessed by ELISA (described in section 2.4.4.2) with anti-Kunitz 1 domain antibody used for 
coating, and antibodies directed against Kunitz 2 domain or C-terminal tail used for 
detection of total or full-length TFPI, respectively (Figure 3.5B). Fractions A7-A11 containing 
only full-length TFPI (eluted with ~0.6M NaCl) were pooled and purified further using a 
HiTrap HP column coupled with monoclonal antibody against Kunitz 1 domain. The 
chromatogram from this purification step is presented in Figure 3.5C. TFPI was eluted with 
A B 
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0.1M glycine, pH 2.7 and appeared as a single peak. Samples from different purification 
steps were assessed using SDS-PAGE under non-reducing conditions. A silver-stained SDS-
PAGE (Figure 3.5D) showed pure WT TFPI and TFPI E226Q detected at the expected 
molecular weight (~41kDa). This was confirmed with Western blotting (Figure 3.5E). The 
yield from 750mL expression media was ~5µg for WT TFPI and ~13µg for TFPI E226Q, 
respectively. 
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Figure 3.5 Purification of WT TFPI using a heparin column and antibody affinity and analysis of the 
purification steps fractions using ELISA, silver staining and Western blotting. 
HEK293T were transiently transfected with cDNA encoding for WT TFPI. Conditioned media expressing the 
protein was harvested and purified using a heparin column where TFPI was eluted with a linear gradient of 
0.15-2M NaCl (A). All elution fractions were analysed using TFPI ELISA (B). Fractions containing mostly full-
length TFPI were pulled and purified further on a HP column coupled with anti-Kunitz 1 domain antibodies, 
and TFPI was eluted with 0.1M glycine, pH 2.7 (C). The samples from both purification steps were subjected to 
a gradient SDS-PAGE under the non-reducing conditions. The result of the purification was assessed by silver 
staining 500ng of proteins (D) or using Western blotting were TFPI (40ng) was detected with a polyclonal anti-
TFPI antibody followed by a polyclonal HRP-conjugated antibody (E). The samples assessed comprised: 
conditioned media (CM), flow-through from a heparin column (FT 1), wash from a heparin column (wash 1), 
elution form a heparin column (E 1), flow-through from antibody affinity column (FT 2), wash from antibody 
affinity column (wash 2) and elution from antibody affinity column (E 2). 
A B 
C 
D E 
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3.1.3.2 Quantification of TFPI using ELISA 
Pure TFPI and TFPI in concentrated media were quantified using ELISA. A standard curve of 
0-2nM of plasma purified TFPI was fitted to a sigmoidal dose-response curve (Figure 3.6) 
and samples were diluted to ensure they fell in the unsaturated part of the curve. The mean 
inter-assay coefficient variation derived from minimum three ELISAs was less than 5%. The 
estimated amounts of full-length TFPI in E226Q concentrates was 80%, whereas in WT 
concentrates it was 100% for both, media and pure TFPI. Media WT TFPI was used for co-
immunoprecipitation experiments, whereas pure WT and E226Q preparations were used in 
FXa assays in chapter 3.3. 
Figure 3.6 Standard curves of TFPI in media assessed using ELISA. 
Pure plasma TFPI was used as a standard curve (0-2nM). Anti-Kunitz 2 domain and anti-C-terminal tail 
antibodies, for detection of total TFPI and full-length TFPI respectively, were used. Biotinylated anti-Kunitz 1 
domain antibody was used for primary detection. For the secondary detection, HRP-conjugated streptavidin 
was used. The samples were diluted in 3% BSA in PBS and all antibodies were diluted in 0.5% BSA in PBS.
3.1.4 Purification and quantification of FV 
3.1.4.1 Purification of FV on a SP-Sepharose column and a QFF column 
During this project I required FV R506Q/R679Q variant (in concentrated media) to evaluate 
the protein S enhancement in the TFPI-mediated inactivation of FVa at Arg306. I also aimed 
to explore the role of WT FV in the TFPI pathway, for which I needed pure full-length FV. FV 
was expressed by stable transfection in BHK cells. Harvested FV media was either 
concentrated and assayed directly, or purified using newly optimised methods. Purification 
procedures were extensively assessed and carefully adapted during this thesis (data not 
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shown). FV is prone to proteolysis and it was important for me to minimise its cleavage to 
ensure that specifically the functions of full-length FV are being assessed (section 3.3). To 
achieve this, concentrations as well as timing of addition of the protease inhibitors were 
cautiously optimised. Also the length of elution gradients and salt concentrations in the 
elution buffers were tailored to achieve better separation of full-length FV from its cleaved 
forms. FV was first purified using cation exchange chromatography. A representative 
chromatogram from purification of FV using a cation chromatography, displaying mAU at 
280nm plotted against the volume of liquid flowing through the column, is shown in Figure 
3.7A. FV was eluted with 0.3M NaCl and eluted in two symmetrical peaks. Dot blot analysis 
using polyclonal anti-FV antibody for detection (not shown) revealed that only the first peak 
contained full-length FV. These fractions were pooled and purified further using anion 
exchange chromatography. As seen in a chromatogram shown in Figure 3.7B, FV was eluted 
with ~0.25M NaCl and appeared as a single peak. The fractions analysis using Western 
blotting (data not shown) revealed that most of the eluate comprised full-length FV. The 
small number of fractions containing proteolysed FV was not included in the final 
preparation. Samples from different purification steps were assessed using SDS-PAGE under 
non-reducing conditions. A silver-stained SDS-PAGE (Figure 3.7C) shows pure full-length FV, 
present as a single band at approximately 330kDa. The presence of FV in the final elution 
was confirmed using Western blotting by detecting FV with polyclonal antibody against FV 
(Figure 3.5D). The yield from 2.3L expression media was ~0.2mg for pure WT FV, and ~0.6μg 
for FV R506Q/R679Q in media concentrated from 0.75L. Apart from the lower starting 
volume of the expression media, lower yields of FV R506Q/R679Q can be explained by the 
presence of many proteolytic enzymes present in conditioned media that lead to 
degradation of unpurified FV R506Q/R679Q. Very low final concentration of this FV variant 
was not an issue, as for this work very small amounts of FV were required for FVa 
inactivation assays (see section 3.2.2.3). 
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Figure 3.7 Purification of FV using cation and anion exchange chromatography and analysis of the 
purification steps fractions using silver staining and Western blotting.  
BHK cells stably expressing FV were used as a source of the protein. Conditioned media expressing the protein 
was harvested and purified on a SP Sepharose column (A) followed by a Q Sepharose column (B), where FV 
was eluted with 0.3M NaCl and a linear gradient of 0.2-0.7M NaCl, respectively. The samples from each 
purification step were subjected to a gradient SDS-PAGE under the non-reducing conditions. The result of the 
purification was assessed by silver staining 500ng of proteins (C) or using Western blotting were FV (40ng) was 
detected with a polyclonal antibody against FV followed by a monoclonal HRP-conjugated antibody (D). The 
samples assessed comprised: conditioned media (CM), flow-through from SP (FT 1), wash from SP (wash 1), 
elution form SP (E 1), regeneration from SP (R 1), flow-through from QFF (FT 2), wash from QFF (wash 2), 
elution form QFF (E 2) and regeneration from QFF (R 2). 
A 
B 
C D 
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3.1.4.2 Quantification of FV using ELISA and A280 
Concentrated pure WT full-length FV was quantified using A280 with an extinction 
coefficient 9.6309 and a predicted molecular weight of 330kDa. Media FV R506Q/R679Q was 
quantified using ELISA. Diluted (0-10nM) purified commercial FV was fitted to a sigmoidal 
dose-response curve shown in Figure 3.8. The mean inter-assay coefficient variation 
obtained from three independent ELISAs did not exceed 5%. Media FV R506Q/R679Q was 
used for FVa inactivation assays, whereas pure WT full-length FV was used in FXa assays and 
co-immunoprecipitation experiments. 
Figure 3.8 Standard curve of FV assessed using ELISA. 
Pure plasma FV supplied by HTI was used as a standard curve (0-10nM). 8nM of a monoclonal anti-FV 
antibody, followed by 16nM of a polyclonal HRP-conjugated antibody were used for detection of FV. The 
samples and all antibodies were diluted in 0.5% BSA in TBSCa
2+
.
3.2 TFPI cofactor function of protein S 
3.2.1 Evaluation of TFPI binding and enhancement by protein S variants 
3.2.1.1 Protein S enhancement of TFPI-mediated inhibition of FXa generation 
To identify the functional interaction site for TFPI on protein S, over 40 protein S variants 
were investigated (Table 2.1). The variants used comprised mutated residues (predicted to 
be solvent-exposed) within the Gla-EGF4 domains, or substitutions of both or the individual 
LG subunits in the SHBG-like domain, all essentially spanning the whole protein S molecule. 
With such a large library of mutants, it was essential to find an efficient method for 
screening them for TFPI cofactor function in concentrated conditioned media (by-passing 
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the requirement for initial protein purification). Therefore, I attempted to use FXa 
generation assays to evaluate the protein S cofactor activity towards TFPI in inhibition of 
TF/FVIIa-mediated activation of FX. As shown in Figure 3.9, addition of TFPI inhibited 
activation of FX, which was further enhanced by the presence of protein S, as expected. 
These results agree very well with the studies previously reported by Hackeng et al. in 
2006.31 Subsequently, concentrated conditioned media from untransfected HEK293 cells 
was added to the protein S sample which further potentiated the protein S enhancement of 
the TFPI activity. These results suggest unspecific effects of the concentrated media upon 
the protein S function. Consequently, the FXa generation assay was rejected as a method for 
screening of unpure protein S variants for their TFPI cofactor function. 
Figure 3.9 Inhibition of FXa generation by TFPI and protein S. 
1pM TF was incubated with 0.5nM FVIIa and 25µM phospholipid vesicles in TBSCa
2+
 at 37°C. FXa generation 
was initiated with 160nM FX in the presence or absence of 2nM TFPI, presence or absence of 100nM protein S 
and presence or absence of 25µL concentrated media (CM). Aliquots from the reaction mixture were taken at 
0, 30, 60 and 120 seconds and the presence of FXa was determined using a chromogenic substrate (S-2765). 
3.2.1.2 Evaluation of protein S variants interaction with TFPI using co-immunoprecipitation 
It has been suggested that free protein S binds full-length TFPI in plasma.228 It is also known 
that an interaction between protein S and TFPI is needed for protein S to exert its TFPI 
cofactor function.228-230 For these reasons, I optimised TFPI/protein S co-
immunoprecipitation as a screening method to assess the TFPI/protein S interaction in 
concentrated conditioned media. 50nM TFPI and 40nM protein S were diluted in 
concentrated control media and mixed with magnetic beads coated with anti-TFPI Kunitz 1 
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domain antibodies. Bound proteins were eluted and detected using Western blotting. These 
results are presented in Figure 3.10. Equal amount of TFPI was pulled down using this 
approach, regardless of the presence or absence of protein S. Importantly, protein S was 
successfully co-immunoprecipitated in the presence of TFPI, confirming direct binding 
between these two proteins. 
Figure 3.10 Analysis of TFPI and protein S co-immunoprecipitation using Western blotting.  
50nM WT TFPI media and 40nM WT protein S media diluted in concentrated control media were incubated 
with magnetic beads coupled with monoclonal anti-human TFPI Kunitz 1 domain antibodies. Samples were 
eluted from the beads, loaded on SDS-PAGE to allow protein separation under non-reducing conditions, and 
analysed with Western blotting using polyclonal anti-TFPI antibodies (left blot) and polyclonal anti-protein S 
antibodies (right blot), followed by polyclonal HRP-conjugated antibodies for secondary detection. 50ng TFPI 
and 10ng protein S not incubated with the beads were loaded on the SDS-PAGE and served as positive controls 
(+ve Ctrl). 
To confirm that co-immunoprecipitation is a valid method to study direct interaction 
between protein S and TFPI in media, TFPI E226Q, a variant known to be unable to interact 
with protein S,230 was assessed using the approach described above. The results are 
presented in Figure 3.11. While, protein S co-immunoprecipitated with WT TFPI, only trace 
amounts of protein S was detected after co-immunoprecipitation with TFPI E226Q. This 
markedly reduced interaction between protein S and TFPI E226Q, serving as a negative 
control, confirmed the specificity of the assay. This method appeared to be suitable for 
screening protein S variants in media to identify variants unable to interact with TFPI. 
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Figure 3.11 Analysis of TFPI E226Q and protein S co-immunoprecipitation using Western blotting.  
50nM WT TFPI/TFPI E226Q media and 40nM WT protein S media diluted in concentrated control media were 
incubated with magnetic beads coupled with anti-human TFPI Kunitz 1 domain antibodies. Samples were 
eluted from the beads, loaded on SDS-PAGE to allow protein separation under non-reducing conditions, and 
analysed with Western blotting using polyclonal anti-TFPI antibodies (left blot) and polyclonal anti-protein S 
antibodies (right blot), followed by polyclonal HRP-conjugated antibodies for detection. 40ng TFPI and 10ng 
protein S not incubated with the beads were loaded on the SDS-PAGE ad served as positive controls (+ve Ctrl). 
Having identified a method to study interaction between protein S and TFPI in media, the 
ability of protein S variants to co-immunoprecipitate with TFPI was assessed and compared 
to WT protein S binding to TFPI using this approach. Using two independent screenings of all 
available protein S mutants, the intensity of the bands on Western blots were analysed and 
plotted as a percentage of co-immunoprecipitation with TFPI, where co-
immunoprecipitated WT protein S represents 100% (blue bar). The results are presented in 
Figure 3.12. The majority of protein S variants co-immunoprecipitated with TFPI in either 
similar or only moderately decreased levels compared to WT protein S. A few variants 
showed around 40% reduction in ability to bind TFPI. One of these, Face 1, is a composite 
mutant containing N33S/P35T/E36A/Y39V. However, when each of the mutations 
comprising this variant was introduced separately, all four protein S variants exerted almost 
normal binding to TFPI. An alternative mutant expressing lower ability to bind TFPI in this 
assay was protein S N74A. Nevertheless, this variant has been previously investigated by 
one of my colleagues for its TFPI cofactor function using a purified system and has been 
shown to express normal TFPI enhancement (Dr Helena Andersson, personal 
communication). These contradicting results indicated that co-immunoprecipitation may 
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not be viable method for studying TFPI cofactor function of protein S variants. Protein S 
variants S144A and K146A also showed reduced co-immunoprecipitation with TFPI. 
However, when I followed up this observation by purifying these two variants in order to 
investigate their function further, both mutants expressed very poorly, indicating probable 
protein miss-folding or lack of γ-carboxylation. Therefore, I was unable to identify any viable 
variants which could be potentially important for the TFPI interaction using this approach. 
Possible reasons behind a high variability in the intensity of the bands might be unspecific 
binding of the variants to the beads and variability in amounts of co-immunoprecipitated 
WT protein S. As a result, the difference between the TFPI-mediated and unspecific binding 
of protein S to the beads was poorly defined, especially with continuous usage of the beads. 
Overall, this method was very time-consuming and neither sensitive nor quantitative 
enough, and therefore not suitable as a screening tool for binding of protein S mutants to 
TFPI. 
Figure 3.12 Screening of protein S variants for interaction with TFPI using co-immunoprecipitation. 
TFPI and protein S interaction was evaluated by co-immunoprecipitation of protein S variants with TFPI. 50nM 
WT TFPI media and 40nM protein S variant media diluted in concentrated control media were incubated with 
magnetic beads coupled with monoclonal anti-human TFPI Kunitz 1 domain antibodies. Samples were eluted 
from the beads, loaded on SDS-PAGE to allow protein separation in non-reducing conditions, and analysed by 
Western blotting using polyclonal anti-human protein S antibody followed by polyclonal goat anti-rabbit HRP-
conjugated antibody. The intensity of bands on Western blots were analysed with MacBiophotonics ImageJ. 
WT protein S co-immunoprecipitation with TFPI represents 100% (n=2). 
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3.2.1.3 Evaluation of the TFPI cofactor function of protein S in plamsa using CAT 
Following the above inconclusive co-immunoprecipitation approach, I employed thrombin 
generation using the CAT assay to evaluate the enhancement of TFPI by the protein variants 
expressed in media. CAT is a plasma-based assay which allows evaluation of inhibition of 
thrombin generation using unpurified proteins. Thrombin generation assays utilising CAT are 
widely used to study coagulation and, importantly, have been successful in demonstrating 
protein S enhancing effects upon APC and TFPI functions in plasma.161,175 Normal human 
plasma contains both TFPI and protein S. Since protein S is already present in normal 
plasma, this could not be used to assess the TFPI cofactor function of protein S variants. For 
this reason I attempted to deplete normal human plasma from protein S using 
tosylactivated magnetic beads coated with polyclonal anti-human protein S antibodies. 
However, even when the process of protein S immunodepletion was repeated 9 times, trace 
amounts of protein S remained in the plasma (data not shown). As a result, I evaluated the 
protein S enhancement of TFPI in commercially available lyophilised protein S-deficient 
plasmas supplied by two different companies, Affinity Biologicals and Hyphen Biomed. 
Compatible with the previous findings of my colleague Dr Helena Andersson, I observed 
inconsistent (variable peak heights and lag times) TFPI anticoagulant effects and the protein 
S enhancement between individual experiments when using these plasmas (results not 
shown). Consequently, neither of the two plasmas could serve as an effective tool to 
compare the activity of protein S variants to WT protein S. Finally, frozen protein S-depleted 
plasma supplied by ERL was used in thrombin generation experiments. A dose-dependent 
decrease in thrombin generation was observed after addition of increasing concentrations 
of TFPI (0-2nM), presented in Figure 3.13A. The inhibitory effects were demonstrated as a 
reduction of the thrombin peak as well as ETP values, and as an increase in lag time. As 
reported previously,228,230 addition of protein S alone had no effect on the thrombin 
generation, whereas it greatly enhanced TFPI anticoagulant activity (Figure 3.13B). To 
confirm the specificity of the assay and that the inhibitory effects were a direct consequence 
of TFPI activity and TFPI cofactor function of protein S, inhibitory antibodies against TFPI and 
protein S were added to the selected samples. Polyclonal antibodies against protein S added 
alone did not affect thrombin generation, confirming that protein S had been fully removed 
from the plasma. Similarly, monoclonal antibodies against TFPI did not have any effect on 
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thrombin generation in the absence of TFPI, indicating that the anticoagulant pool of TFPI in 
the plasma has likely been co-depleted with protein S. As expected, addition of anti-TFPI 
antibodies in the presence of TFPI reversed TFPI-mediated inhibition of thrombin. The 
presence of antibodies against TFPI also restored thrombin generation in the sample 
containing both TFPI and protein S, confirming that protein S has no anticoagulant effect in 
the absence of TFPI. Finally, addition of anti-protein S antibodies in the presence of TFPI and 
protein S specifically reversed TFPI cofactor function of protein S, while inhibitory activity of 
TFPI remained. Collectively, these results suggested that this method appeared to be 
suitable for screening protein S mutants expressed in media to initially identify variants with 
reduced TFPI cofactor function. 
Figure 3.13 Protein S enhancement of the TFPI-mediated inhibition of thrombin generation in protein S-
depleted plasma.  
Thrombin generation was measured in protein S-depleted plasma supplemented with 50µM phospholipids and 
1pM TF in the presence of 0-2nM TFPI (A) or 1nM TFPI in the presence or absence of 50nM WT PS (B). (B) 
Inhibitory antibodies against TFPI (a mixture of 120nM anti-TFPI Kunitz 1 domain, 120nM anti-TFPI Kunitz 2 
domain and 120nM anti-TFPI C-terminus) and 2.8µM of polyclonal inhibitory antibody against protein S were 
added accordingly. PS, protein S. 
3.2.1.4 Screening of protein S variants for TFPI cofactor function using CAT 
I investigated the functional interaction site of protein S for TFPI using the library of 44 
protein S variants comprising mutations of solvent-exposed residues spanning the entire 
protein S molecule. The screening of WT protein S and the protein S variants for their TFPI 
cofactor function was performed at 1nM TFPI and 50nM protein S in protein S-depleted 
plasma (Figure 3.14). The protein S Gla-EGF4 variants were added as concentrated 
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conditioned media, whereas protein S/Gas6 chimeras were added as pure proteins. Prior to 
the screens, WT protein S was studied both as concentrated conditioned media and pure 
protein, and both enhanced TFPI equally well (result not shown). The thrombin generation 
curves were analysed and plotted as a percentage of enhancement of TFPI, where function 
of WT protein S represents 100% (blue bar). In the two independent screenings, TFPI was 
efficiently enhanced by recombinant WT protein S, as expected. While the majority of 
protein S variants exhibited appreciable enhancement of TFPI similar to WT protein S, two 
variants protein S/Gas6 chimera I and III (red bars) showed considerably reduced ability to 
enhance TFPI in inhibiting thrombin generation. Chimera I, containing the SHBG-like domain 
LG1 subunit substitution, lost over 65% of its TFPI cofactor function. Chimera III, in which 
the whole SHBG-like domain been replaced, lost approximately 80% of its ability to enhance 
TFPI. These results indicated that the SHBG-like domain of protein S, in particular its LG1 
subunit, may play an important role in the TFPI cofactor function of protein S. Hence, in my 
subsequent work, I studied the protein S/Gas6 chimeras in greater detail. 
Figure 3.14 Screening of protein S variants for the TFPI cofactor function in protein S-depleted plasma. 
The TFPI cofactor function of WT protein S and protein S variants was evaluated at 1nM TFPI and 50nM protein 
S in protein S-depleted plasma supplemented with 50µM phospholipids and 1pM TF. Protein S variants with 
amino acid substitutions in the Gla-EGF4 domains were screened in concentrated conditioned media, whereas 
protein S/Gas6 chimeras were purified prior to all experiments. The relative protein S enhancement was 
determined as the decrease in peak height compared to WT protein S. The decrease in peak height in the 
presence of WT protein S compared to TFPI alone was set as 100% (n=2). PS, protein S. 
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Since the aim of my PhD project was to identify protein S residues important for interaction 
with TFPI, I deliberately selected to assess only protein S Gla domain substitutions known to 
not affect the ability of protein S to bind to phospholipid membranes. Variants E36A, Face1 
and GLA2 have been shown previously to bind to phospholipid surfaces with equal affinity 
to WT protein S.161,207 Since N33S, P35T and Y39V are part of Face1 and D38N are located 
very closely to E36A, it is unlikely that any of these individual substitutions would affect the 
phospholipid binding of the Gla domain. Nevertheless, Face1 and GLA2, two composite 
protein S variants together containing 11 out of the 12 studied substitutions within the Gla 
domain, were purified and examined further in the FXa inhibition assay. Both variants 
enhanced the TFPI-mediated inhibition of FXa equally well as WT protein S (see Figure 1 in 
the Appendix). I therefore confirmed that these residues are not essential for the TFPI 
cofactor function of protein S, or for phospholipid binding as well as that the CAT assay 
reflects the TFPI enhancement by protein S observed in purified systems. 
3.2.2 Characterisation of protein S/Gas 6 chimeras 
3.2.2.1 Analysis of the purity, cleavage and multimerisation of protein S/Gas 6 chimeras 
SDS-PAGE under non-reducing and reducing conditions, followed by silver staining of 
purified protein S/Gas6 chimeras were performed and results were compared to WT protein 
S to assess protein purity and to visualise any proteolysis. As presented on the left side of 
the gel in Figure 3.15A, WT protein S and the chimeras I-III analysed under non-reducing 
conditions and silver-stained, migrated as single bands of expected molecular weights being 
73kDa for WT protein S, 71KDa for chimera I, 67kDa for chimera II and 69kDa for chimera III. 
I therefore concluded that all protein S preparations were suitably pure for the in vitro 
experiments I intended to perform.  
Cleavage of protein S has previously been reported to occur after one or more of the three 
residues, Arg49, Arg60, Arg70 in the TSR domain.162,165,166 Whether this cleavage affects the 
TFPI cofactor function of protein S remains to be determined. Under normal circumstances, 
following the cleavage, the Gla domain and EGF1 are held together by the disulphide bond 
between Cys47 and Cys72.162 However, addition of a reducing agent breaks the disulphide 
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bond. Hence, as visualised on the right side of the gel in Figure 3.15A, addition of a reducing 
agent (DTT) resulted in appearance of another band of lower molecular weight, 
corresponding to protein S fragment cleaved in the TSR. The protein S cleavage was slightly 
more apparent in the chimeras (~30%) compared to the expected cleavage of WT protein 
(~15%). However this did not appear to have any major impact on the functions of these 
protein S variants, as shown in later experiments comprising evaluation of the APC cofactor 
function of the chimeras (section 3.2.2.3). 
Multimerisation of protein S has been linked to increased affinity to phospholipid 
surfaces.185,186,194 To assess multimer formation of WT protein S and protein S/Gas6 
chimeras, a native PAGE gel was silver-stained, shown in Figure 3.15B. All protein S 
preparations appeared to be mainly monomeric, with chimera II potentially containing trace 
of dimers. Nevertheless, the function of chimera II did not appear to be affected, as this 
variant consistently demonstrated expected TFPI and APC cofactor functions in the 
subsequent assays. 
Figure 3.15 Silver stains of SDS-PAGE and Native PAGE of WT protein S and protein S/Gas6 chimeras.  
500ng of purified WT protein S and protein S/Gas6 chimera I-III were subjected to a 10% SDS-PAGE under non-
reducing (NR) and reducing (R) conditions (A) or a 4-15% Native PAGE (B) and silver-stained. PS, protein S; Ch, 
protein S/Gas chimera. 
A B 
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3.2.2.2 Binding of protein S/Gas 6 chimeras to domain-specific monoclonal antibodies 
Substitution of certain residues can occasionally lead to changes in protein folding or can 
affect the structure of the domain in which the substitution has been introduced, or even its 
adjacent domains. I assessed protein folding and the integrity of the domain structure of 
protein S/Gas6 chimeras I-III by studying their binding to domain-specific monoclonal 
antibodies. For this, titrated WT protein S and the protein S/Gas6 chimeras I-III were 
incubated on a plate coated with monoclonal antibodies recognising either the Gla (MK21), 
TSR (MK67), EGF1 (MK54) or EGF3-EGF4 (MK41) domains. Bound protein S was detected 
using a biotinylated monoclonal antibody as described in the Methods section 2.4.7. Binding 
curves are presented in Figure 3.17 and were fitted with a one site binding equation. 
Evidently, all three chimeras bound monoclonal antibodies against Gla domain (Figure 
3.16A), TSR (Figure 3.16B), EGF1 (Figure 3.16C) and EGF3-EGF4 (Figure 3.16D) equally well as 
WT protein S. Table 3.1 shows the mean ± SD of obtained Kd(app) values of three independent 
experiments. Mann-Whitney test analysis revealed no significant difference (P=~1) in 
binding between the chimeras and WT protein S for any of the antibodies tested. The results 
suggest that replacement of the SHBG-like domain or its individual subunits did not result in 
any major conformational changes within these domains. 
116 
Figure 3.16 Binding of WT protein S and protein S/Gas6 chimeras to domain-specific monoclonal antibodies. 
Protein S was incubated in a 96-well plate coated with 1μg/mL of monoclonal antibodies recognising either the 
Gla domain (MK21; A), TSR (MK67; B), EGF1 (MK54; C) or EGF3-EGF4 (MK41; D). Bound protein S was detected 
with 20nM biotinylated monoclonal anti-protein S antibody followed by HRP-conjugated streptavidin (diluted 
1:10000). Non-linear regression curves describing a one-site binding were fitted (n=3). PS, protein S. 
Table 3.1 Binding of protein S to domain-specific monoclonal antibodies. 
Binding of WT protein S and protein S/Gas6 chimeras to domain-specific monoclonal antibodies recognising 
either the Gla domain (MK21), TSR (MK67), EGF1 (MK54) or EGF3-EGF4 (MK41) were evaluated. 
WT PS chimera I chimera II chimera III 
MK 21 (Gla) 1.93 ± 0.78 1.67 ± 0.33 1.62 ± 0.78 1.92 ± 0.83 
MK 67 (TSR) 0.22 ± 0.09 0.18 ± 0.03 0.13 ± 0.06 0.15 ± 0.09 
MK 54 (EGF1) 0.25 ± 0.13 0.21 ± 0.12 0.17 ± 0.06 0.20 ± 0.07 
MK 41 (EGF3-EGF4) 0.76 ± 0.18 1.00 ± 0.32 0.50 ± 0.26 0.75 ± 0.46 
Kd(app) values obtained from 3 independent experiments are given in nM and are expressed as mean ± SD; 
P>0.05 according to the Mann-Whitney test. PS, protein S. 
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3.2.2.3 Evaluation of APC cofactor function of protein S/Gas6 chimeras using FVa 
inactivation assays 
To further evaluate the functionality of protein S/gas6 chimeras, I attempted to assess their 
ability to enhance APC. It is well known that protein S acts as a cofactor for APC in 
inactivation of FVa. This enhancement is dependent on the presence of phospholipid 
surfaces as well as direct binding between protein S and APC.161,175,221 Hence, by studying 
enhancement of APC-mediated inactivation of FVa by the chimeras, I was able to evaluate 
protein S interaction with APC and phospholipids.  
One of the optimisation steps involved a prothrombinase assay in which activation of FV by 
thrombin and FVa assembly to a complex with FXa were assessed. FV incubation with 
0.5U/mL of thrombin successfully activated FV. Effective cleavage of the chromogenic 
substrate S-2238 was observed by the thrombin generated through the activity of the 
prothrombinase due to FVa (Figure 3.17A). In contrast, little thrombin was formed when FV 
was not activated. The activation of FV was further confirmed by Western blotting (results 
not shown). As shown in Figure 3.17B, prothrombinase is dependent on FXa, and a linear 
association between FVa concentration and the prothrombinase activity can be observed. 
This suggests that concentrations of FVa not exceeding 10pM in the prothrombinase step 
can be used to accurately quantify remaining FVa concentrations and activity following its 
inactivation by APC and protein S.   
To specifically study protein S enhancement of APC-mediated inactivation of FVa at Arg306, 
a FV R506Q/R679Q variant, which can only be cleaved at Arg306, was utilised. Addition of 
increasing concentrations of activated FV R506Q/R679Q lead to increased activity of the 
prothrombinase complex (Figure 3.17C). Similarly to FVa, increasing concentrations of FVa 
R506Q/R679Q also enhanced prothrombinase in a linear fashion, as presented in Figure 
3.17D. These results show that FV R506Q/R679Q is efficiently activated by thrombin and the 
concentration selected is sufficient to form an active prothrombinase complex. Since activity 
of 8pM of FVa R506Q/R679Q is within the linear range, I was able to assume that this 
concentration will allow me to accurately determine reductions in FVa R506Q/R679Q after 
inactivation by APC and protein S. Hence, in all following experiments, 8pM of FVa 
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R506Q/R679Q was used to evaluate protein S enhancement of APC-mediated cleavage at 
Arg306. 
Figure 3.17 Activity of FV(a) and FV(a) R506Q/R679Q in the prothrombinase assay. 
0.8nM (A) or 0-10pM (B) of plasma purified FV, and 0.8nM (C) or 0-10pM (D) of FV R506Q/R679Q was 
incubated with or without 0.5 U/mL of human thrombin for 10 minutes at 37°C. Activation was stopped with 
the addition of 1.5 U/mL of hirudin and the FV activity was measured with a prothrombinase assay by 
determing cleavage of the chromogenic substrate S-2338 for 20 minutes. For B and D, linear regression of 
mA405 slopes obtained from the prothrombinase assays were plotted against the FV concentrations. 
Representative results from 2 independent experiments are shown.
Following activation of FV R506Q/R679Q, its inactivation was performed in the presence or 
absence of APC and protein S. The remaining FVa activity was measured using the 
prothrombinase assay. APC cleaves FVa at Arg306 inefficiently on its own. As shown in 
Figure 3.18A, addition of protein S resulted in a dramatic reduction of FVa R506Q/R679Q 
activity. By titrating APC in the presence or absence of protein S (shown in Figure 3.18B), it 
was demonstrated that while even 4nM of APC alone were not sufficient in inactivating FVa 
A
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under these conditions, 0.125nM of APC efficiently cleaved FVa at Arg306 when protein S 
was present. Importantly, while addition of increasing concentrations of protein S in the 
presence of 0.25nM APC greatly enhanced FVa inactivation, addition of protein S alone did 
not affect the activity of the prothrombinase complex (Figure 3.18C), demonstrating the 
specificity of the protein S cofactor effects. 
To further validate the assay, two protein S variants, E36A and D95A, previously identified 
to be important for the APC cofactor function,161,175 were assessed for their enhancement of 
the APC-mediated FVa cleavage at Arg306 using FVa inactivation assay. As expected, both 
variants showed substantial reduction in ability to enhance APC when compared to WT 
protein S (Figure 3.18D). 
Figure 3.18 Enhancement of APC-mediated cleavage of FVa at Arg306 by WT protein S and protein S variants 
E36A and D95A. 
0.8nM FVa R506Q/R679Q and phospholipid vesicles were incubated with or without 0.25nM APC in the 
presence or absence of 100nM protein S (A), with APC (0-4nM) in the presence or absence of 100nM protein S 
(B), in the presence or absence of 0.25nM APC with 0-100nM protein S (C) or in the presence of 0.25nM APC 
with 0-100nM WT protein S, protein S E36A, protein S D95A (D) for 10 minutes at 37°C. The remaining FVa 
activity was measured with a prothrombinase assay. The percentage of remaining FVa R506Q/R679Q activity 
was plotted against the APC (B) and protein S (C-D) concentrations. Representative results from 2 independent 
experiments are shown. PS, protein S. 
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Protein S/Gas 6 chimeras folding and domain structure integrity was initially evaluated using 
monoclonal antibody binding. To assess the chimeras functionally, the FVa inactivation 
assay was utilised to specifically study their enhancement of APC-mediated cleavage of FVa 
R506Q/R679Q at Arg306. FVa inactivation was performed in the presence of 0.25nM APC 
and 0-100nM of purified WT protein S and protein S/Gas6 chimeras. Following a 10-minute 
inactivation, the residual FVa activity was measured in a prothrombinase assay. As 
expected, WT protein S efficiently enhanced APC mediated cleavage at Arg306 of FVa 
(Figure 3.19). Importantly, all three chimeras enhanced the APC to the same extent as WT 
protein S.  
Using the obtained FVa inactivation curves, the concentrations of protein S required to 
reach 50% of the maximal enhancement of APC-mediated inactivation of FVa, EC50 values, 
were determined and reported in Table 3.2. According to Mann-Whitney tests there were 
no significant differences between EC50 values obtained for WT protein S and the chimeras. 
The results suggest that the substitution of the SHBG-like domain or its individual subunits 
did not affect the enhancement of APC-mediated FVa cleavage at the Arg306 position. 
Additionally, these results indirectly demonstrate that the chimeras bind phospholipids, as 
this is required for efficient enhancement of FVa inactivation in this assay. Therefore, I 
concluded that reduced enhancement of TFPI cofactor function of protein S/Gas6 chimera I 
and III seen in CAT was not a consequence of defective phospholipid binding. 
Figure 3.19 Enhancement of APC-mediated cleavage of FVa at Arg306 by WT protein S and protein S/Gas6 
chimeras I-III. 
8nM FVa R506Q/R679Q and phospholipid vesicles were incubated with protein S (0-100nM) in the presence of 
0.25nM APC for 10 minutes at 37°C. The remaining FVa activity was measured with a prothrombinase assay. 
The percentage of remaining FVa R506Q/R679Q activity was plotted against the protein S concentrations as 
mean ± SD (n=3). PS, protein S. 
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Table 3.2 Enhancement of APC-mediated cleavage of FVa at Arg306 by protein S. 
Enhancement of APC-mediated cleavage of FVa at Arg306 by protein S was determined from FVa inactivation 
assays presented in Figure 3.19. 
WT PS chimera I chimera II chimera III 
EC50 for FVa R506Q/R679Q 
inactivation 
5.18 ± 0.36 5.20 ± 1.19 6.31 ± 0.53 4.92 ± 0.95 
EC50 values obtained from 3 independent experiments are given in nM and are expressed as mean ± SD; 
P>0.05 according to the Mann-Whitney test. PS, protein S. 
3.2.3 Evaluation of TFPI binding and enhancement by protein S/Gas6 chimeras 
3.2.3.1 Evaluation of the TFPI cofactor function of WT PS and protein S/Gas 6 chimeras using 
CAT  
Following the initial observation of reduced TFPI enhancement by two protein S/Gas6 
chimeras in inhibition of thrombin generation (section 3.2.1.4), I further assessed the 
importance of the SHGB-like domain in the TFPI cofactor function by titrating the chimeras 
in the CAT assay. In detail, pure WT protein S and protein S/Gas6 chimeras I-III were titrated 
(0-100nM) in the presence of 1nM TFPI in protein S-depleted plasma, where thrombin 
generation was induced by addition of TF (Figure 3.20). Chimera II enhanced TFPI to a 
similar extent to that of WT protein S, as only a minimal difference in the EC50 values was 
noted (18.6 ± 5.6 vs 20.4 ± 2.1nM; presented as mean ± SD) (Figure 3.20A and C). On the 
other hand, chimera I and III had limited inhibitory effect on thrombin generation (Figure 
3.20B and D). These findings supported the initial screening results presented in section 
3.2.1.4. Figure 3.20E shows the obtained thrombin peak heights values plotted against 
protein S concentrations of each variant. Approximately the same concentrations of WT 
protein S and chimera II were needed for the same decrease (~70%) in thrombin generation. 
Chimera I decreased the peak height by only 45% at a concentration of 100nM, while 
chimera III was essentially unable to enhance TFPI. Under these experimental conditions, 
neither of the protein S variants affected thrombin generation in the absence of TFPI (Figure 
3.20F). These results strongly suggest that the protein S SHBG-like domain, in particular the 
LG1 subunit, plays an important role in the TFPI cofactor function in plasma. 
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Figure 3.20 Enhancement of the TFPI-mediated inhibition of thrombin generation by WT protein S and 
protein S/Gas6 chimera I-III. 
Thrombin generation was measured in protein S-depleted plasma supplemented with 50μM phospholipids and 
1pM TF, in the presence or absence of 1nM TFPI, and in the presence or absence of titrated (0-100nM) WT 
protein S (A), chimera I (B), chimera II (C) or chimera III (D). Representative experiments are shown (n=3). (E) 
Peak thrombin was plotted against protein S concentrations. The peak height in the presence of TFPI alone 
represents 100%. Results are expressed as mean ± SD (n=3). (F) Thrombin generation was measured in protein 
S-depleted plasma supplemented with 50μM phospholipids and 1pM TF, in the presence of 100nM and in the 
presence or absence of 1nM TFPI. PS, protein S. 
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3.2.3.2 Evaluation of the TFPI cofactor function of WT PS and protein S/Gas 6 chimeras using 
FXa inhibition assays  
To more precisely assess and quantify the influence of protein S upon TFPI function, a pure 
component system that specifically determines FXa inactivation, was implemented. TFPI, 
obtained as a gift from Chemoserotheraputic Institute in Kaketsuken, Japan, was used in the 
experiments described in this section. 
The activity of FXa was determined by measuring the conversion of the chromogenic 
substrate cleaved by FXa in real time. Progressive inhibition of FXa activity by increasing 
concentrations of added TFPI can be observed in Figure 3.21A. To assess the TFPI cofactor 
function of protein S, 1.5-2nM of TFPI was used in the following assays to clearly detect the 
enhancing effect in the presence of protein S. As expected, addition of 100nM protein S 
greatly potentiated the anticoagulant activity of TFPI (Figures 3.21B-C). Importantly, under 
these experimental conditions, protein S has no anticoagulant effect in the absence of TFPI, 
which is consistent with the previously published data.31,229,230 
Inhibitory antibodies against protein S and TFPI were used to validate the specificity of the 
protein S enhancement of TFPI. Inhibitory polyclonal antibodies against protein S completely 
reversed the enhancement of TFPI seen in the presence of protein S but had no effect in the 
absence of protein S (Figure 3.21B). Furthermore, while addition of inhibitory monoclonal 
antibodies against TFPI Kunitz 2 domain did not affect FXa activity itself, they successfully 
repressed all inhibition of FXa mediated by TFPI in the presence or absence of protein S 
(Figure 3.21C). These results demonstrate that the protein S effect upon FXa activity is 
strictly TFPI-dependent and FXa inhibition assays serve as a reliable method to study TFPI 
cofactor function of the protein S/Gas 6 chimeras.  
124 
 
Figure 3.21 Enhancement of TFPI in the inhibition of FXa by protein S. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of 0-4nM TFPI (A) or 1.5nM TFPI in the presence or 
absence of 100nM WT protein S (B-C). A polyclonal antibodies against protein S (1µM; B) and inhibitory 
antibodies against TFPI (15nM of anti-TFPI Kunitz 2 domain; C) and were added accordingly. Representative 
experiments are shown (n=2). PS, protein S. 
It has previously been demonstrated that TFPI enhancement by protein S depends on the 
presence of negatively-charged phospholipid surfaces.31 To further validate the assay, I 
studied the TFPI and TFPI/protein S effects upon the FXa inhibition in the presence and 
absence of saturated amounts of phospholipids (25μM), presented in Figure 3.22A-B. 
Consistently with the literature,229,379 TFPI mediated inhibition of FXa did not absolutely 
require phospholipids, although TFPI activity was severely reduced in their absence (Figure 
3.22B). This could be explained by close co-localisation of FXa and TFPI on the phospholipid 
surfaces. The positively charged C-terminal tail of TFPI has been suggested to interact with 
negatively charged surfaces.111 This weak TFPI-phospholipid interaction might be potentially 
encouraged by FXa.112 Nevertheless, the role of the TFPI C-terminus in binding to 
phospholipids in more physiological settings when other proteins are present, has never 
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been confirmed. While protein S greatly enhanced TFPI activity in the presence of 
phospholipids (Figure 3.22A), no TFPI enhancement by protein S was observed when 
phospholipids were absent (Figure 3.22B), demonstrating that the TFPI cofactor function of 
protein S is highly membrane-dependant. 
Figure 3.22 Phospholipid dependence of enhancement of TFPI in the inhibition of FXa by protein S. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
or absence of 1.5nM TFPI in the presence or absence of 100nM WT protein S in the presence (A) or absence 
(B) of 25μM phospholipids. Representative experiments are shown (n=2). PS, protein S. 
Following the initial assessment of the TFPI cofactor function of protein S in plasma using 
CAT, the efficiencies of protein S/Gas 6 chimeras to enhance TFPI were evaluated using 
purified FXa inhibition assays. Progress curves of FXa inhibition by TFPI and increasing 
concentrations of WT protein S or protein S variants are presented in Figure 3.23A-D. WT 
protein S effectively enhanced TFPI-mediated inhibition of FXa in a dose-dependent manner, 
as expected (Figure 3.23A). Chimera II, containing SHBG LG2 substitution, also efficiently 
potentiated TFPI anticoagulant activity, demonstrating strong and dose-dependent 
enhancement comparable to that of WT protein S (Figure 3.23C). On the other hand, 
chimera I, comprising the LG1 substitution, showed severely reduced ability to enhance TFPI 
(Figure 3.23B). Finally, in agreement with the plasma-based assays, essentially no 
enhancement of TFPI initial inhibition of FXa was detected after addition of chimera III, in 
which the entire SHBG-like domain has been replaced (Figure 3.23D).  
The initial rates of S-2765 hydrolysis by FXa in the presence of TFPI and increasing 
concentrations of protein S were determined and plotted against protein S concentration in 
Figure 3.23E. The EC50 values for protein S enhancement of TFPI were then derived. An 
approximately 2.7-fold increase in EC50 (39.6 ± 22.2 vs 14.6 ± 8.2nM; presented as mean ± 
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SD) was estimated for chimera II, when compared to WT protein S. Limited enhancement of 
TFPI was detected after addition of chimera I and chimera III, which was in agreement with 
the plasma-based assays. Like Hackeng et al.,31 by eye (looking at the curves at 20-30 
minutes of the reaction) I observed very little protein S enhancement in the final velocities 
and I was unable to calculate any reliable EC50 using this constant. Overall, these results 
confirm the importance of the protein S SHBG-like domain, and more specifically the LG1 
subunit, in the TFPI cofactor function. 
Figure 3.23 Enhancement of TFPI in the inhibition of FXa by WT protein S and protein S/Gas6 chimera I-III. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of TFPI (2nM) and increasing concentrations (0-160nM) of 
WT protein S (A), chimera I (B), chimera II (C) or chimera III (D). Results from representative experiments are 
shown (n=3). (E) The initial velocities (V0) were calculated and plotted against protein S concentration. Values 
are given as mean ± SD and are expressed as percentage of the V0 in the presence of TFPI alone (n=3). PS, 
protein S. 
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3.2.4 Evaluation of TFPI enhancement by C4BP-bound protein S using FXa inhibition assays 
In circulation, a large proportion of protein S binds to C4BP.150,380 The affinity between 
protein S and C4BP (Kd = 0.1nM
263) is much higher than between TFPI and protein S, but
both interactions appear to be mediated through the protein S SHBG-like domain.178,179,381 I 
therefore attempted to further confirm the importance of the protein SHBG-like domain in 
the TFPI cofactor function by evaluating the effects of C4BP binding upon the protein S 
enhancement of TFPI in inhibition of FXa. The enhancement of TFPI-mediated inhibition of 
FXa by C4BP-bound protein S was studied and compared to the TFPI enhancement by free 
protein S using FXa inhibition assays. The results are presented in Figure 3.24. Protein S 
successfully enhanced TFPI-mediated inhibition of FXa in a dose-dependent manner, as 
expected (Figure 3.24A). However, only a minimal enhancement by C4BP-bound protein S 
was detected (Figure 3.24C). C4BP added alone did not affect FXa or TFPI inhibitory function 
(Figure 3.24B). Figure 3.24D shows the initial rates of FXa inhibition in the presence of TFPI, 
protein S and C4BP-bound protein S plotted against protein S concentrations. While protein 
S alone greatly enhanced TFPI anticoagulant activity, addition of C4BP-bound protein S 
resulted in a negligible TFPI enhancement. These results support the findings on the protein 
S/Gas6 chimeras and strongly indicate the importance of protein S SHBG-like domain in its 
TFPI cofactor function. 
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Figure 3.24 Enhancement of TFPI in the inhibition of FXa by protein S, C4BP and C4BP-bound protein S.  
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of TFPI (2nM) and increasing concentrations (0-160nM) of 
protein S (A), 0-320nM C4BP (B), and C4BP-bound protein S in a 2:1 ratio (C). Representative experiments are 
shown (n=3). (D) V0 was calculated and plotted against protein S concentration. Values are given as mean ± SD 
and are expressed as percentage of the V0 in the presence of TFPI alone (n=3). PS, protein S. 
3.2.5 Evaluation of protein S/Gas6 chimeras binding to TFPI using SPR 
The functional assays presented in this thesis have shown that the protein S SHBG-like 
domain, specifically the LG1 subunit, is essential for protein S to act as a cofactor for TFPI. 
Several studies have shown that protein S binds to TFPI directly.228-230 Importantly, it was 
demonstrated that protein S must be bound to TFPI, through the Kunitz 3 domain, to 
mediate its cofactor function.229 I therefore implemented SPR to examine the role of the 
protein S SHBG-like domain and its individual subunits in the direct interaction with TFPI. 
Purified protein S (0-1000nM) was perfused over immobilised TFPI. WT protein S bound to 
TFPI in a dose-dependent manner, as expected (Figure 3.25A). Consistent with previously 
published studies,228-230 the affinity for the TFPI/protein S interaction could not be derived. 
The reason for this was lack of possibility of the fitted curves reaching equilibrium at the 
concentrations used. Nevertheless, the data obtained in SPR experiments complemented 
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the results from the FXa inhibition assays. Substitution of the LG1 subunit in chimera I 
resulted in severe reduction of binding to TFPI (Figure 3.25B). Chimera II, in which the LG2 
has been replaced, exhibited moderately decreased affinity for TFPI, as presented in Figure 
3.25C. Finally, substitution of the whole SHGB-domain in chimera III resulted in an almost 
complete lack of binding to TFPI (Figure 3.25D). These results suggest that there is a direct 
interaction between the protein S SHBG-like domain and TFPI. 
Figure 3.25 Binding of WT protein S and protein S/Gas6 chimeras I-III to TFPI studied with SPR.  
A CM5 chip was coupled with TFPI immobilised to 2500 response units. The flow cell was perfused with 
increasing concentrations (0-1000nM) of WT protein S (A), protein S chimera I (B), protein S chimera II (C) or 
protein S chimera III (D). Results from a representative experiment are shown (n=2). RU, response units. 
3.2.6 Discussion 
The importance of the TFPI cofactor function of protein S in the regulation of the initiation 
of coagulation has been suggested by several studies.31,223 The molecular mechanisms 
underlying these processes are yet to be fully characterised. The essential role of the TFPI 
Kunitz 3 domain in the protein S cofactor function was demonstrated by Ndonwi et al. in 
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2010.229 This was followed by the identification of Glu226 within this domain comprising a 
specific functional interaction site for protein S.230 Considerable evidence has accumulated 
demonstrating that the enhancement by protein S is limited to the free full-length form of 
TFPI, which is either circulating in plasma or released from endothelial cells and platelets. 
Wood and co-workers recently reported lack of protein S cofactor function for the 
membrane-associated TFPIβ, a form of TFPI which does not contain Kunitz 3 domain.75 In 
agreement with this data, experiments performed by Peraramelli et al. also demonstrated 
abolished protein S enhancement of anticoagulant activity of a recombinant TFPI variant 
lacking Kunitz 3 domain. These findings therefore confirmed the importance of Kunitz 3 
domain in TFPI enhancement in inhibition of FXa as well as the TF/FVIIa complex.76,77,224 
Despite in depth characterisation of the protein S functional interaction site on TFPI, the 
complementary interaction site on protein S has not been subject of prior investigations. To 
explore this, I utilised protein S variants comprising single or composite substitutions of 
solvent-exposed amino acid residues spanning the whole protein S molecule and attempted 
to evaluate their importance for the protein S enhancement of anticoagulant activity of 
TFPI. With a library consisting of over 40 protein S variants, my first challenge was to find a 
method that would allow me to assess the TFPI cofactor function of all variants in 
concentrated conditioned media, thereby avoiding the need for purification. The 
concentrated media was found to directly interfere with pure component assays, such as 
FXa inhibition assays and FXa generation assays. In addition, co-immunoprecipitation 
experiments with concentrated media containing the protein S variants gave inconclusive 
results. Ultimately, CAT was used to screen the protein S variants for their TFPI cofactor 
activities. This assay permits evaluation of coagulation in a plasma milieu, suggesting that it 
might represent a more physiological environment that is provided by purified systems. 
During my work I studied protein S mostly in concentrated conditioned media, but also 
some as pure proteins. Protein S was purified when needed, using barium citrate 
precipitation followed by anion exchange chromatography. Purification procedures have 
been suggested to result in protein S multimer formation, potentially affecting protein S 
activity.185,186 Importantly, in my research, regardless of degree of purity, equal 
enhancement of TFPI in inhibition of thrombin generation was observed. Additionally, my 
colleagues have previously shown that concentrated conditioned media from mock 
131 
transfected cells had no effect on the thrombin generation in CAT assays, neither in the 
absence or presence of TFPI.381 Also, the addition of antibodies specific for TFPI and for 
protein S, presented in Figure 3.13, demonstrated co-depletion of TFPI from protein S-
depleted plasma used to assess TFPI cofactor function of protein S. Furthermore, 
supplementing these antibodies in the presence of TFPI and protein S, showed specificity of 
the protein S enhancement of the TFPI anticoagulant activity. These results signified that 
CAT was a suitable method for screening my protein S variants for TFPI enhancement. My 
aim was to indentify residues/domains specifically important for the TFPI cofactor function 
of protein S. For this reason, I have chosen to study only protein S Gla domain substitutions 
previously known to not affect the ability of protein S to bind to phospholipid 
membranes.161,207 The CAT assays revealed appreciable enhancement of the TFPI-mediated 
inhibition of thrombin by the majority of the protein S variants. However, two variants, 
protein S/Gas6 chimera I and III, showed considerably reduced ability to enhance TFPI 
(Figure 3.14). These initial results indicated that the SHBG-like domain of protein S, in 
particular its LG1 subunit, was potentially involved in the TFPI cofactor function of protein S. 
Following this initial screen of all protein S variants, I studied the protein S/Gas6 chimeras in 
greater detail. Analysis of protein S function can be complicated due to its propensity to 
multimerise upon purification.185,186 Prior to further functional examination, I confirmed 
that no multimerisation of the chimeras, shown in Figure 3.15B, which could potentially 
affect their cofactor properties, had taken place during protein expression or purification. 
The SDS-PAGE under the reducing conditions presented in Figure 3.15A revealed partial 
cleavage of WT protein S as expected, and a slightly increased cleavage of the chimeras. 
However, this did not appear to compromise activity of the chimeras, as all three variants 
exerted normal APC cofactor function in inactivating FVa. This slight discrepancy from the 
report of protein S cleavages affecting its cofactor functions in a clotting assay,163 remains 
unexplained. To exclude the possibility of the SHBG substitution triggering conformational 
changes within the remaining domains, I assessed binding of the monoclonal antibodies 
directed against various domains of the chimeras, and confirmed that their affinities were 
equal to those obtained with WT protein S (Figure 3.16). 
Protein S binding to phospholipid membranes underpins all its known cofactor functions. In 
my research, I utilised FVa inactivation assay to examine correct folding of the chimeras, to 
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study their ability to act as cofactors for APC, and also as an indirect method to evaluate 
their phospholipid binding. The SHBG-like domain of protein S has been reported to be 
important for the APC cofactor function in plasma.179 In purified assays on the other hand, 
the SHBG domain did not appear to be crucial for FVa degradation, while it was still essential 
for the FV-dependent enhancement of FVIIIa inactivation.179,222 Nevertheless, since this APC 
cofactor function of protein S is strictly dependent on phospholipid binding, experiments 
preformed during this thesis (Figure 3.19) demonstrated typical APC cofactor function and 
therefore the correct folding, as well as ability to bind membrane surfaces of all three 
chimeras. 
Following the identification of two protein S/Gas6 chimeric variants expressing substantial 
decrease in their TFPI cofactor function in plasma-based CAT assays, FXa inhibition assays 
using purified proteins were utilised (Figure 3.23). These further confirmed the importance 
of the SHBG-like domain, in particular the LG1 subunit for enhancement of TFPI. The initial 
velocities were determined using a non-linear curve fit as previously has been 
described31,229,230 and used to obtain the EC50 values for the initial inhibition of FXa. It is
worth noting that Ndonwi et al. quantified the protein S enhancement of TFPI as a change in 
VS determining the EC50, while Hackeng et al. did so as a change in V0, determing the Ki. As 
was shown by Hackeng and co-workers,31 I also detected small protein S enhancement in Vs
and was therefore unable to calculate any reliable EC50 for the chimeras as well as for WT 
protein S using this constant. My results from the FXa inhibition assays correlated well with 
those obtained using the plasma-based thrombin generation assays, confirming the 
importance of the SHBG-like domain, specifically the LG1 subunit, in the TFPI enhancement.  
The protein S SHBG-like domain has been identified as the binding site for C4BP.158 Several 
studies have linked reduced protein S levels with low concentrations of C4BP containing a β 
chain. In particular, patients receiving warfarin treatment were shown to have decreased 
concentrations of circulating C4BP containing a β chain.382 Further work by Carlsson et al. 
have revealed that expression of protein S stimulates expression of C4BP β chains. They also 
suggest that protein S and the C4BP are secreted already as a complex.383 Both protein S LG 
subunits are believed to have a role in binding to C4BP,158 but despite considerable effort 
the specific interaction site has not been identified. 
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Protein S binds to β chain-containing C4BP with a very high affinity (Kd=0.1nM).
263 A ~40%
decrease of the protein S enhancement of the TFPI-mediated inhibition of thrombin 
generation by addition of a molar excess of C4BP to free protein S was observed by Hackeng 
et al.31 Subsequent immunodepletion experiments also suggested that protein S bound to 
C4BP does not interact with TFPI.228 I evaluated the enhancement of TFPI-mediated FXa 
inhibition by C4BP-bound protein S compared to free protein S. A substantial reduction in 
the TFPI cofactor function of C4BP-bound protein S was noted (Figure 3.24), which 
corresponded well with the first report.31 These results further confirmed the important role 
of the SHBG-like domain in the TFPI cofactor function of protein S. Taken together, while 
both LG subunits have been indicated to confer binding to C4BP,158 my data highlights the 
greater importance of the LG1 subunit for enhancement of TFPI. The exact mechanism 
behind this reduction in the TFPI enhancement by protein S bound to C4BP, was not 
investigated during this project. 
Protein S enhancement of TFPI is facilitated by their direct interactions. Apart from 
immunoprecipitation assays demonstrating formation of a TFPI/protein S complex in 
circulation,228 direct binding between protein S and TFPI has been established by SPR.228-230 
During my work, I used SPR to study the protein S interaction with TFPI. The results are 
presented in Figure 3.25. Interestingly, the affinity of the protein S binding to TFPI observed 
using this method (~1µM) was much weaker than the ones noted in the functional assays. 
This can be explained by the nature of the SPR, in which TFPI is immobilised on a surface of 
the chip, and then protein S is applied under flow. Functional studies provide a more static 
environment, where protein interactions occur in the suspension, and importantly 
phospholipids are supplemented. It is possible that the immobilisation of the TFPI molecules 
partially blocks protein S access to its binding site, whereas during the activity assays, 
proteins can interact in reaction wells freely. Nevertheless, the SPR experiments revealed 
that the protein S SHBG-like domain is directly involved in an interaction with TFPI. A 
contribution of both LG subunits to binding to TFPI can be speculated, but LG1 
demonstrated greater importance, as chimera I interacted with TFPI with an appreciably 
lower affinity than chimera II. 
Collectively, results of my research indicate that protein S and TFPI associate through a 
direct interaction between the SHBG-like domain of protein S (most likely its LG1 subunit) 
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and the TFPI Kunitz 3 domain, particularly with Glu226. This interaction mediates TFPI 
binding to the FXa and potentiates its efficient inhibition (Figure 3.26). 
Figure 3.26 Proposed model of protein S interaction with TFPI and enhanced inhibition of FXa. 
My results suggest that the mechanism of protein S cofactor enhancement of TFPI involves formation of a 
complex between the SHBG-like domain of protein S and Glu226 within the Kunitz 3 domain of TFPI (K3). 
Protein S localises TFPI in a position favourable for the interaction of Kunitz 2 domain (K2) with the SP domain 
of FXa. The boxes represent the respective models of the protein S SHBG-like domain and the TFPI Kunitz 3 
domain. TFPI Glu226 is highlighted in brown and the residues substituted in protein S/Gas6 chimera I are 
highlighted in purple. The TFPI Kunitz 3 domain and the protein S SHGB-like domain models are adapted from 
Mine et al. and Villoutreix et al., respectively.
158,384
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3.3 TFPI cofactor functions of protein S and FV 
3.3.1 Evaluation of the TFPI enhancement by protein S and FV using FXa inhibition assays 
3.3.1.1 The role of FV in FXa inhibition by TFPI in the presence of protein S 
The interaction between TFPI and FVshort, has been demonstrated to increase 
anticoagulant activity of TFPI.307 TFPI has also been suggested to bind to FV and FVa,121,342 
but the functional implications of these interactions are not known. I aimed to assess the 
effects of FV binding to TFPI upon TFPI anticoagulant functions. For this, I utilised FXa 
inhibition assays. As presented in Figure 3.27A, addition of 0.5nM TFPI resulted in decreased 
FXa activity, and this reduction was enhanced by the presence of 20nM protein S, as 
expected. The addition of FV alone or FV in combination with protein S did not affect FXa 
activity in the absence of TFPI. Also, addition of FV to TFPI did not alter TFPI function, 
suggesting that FV by itself does not act as a cofactor for TFPI in the inhibition of FXa. In 
contrast, FV addition (30nM) in the presence of protein S further enhanced TFPI-mediated 
FXa inhibition, demonstrated by a substantial downwards shift of the progress curve. This 
result suggests a novel, protein S-dependent cofactor function for the TFPI-mediated 
inhibition of FXa by FV.  
To verify the specificity of this cofactor function, inhibitory antibodies against FV and 
protein S were added to appropriate samples (Figures 3.26B-C). As shown in Figure 3.27B, 
monoclonal antibodies against FV had no effect on FXa activity when added alone or in the 
presence of TFPI. The antibodies successfully abolished the previously seen TFPI 
enhancement by FV in the presence of protein S. This data confirms that the potentiating 
effect upon the protein S and TFPI activity is mediated by FV. As noted in my previous 
results (section 3.2.3.2), antibodies against protein S reversed the enhancement by protein S 
(Figure 3.27C). Furthermore, addition of polyclonal anti-protein S antibodies also fully 
inhibited the combined protein S and FV effect, suggesting that the TFPI enhancement by FV 
is completely dependent on protein S. 
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Figure 3.27 Enhancement of TFPI in the inhibition of FXa by protein S and FV. 
(A-C) FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the 
presence of 25μM phospholipids, in the presence or absence of 0.5nM TFPI, 20nM protein S and 30nM FV. 
200nM of monoclonal anti-FV antibodies (B) and 200nM of polyclonal anti-protein S antibodies (C) were added 
accordingly. Representative experiment is shown (n=3). PS, protein S. 
TFPI enhancement by protein S depends on the presence on negatively-charged 
phospholipid surfaces.31 Binding to phospholipids has been indicated to be conferred by the 
FV C2 domain.385 The fact that the antibodies used in above FXa inhibition assays were 
directed against the light chain of FV (comprising the C2 domain), suggests that phospolipid 
binding of FV was potentially impaired, resulting in lost ability to enhance TFPI. To further 
confirm the importance of phospholipids in the FV cofactor function for TFPI/protein S 
anticoagulant activity, I studied these effects upon the FXa inhibition in the presence and 
absence of phospholipids (25μM), presented in Figure 3.28A-B. In line with the previous 
data, enhancement of TFPI activity by protein S and effective potentiation of TFPI/protein S-
mediated inhibition of FXa by FV was observed in the presence of phospholipids (Figure 
3.28A). Since only 0.5nM TFPI was used (to better visualise the enhancing effects of FV), 
essentially no FXa inhibition by TFPI addition alone was seen when phospholipids were 
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absent (Figure 3.28B). As expected and shown previously,31 protein S cofactor function upon 
the TFPI-mediated inhibition of FXa was lost in the absence of the membrane surfaces. 
Likewise, the FV enhancement was abolished in the absence of phospholipids, suggesting 
that FV requires presence of negatively-charged surfaces to exert its TFPI/protein S cofactor 
function. 
Figure 3.28 Phospholipid dependence of enhancement of TFPI in the inhibition of FXa by protein S and FV. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
or absence of 0.5nM TFPI, 20nM protein S and 30nM FV, and in the presence (A) or absence (B) of 25μM 
phospholipids. Representative experiment is shown (n=3). PS, protein S. 
As I mentioned previously, FV is prone to proteolysis. Although the FV preparation appeared 
intact prior its functional analysis, cleavage of FV could have taken place during the FXa 
inhibition assays. To verify that the enhancement of anticoagulant TFPI/protein S activity 
seen in FXa inhibition assays are not exerted by proteolysed FV, the cofactor function of 
thrombin-activated FV was assessed (Figure 3.29A-B). Interestingly, addition of FVa 
(regardless of its concentration) by itself and in combination with protein S, slightly 
decreased FXa activity. The reason for this is currently unclear. Importantly, addition of 
7.5nM of FVa did not affect TFPI activity regardless of the presence of protein S, suggesting 
that potentiating effect upon TFPI/protein S-mediated FXa inhibition is not mediated by 
trace amounts of FVa (Figure 3.29A). Interestingly, addition of 30nM of FVa reversed the 
enhancing effects of both FV and protein S, as well as the anticoagulant activity of TFPI 
(Figure 3.29B). This phenomenon could potentially be explained by a competition between 
TFPI and FVa for binding to FXa under these experimental conditions. Nevertheless, this 
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data provides clear evidence that potentiating effect upon TFPI/protein S-mediated FXa 
inhibition is not mediated by FVa.  
 
Figure 3.29 TFPI inhibition of FXa and effect of protein S and FVa. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of 0.5nM TFPI, 20nM protein S and 7.5nM (A)  or 30nM (B) 
thrombin-activated FV. Representative experiment is shown (n=3). 
 
To further confirm that the enhancement of TFPI and protein S in inhibition of FXa is 
mediated by full-length FV, plasma-purified FV (HTI), was studied in parallel to recombinant 
FV, which I had used in previous experiments. Both, the in-house preparation of 
recombinant FV (Figure 3.30B), and plasma-purified FV (Figure 3.30C), decreased FXa 
activity to the same extent in the presence of TFPI and protein S. The high inhibitory effect 
of TFPI in these experiments might be potentially explained by the variability of the FXa 
activity between different batches. These results appear to confirm that the enhancement 
of TFPI and protein S in inhibiting FXa in most likely specifically facilitated by full-length form 
of FV. 
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Figure 3.30 Comparison of in-house FV preparation and plasma-purified FV in the enhancement of TFPI and 
protein S in the inhibition of FXa. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, presence or absence of 0.5nM TFPI, presence or absence of 20nM protein S (A), 
presence or absence of 30nM of recombinant in-house FV (B) and in the presence or absence of 30nM plasma-
purified FV (C). Representative experiments are shown (n=3). PS, protein S. FVpp, plasma-purified FV. 
3.3.1.2 Kinetic quantification of TFPI cofactor function of protein S and FV using FXa 
inhibition assays 
In the next step, I attempted to kinetically quantify the FXa inhibition by TFPI, protein S and 
FV. While in previous assays I used reduced protein S concentrations to better visualise FV 
enhancing effects, in the kinetic experiments concentrations close to physiological amounts 
of free protein S in plasma were implemented. Figure 3.31A shows a dose-dependent 
inhibition of FXa activity by addition of TFPI. Only high concentrations of TFPI, in the 2-4nM 
range, effectively inhibited FXa. The same response pattern was observed when TFPI was 
added in the presence of FV (Figure 3.31B). Addition of 100nM protein S efficiently 
enhanced TFPI-mediated inhibition of FXa, reflected as a progressively enhanced inhibition 
with increasing concentrations of TFPI (Figure 3.31C). With protein S, appreciable inhibition 
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of FXa was achieved at TFPI concentrations exceeding 0.5nM. Addition of 30nM FV in the 
presence of protein S further potentiated anticoagulant effects exerted by TFPI and protein 
S, visualised in Figure 3.31D. The cofactor function of FV was more evident at low 
concentration of TFPI that not exceeded 0.25nM. This is due to the fact that inhibition 
generated by the TFPI cofactor function of protein S becomes very effective at higher TFPI 
concentrations. 
Figure 3.31 FXa inhibition by TFPI in the presence and absence of protein S and FV.  
0-4nM WT TFPI (A), in the presence of 30nM FV (B), or 0-2nM TFPI in the presence of 100nM protein S (C), and 
in the presence of 100nM protein S and 30nM FV (D) were added to 200µM substrate S-2765, 25µM of 
phospholipids vesicles (DOPC/DOPS/DOPE, 60:20:20) and 5nM CaCl2; all diluted in TBS and 0.5% BSA. 0.5nM 
FXa was used to initiate the reaction and FXa activity was measured as the absorption of cleaved chromogenic 
substrate at 405nm, over time. Representative experiment from n=4 are shown. PS, protein S. 
The initial and steady state velocities of FXa activity, V0 and Vs, were derived for different 
TFPI concentrations in the presence and absence of protein S and FV. Increasing 
concentrations of TFPI, alone or together with FV, gave dose-dependent decreases in the V0 
(Figure 3.32A). Under these experimental conditions, TFPI was inefficient in inhibiting FXa, 
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even at amounts exceeding its plasma concentration. Protein S effectively enhanced the 
initial TFPI-mediated inhibition of FXa activity, as expected. The initial FXa activity was 
further reduced by TFPI in the presence of both protein S and FV, with most prominent 
enhancement achieved at low concentrations of TFPI (0.25nM and below). Likewise, 
increasing concentrations of TFPI, alone or together with FV, gave very similar dose-
dependent decrease in the Vs (Figure 3.32B). Unlike reported by Hackeng et al.,
31 moderate
enhancement of the steady state TFPI-mediated inhibition of FXa activity was noted. The 
final FXa activity was slightly reduced further by TFPI in the presence of protein S and FV.  
Subsequently, using the initial and steady state velocity values, Vmax//V0 or Vs (Vmax 
represents the FXa activity in the absence of inhibitors) were calculated and plotted against 
TFPI concentrations (Figure 3.32C-D). The x-intercept was derived and used to calculate the 
inhibitory constants Ki and Ki* which are presented in Table 3.3. The Ki for FXa inhibition by 
TFPI alone was 1.27nM, and 1.46nM in the presence of FV. The Ki value for TFPI inhibition of 
FXa in the presence of protein S Ki was reduced to 0.13nM, close to the plasma 
concentration of full-length TFPI. These values reached statistical significance compared to 
TFPI alone and correspond well with previous reports. FV decreased the Ki further in the 
presence of protein S and TFPI to 0.04nM. 
The Ki* for FXa inhibition by TFPI alone and TFPI combined with FV were 0.15nM and 
0.12nM, respectively. The Ki* value obtained for TFPI in the presence of protein S decreased 
marginally down to 0.07nM. The Ki* derived for TFPI in the presence of protein S and FV was 
0.05nM, but not statistically different compared to TFPI and protein S. It can be therefore 
concluded that FV exerts its cofactor function specifically upon the TFPI/protein S-mediated 
inhibition of initial activity of FXa, whereas the final inhibitory constant remains unaffected.  
In summary, protein S enhanced TFPI-mediated initial inhibition of FXa activity by 10-fold by 
comparison to TFPI alone. FV further enhanced the inhibition of FXa by TFPI in the presence 
of protein S by an additional 3.2-fold when compared to effect of TFPI and protein S, and 32-
fold in comparison to TFPI alone. 
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Figure 3.32 Kinetic analysis of FXa inhibition by TFPI in the presence and absence of protein S and FV. 
0-4nM WT TFPI, 100nM protein S and 30nM FV were added to 200µM substrate S-2765, 25µM of 
phospholipids vesicles (DOPC/DOPS/DOPE, 60:20:20) and 5nM CaCl2; all diluted in TBS and 0.5% BSA. 0.5nM 
FXa was used to initiate the reaction and FXa activity was measured as the absorption of cleaved chromogenic 
substrate at 405nm, over time. (A) V0 plotted against TFPI concentration (n=4); (B) VS plotted against TFPI 
concentration (n=4); (C) Vmax/V0 plotted against TFPI concentration (n=4); (D) Vmax/VS plotted against TFPI 
concentration (n=4). PS, protein S. 
Table 3.3 Inihibitory constants (Ki and Ki*) for the inhibition of FXa by TFPI in the presence and absence of 
protein S and FV assessed using FXa inhibition assays. 
Enhancement of TFPI-mediated inhibition of FXa by protein S and FV was assessed using FXa inhibition assays. 
TFPI TFPI + FV TFPI + PS TFPI + PS + FV 
Ki 1.27 ± 0.35 1.46 ± 0.5 0.13 ± 0.07* 0.04 ± 0.01*† 
Ki* 0.15 ± 0.08 0.12 ± 0.03 0.07 ± 0.01* 0.05 ± 0.01* 
Results given in nM and expressed as mean ± SD, n=4. PS, protein S. *P<0.05 compared to TFPI and TFPI+FV. 
†P<0.05 compared to TFPI+PS. 
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3.3.1.3 The role of FV in FXa inhibition by TFPI variants in the presence of protein S 
It has previously been reported that TFPI binds FV through the TFPI C-terminal tail.121 The 
interaction and enhancement of TFPI by protein S is mediated through the TFPI Kunitz 3 
domain residues Arg199 and Glu226.229,230 I therefore attempted to investigate whether the 
FV enhancement of TFPI/protein S-mediated inhibition of FXa is dependent on the presence 
of the C-terminus of TFPI, and an interaction between protein S and TFPI. For this, the role 
of FV in the presence of protein S and three variants of TFPI was assessed using FXa 
inhibition assays, presented in Figure 3.33. 
Truncated TFPI lacking its C-terminal tail (TFPI ΔCt) exhibits substantially deceased FXa 
inhibitory activity in comparison to full-length TFPI. This has been previously reported.229 
Hence, I added increased (2nM) TFPI ΔCt concentrations in the functional assays, in order to 
reach an equivalent level of inhibition to that observed for 0.5nM of WT TFPI. When TFPI 
ΔCt was added in combination with protein S, an expected reduction in inhibition on FXa 
activity,229 was observed (Figure 3.33B). This decrease in FXa activity was further enhanced 
by the addition of FV, suggesting that the TFPI C-terminal tail is not an essential component 
of FV enhancement of TFPI/protein S-mediated inhibition of FXa. 
The effects of FV upon inhibition of FXa mediated by TFPI R199Q and E226Q in the presence 
of protein S are displayed in Figure 3.33C-D. These TFPI variants express moderately and 
severely decreased affinity towards protein S, respectively.229,230 In agreement with the 
previous reports, substantially reduced enhancement by protein S was observed for both 
variants. Addition of FV in the presence of the two TFPI variants did not affect the pre-
existing inhibition of FXa activity, whereas when FV was added in combination with protein 
S, further enhancement of FXa inhibition was noted. This is demonstrated by prominent 
downward shifts of the two progress curves, comparable to the inhibition achieved in the 
presence of WT TFPI. These data indicate that although the presence of TFPI and protein S 
are required for the enhancing activity of FV, this cofactor function of FV is not strictly 
dependent on an optimal TFPI/protein S interaction, or FV can compensate for this 
deficiency. 
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Figure 3.33 Enhancement of WT TFPI and TFPI variants in the inhibition of FXa by WT protein S and FV. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of 0.5nM WT TFPI (A), 2nM TFPI ΔCt (B), 0.5nM TFPI R199Q 
(C), 0.5nM WT E226Q (D) and 20nM protein S and 30nM FV. Representative experiments are shown (n=3). PS, 
protein S. 
3.3.1.4 The role of FV in FXa inhibition by TFPI in the presence of protein S variants 
My recent work demonstrated that binding and enhancement of TFPI is mediated through 
the protein S SHBG-like domain.381 The SHBG-like domain has also been reported to serve as 
a docking site for FV.179,222 Protein S/Gas 6 chimeras containing large substitutions within 
the SHBG-like domain, were employed in FXa inhibition assays to evaluate the importance 
of this domain for the FV enhancement. As expected, no inhibition of FXa activity by the 
chimeras added alone or in combination with FV, was observed (Figure 3.34B-D). In line with 
the results presented in section 3.2.3.2, WT protein S and chimera II (comprising the LG2 
subunit replacement) efficiently enhanced TFPI-mediated inhibition of FXa, shown in Figure 
3.34A and 3.34C, respectively. As seen previously, addition of chimera I (containing the LG1 
substitution) and chimera III (with the entire SHBG-like domain swap) showed a minimal 
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enhancement of the TFPI anticoagulant activity (Figure 3.34B and Figure 3.34D, 
respectively), due to decreased affinities for protein S binding to TFPI. FV further enhanced 
FXa inhibition mediated by TFPI and WT protein S, as usual (Figure 3.34A). Efficient 
enhancement of TFPI, comparable to WT protein S, was achieved by addition of chimera I or 
chimera II in the presence FV, as shown in Figure 3.34B and Figure 3.34C respectively. Only 
substitution of the whole SHBG-like domain in chimera III resulted in loss of the FV 
enhancement (Figure 3.34D). These data, combined with the results presented for TFPI 
R199Q and TFPI E226Q variants, suggest that the FV cofactor function upon the TFPI/protein 
S-mediated inhibition of FXa is dependent on the presence of protein S, but it is not strictly 
dependent on a full affinity interaction between TFPI and protein S. However, it appears 
that the FV enhancement is mediated by the protein S SHBG-like domain. 
Figure 3.34 Enhancement of TFPI in the inhibition of FXa by WT protein S, protein S variants and FV. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of 0.5nM TFPI and 20nM WT protein S (A), chimera I (B), 
chimera II (C), chimera III (D) and 30nM FV. Representative experiments are shown (n=3). PS, protein S. 
146 
3.3.2 Evaluation of protein S and FV binding to TFPI using co-immunoprecipitation 
It is known that free protein S binds full-length TFPI in plasma.228 It has also been suggested 
that FV binds TFPI in circulation through its basic C-terminal tail.121 To verify that the 
enhancing effects upon the TFPI/protein S anticoagulant activities exerted by FV are due to 
its direct interaction with TFPI and protein S, I used a co-immunoprecipitation approach. To 
ensure that the antibody against the TFPI Kunitz 1 domain used in the following binding 
studies does not affect inactivation of FXa and therefore, according to my hypothesis, direct 
binding of TFPI and its two cofactors, I assessed the anti-Kunitz 1 domain antibody effects in 
the FXa inhibition assay. As shown in Figure 3.35, addition of the antibody produced no 
inhibition of TFPI in the presence or absence of its two cofactors. Hence, I was able to utilise 
this antibody as a tool for immunoprecipitation of TFPI and co-immunoprecipitation of its 
cofactors in the subsequent binding studies. 
Figure 3.35 Enhancement of TFPI in the inhibition of FXa by protein S and FV. 
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, in the presence or absence of 0.5nM TFPI, 20nM protein S, 30nM FV and 5nM of 
monoclonal antibodies against the TFPI Kunitz 1 domain. Representative experiment is shown (n=3). PS, 
protein S. 
The co-immunoprecipitation assay was further optimised for higher sensitivity and 
specificity compared to the one used in section 3.2.1.2. The protein interactions were 
assessed by mixing 20nM TFPI, 40nM protein S and 40nM FV with magnetic beads coupled 
with anti-TFPI Kunitz 1 domain antibodies. Bound protein S was eluted as previously 
described for experiments reported in section 3.2.1.2. Following unreduced SDS-PAGE, 
eluted TFPI, protein S and FV were detected by Western blotting using polyclonal 
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antibodies, as illustrated in Figure 3.36. Equal amounts of TFPI were successfully pulled 
down by the anti-TFPI Kunitz 1 domain antibodies, regardless of the presence or absence of 
protein S or FV (Lanes 1, 5, 6 and 7 in Figure 3.36A). While no protein S was pulled down in 
the absence of TFPI, it successfully co-immunoprecipitated with TFPI (Lane 6 in Figure 
3.36B), confirming previous reports of TFPI/protein S direct biding.121,228,230,381 Furthermore, 
increased amounts of protein S were pulled down (Lane 7) when all three proteins were 
present in the sample, compared to when protein S was incubated with TFPI alone. 
Similarly, no FV was detected in the absence of TFPI, whereas it was successfully pulled out 
with TFPI (Lane 5 in Figure 3.36C), supporting previous publications suggesting interactions 
between TFPI and FV.121,342 Importantly, even more FV co-immunoprecipitated with TFPI in 
the presence of protein S (Lane 7), demonstrating direct binding between the three 
proteins. These results complement the result from the FXa inhibition assays, and support 
the contention that the FV cofactor function observed for the FXa inhibition by TFPI and 
protein S are mediated through direct interactions between TFPI, protein S and FV. 
Figure 3.36 Analysis of protein S and FV co-immunoprecipitation with TFPI using Western blotting. 
20nM TFPI, 40nM protein S and 40nM FV diluted in TBS supplemented with 3mM CaCl2 and 3% BSA was 
incubated with magnetic beads coupled with monoclonal anti-TFPI Kunitz 1 domain antibodies. Samples were 
eluted from the beads, loaded on SDS-PAGE to allow protein separation in non-reducing conditions; and 
detected with Western blotting using polyclonal anti-TFPI antibodies (A), polyclonal anti-protein S antibodies 
(B) and polyclonal anti-FV antibodies (C). 40ng TFPI, 10ng protein S and 40ng FV not incubated with the beads 
were loaded on the SDS-PAGE as positive controls (+ve Ctrl). Representative experiments are shown (n=3). PS, 
protein S. 
A B C 
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3.3.3 Discussion 
Over past few years, several groups have demonstrated that TFPI binds to FV, FVa, FVa* and 
FVshort. While all these interactions have been attributed to the TFPI C-terminus,106,121,307 
the binding site on FVa* and FVshort was shown to comprise the acidic region within their 
partially truncated B domain of FV.106,307 A dramatic decrease in TFPI levels in the plasma of 
patients with severe FV deficiency was reported by Duckers and colleagues in 2008.342 This 
reduced TFPI concentration was associated with its decreased anticoagulant activity. This 
phenomenon most likely protects these patients from severe bleeding that one would 
expect to result from reduced FV levels. Patients suffering from east Texas bleeding disorder 
were recently shown to have high levels of FVshort in circulation.307 This FV isoform was 
shown to bind TFPI and to cause elevation of TFPI levels in plasma. Both of above studies 
suggest a strong association between TFPI and FV levels through a direct binding. While TFPI 
previously has been described as the main inhibitor of the initiation of coagulation, Wood et 
al. have recently demonstrated its role in inhibition of the propagation phase. According to 
their findings, TFPI inhibits prothrombinase through a direct interaction with FVa*.106 
Despite available knowledge on TFPI binding to FV, no information on the effects of this 
interaction upon TFPI anticoagulant activity and its enhancement by protein S has been 
provided to date.  
The assay utilised for the functional study of TFPI/protein S/FV interactions required careful 
consideration. The thrombin generation assay comprises a useful and potentially 
physiologically relevant method, as all plasma proteins are present. However, FV exerts 
important procoagulant functions and its presence is indispensable for thrombin formation. 
Depleting or inhibiting FV would directly result in downregulation of the TF-induced 
generation of thrombin. Moreover, considering that plasma levels of both FV and protein S 
correlate with concentrations of full-length TFPI, depleting one protein from plasma could 
lead to unwanted co-depletions of the other molecules. For these reasons, I was unable to 
use CAT assay to study anticoagulant activities of FV in plasma. 
I therefore explored the role of FV in the TFPI pathway using a purified system. I aimed to 
characterise the role of FV in TFPI-mediated inhibition of FXa and assess whether FV would 
have any impact on the protein S cofactor function. Using this approach, I demonstrated 
149 
efficient FV enhancement of the TFPI-mediated inhibition of FXa in the presence of protein 
S, shown in Figure 3.27. Addition of the inhibitory antibodies against FV and protein S 
confirmed the specificity of the FV enhancement and that this was highly dependent on 
protein S.  
I performed kinetic analysis of the FV enhancement. Like protein S, the enhancement by FV 
mainly increased the initial binding and inhibition of FXa (Figure 3.32). The inhibitory 
constant (reported in Table 3.3) obtained for the initial interaction between TFPI and FXa 
(Ki) was 10-fold higher than the Ki derived in the presence of protein S, which is consistent 
with previous reports.31 Importantly, the Ki for TFPI supplemented with protein S together
with FV was reduced by 32-fold, demonstrating a potential cofactor role of FV for TFPI and 
protein S in the initial inhibition of FXa. The concentration of free full-length TFPI in plasma 
is ~0.16nM.82 According to my assays, the enhancement by FV in the presence of protein S 
was most prominent at low concentrations of TFPI, indicating the potential physiological 
importance of FV activity. 
FV is an unstable protein, being prone to proteolysis in expression systems. During this 
project I spent much time optimising expression and purification protocols to obtain FV as 
pure as possible and minimise its proteolysis. To ensure that the enhancement of TFPI and 
protein S in FXa inhibition is mediated by full-length FV, I performed several control 
experiments. First, I evaluated FV cleavage in the samples pulled out from the FXa inhibition 
assays at different time points (0, 10, 20 and 60 minutes) and assessed using Western 
blotting. No cleavage of FV was noted during the first 10 minutes (results not shown). Since 
the FV cofactor function potentiates initial inhibition of FXa that occurs within the first 
minutes of the reaction, this data confirms that the enhancement of TFPI initial inhibition of 
FXa in the presence of protein S is not exerted by FV being activated during the assay. I also 
assessed the activity of FVa in the inhibition of FXa and the results are presented in Figure 
3.29. Trace amounts of FVa can be potentially present in the FV preparation. I initially 
evaluated the activity of 7.5nM of FVa, but did not observe any effects upon the activity of 
FXa. On the other hand, when FVa concentrations closer to the physiological concentrations 
of FV were added, inhibition of the anticoagulant activities of TFPI and protein S was 
observed. This could be due to a competition between FVa and TFPI for binding to FXa. 
However, the physiological importance of such competition is uncertain. In 1996, Mast et al. 
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performed similar FXa inhibition assays but using very high concentrations of TFPI (4nM). In 
their study, FVa slightly enhanced the activity of TFPI, whereas addition of the same amount 
of FV, enhanced TFPI-mediated inhibition of FXa even further.109 Nevertheless, due to very 
high TFPI concentrations used in this assay, the physiological relevance of this finding is 
questionable. Interestingly, Al Dieri et al. recently showed that FVa dose-dependently 
inhibits the activation of FX by TF/FVIIa. They speculate that FVa, through its light chain, 
binds to the TF/FVII complex and prevents generation of FXa. On the other hand, they 
reported a lack of FVa effects upon the thrombin generation which was triggered via 
intrinsic pathway or by direct activation of FXa.386 In my research, I did not evaluate activity 
of FV or FVa in FXa generation, but based on the results from the FXa inhibition assays, I 
would expect FVa to either not affect or enhance generation of FXa. Whether FV is able to 
enhance the TFPI/protein S-mediated inhibition of FXa generation also remains to be 
elucidated. Yet, my current results support a lack of anticoagulant cofactor function of FVa. 
The importance of the full-length FV was further confirmed using commercial plasma-
purified FV. This FV showed essentially equal enhancement of TFPI-mediated inhibition of 
FXa in the presence of protein S that had been demonstrated by my recombinant FV (Figure 
3.30). The plasma-derived FV preparation could potentially contain traces of FVshort,307 but 
no additional inhibition compared to full-length FV was detected. This data suggests that the 
enhancement of TFPI and protein S is mediated mainly by uncleaved form of FV. 
TFPI lacking its C-terminal tail expresses markedly reduced activity. This has been suggested 
to occur due to its lower affinity for phospholipids,111 although the TFPI C-terminus binding 
to the membranes may be of little relevance in the presence of cofactors for TFPI.229,381 I 
was only able to achieve equivalent level of inhibition that was defined for WT TFPI by 
increasing the concentration of TFPI ΔCt by 4-fold. Consistent with published reports,229 
protein S efficiently enhanced this form of TFPI. To investigate whether the FV enhancement 
of TFPI/protein S-mediated inhibition of FXa is conferred by the C-terminal of TFPI, I 
assessed FV cofactor function for TFPI ΔCt. These results are shown in Figure 3.33A. In the 
presence of protein S, FV efficiently enhanced TFPI lacking its C-terminal tail, indicating that 
the C-terminal tail is not essential for facilitating the cofactor role of FV for TFPI inhibition of 
FXa. This observation was somewhat surprising, considering the suggested interaction 
between the TFPI C-terminal tail and FV.121 According to my data, the presence of another 
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binding site between TFPI and FV is very likely. However, domains or residues within TFPI, 
important for this interaction will have to be evaluated in future studies. 
TFPI R199Q and TFPI E226Q are known to exhibit reduced enhancement by protein S.229,230 I 
evaluated the relevance of Arg199 and Glu226 in the cofactor function of FV (Figure 3.33C-
D). As expected, although these variants were able to inhibit FXa activity, this inhibition was 
poorly potentiated by protein S. In particular, E226Q was not enhanced, which is explained 
by the lack of protein S binding.230 Nevertheless, FV still efficiently facilitated FXa inhibition 
in the presence of these TFPI variants and protein S. It is worth pointing out that a 
marginally greater inhibition of FXa was achieved in the presence of WT TFPI. These results 
can be interpreted in several ways. On one side, it is possible that due to the presence of FV, 
the importance of the position Glu226 (and Arg199) is somewhat overcome. Often, the 
binding sites mediating interactions with one protein, are later shown to become less 
important in the presence of additional proteins. On the other hand, my results can indicate 
that the direct binding between protein S and TFPI is not critical for the enhancement by FV 
to occur, but is needed to achieve maximal inhibition of FXa by cofactor function of FV. The 
detailed mechanism underpinning the TFPI/FV and protein S/FV interactions needs further 
characterisation. 
The anticoagulant properties of FV have previously been implicated in the APC pathway. The 
synergistic role of FV and protein S as cofactors was demonstrated for the APC-mediated 
inactivation of activated FVIII.387 While the cooperative relationship between protein S and 
FV is indisputable, the exact interaction sites involved are yet to be fully characterised. 
However, importantly and similarly to my findings in the TFPI pathway, the protein S SHBG-
like domain was found to be crucial. As presented in Figure 3.34, protein S chimera III 
containing the substitution of the entire SHBG-like domain was unable to enhance TFPI and 
could not be further enhanced by FV. These results strongly suggest that the SHBG-like 
domain is important for the cofactor function of FV, most likely by mediating protein S 
interaction with FV. This is in agreement with previous reports suggesting involvement of 
both LG subunits in FV binding to enhance APC in plasma.179,222 Somewhat surprisingly, my 
results demonstrated that chimera I (with substituted LG1), shown to contain a functional 
interaction site for TFPI, as well as chimera II (containing the LG2 substitution), were both 
efficiently enhanced by FV. This indicates that both LG subunits may have a role in FV 
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enhancement, and the presence of only one is sufficient to mediate interaction with FV. To 
verify this, further kinetic evaluation together with binding studies, most likely using single 
or small composite substitutions, are needed. I hypothesise that the lack of FV 
enhancement in the absence of the whole SHBG-like domain occurs because FV cannot bind 
to protein S. Protein S binding to FV may to some extent overcome the lack of direct 
interaction between protein S and TFPI. Taken together, these data suggest that a functional 
SHBG-like domain is a critical component for FV enhanced FXa inhibition, and an efficient 
interaction between FV and protein S enables maximal cofactor activity for TFPI-mediated 
inhibition of FXa. 
Using co-immunoprecipitation experiments, I examined direct interactions between TFPI, 
protein S and FV. This assay was employed to enable binding studies of these proteins. It 
was revealed that FV potentiates protein S binding to TFPI, and similarly, FV interaction with 
TFPI is further enhanced by the presence of protein S (Figure 3.36). Trace amounts of 
proteolysed FV in the FV preparation and FV eluted in the co-immunoprecipitation assays 
were detected on Western blotting. However, the same FV appeared intact on SDS-PAGE 
presented in Figure 3.7C. This could be potentially explained by the preferential binding of 
the anti-FV antibodies to the FV cleavage product. As mentioned in the previous paragraphs, 
the TFPI/protein S enhancement is unlikely to be mediated by FVa. On the other hand, it is 
difficult to exclude influences of other cleavage products at this time. Generation and 
assessment of the activity of FV resistant to cleavages at Arg709, Arg1018 and Arg1545 in 
further work could be highly informative. Nevertheless, the co-immunoprecipitation results 
indicate that the FV enhancement of TFPI/protein S-mediated inhibition of FXa observed in 
the functional assays probably occurs through direct interactions of FV with TFPI and protein 
S. Yet, further, more quantitative experiments are needed to confirm these findings. 
I have demonstrated a new cofactor function of FV to facilitate the anticoagulant activities 
of TFPI and protein S, most likely occurring through direct binding between these three 
proteins. Importantly, the enhancing effects of FV in the TFPI/protein S complex-mediated 
initial inhibition of FXa were illustrated using highly purified components. While this assay 
represents an informative method to analyse protein interactions and coagulation 
processes, it inevitably excludes many of the variables present in circulation, such as 
presence of additional pro- and anticoagulant proteins as well as proteases. Also, the fact 
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that protein S is known to facilitate TFPI also in inhibition of the TF/FVIIa complex,31,77 
should be taken into consideration when evaluating the importance of FV enhancement 
during the initial stage of coagulation. In future studies, one should explore this novel role of 
FV in more physiological settings to reflect the scenario taking place in vivo. Implementing 
assays that would enable assessing downstream consequences upon assembly and function 
of the prothrombinase complex could help shed more light on the physiological importance 
of this novel role of FV. 
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4. CONCLUDING REMARKS
The research work for my thesis has generated novel information on the anticoagulant 
mechanisms of TFPI by characterising a functional interaction site on protein S important for 
the TFPI enhancement, as well as revealing a potential novel cofactor for TFPI. In this 
concluding chapter, I will attempt to put into perspective the results obtained during my 
research in the light of currently available information in the literature on this subject, and 
elaborate on the regulation of coagulation by TFPI and its two cofactors protein S and FV. 
4.1 Regulation of coagulation by TFPI 
Coagulation is controlled by three distinct anticoagulant pathways, each undertaking a 
distinct role to maintain balanced haemostasis. While the mechanisms underpinning actions 
of the APC pathway and the structural transitions of AT that are necessary for its functions 
are both well understood, it is still uncertain how efficiently TFPI regulates coagulation. One 
concern is the low effectiveness of TFPI in inhibiting the initiation of coagulation. The 
concentration needed for a half maximal reduction of FXa activity (its Ki) is more than 10-
fold higher than the plasma concentration of free full-length TFPI, making TFPI acting on its 
own a very inefficient inhibitor of FXa.31,77 This raised the question of whether there might 
be a functional cofactor that could improve the activities of TFPI. A critical finding was that 
protein S kinetically enhances the inhibitory interaction between TFPI and FXa.31 Protein S 
also augments the TF/FVIIa-mediated generation of FXa, leading to decreased thrombin 
formation.31,77 The concept of cofactors facilitating activities of anticoagulant proteins is 
familiar. For example, APC inhibition of FVa and FVIIIa occurs efficiently only in the presence 
of its cofactors protein S and FV.197,214 It therefore appears that cofactors for anticoagulants, 
such as protein S for APC and TFPI, are able to regulate as well as localise the formation and 
activity of thrombin to ultimately control haemostasis both temporally and spatially.  
Another concern that hinders understanding of the TFPI system, is its diversity in structure 
as well as its varied expression. Nevertheless, it is believed that the heterogeneous 
expression of TFPI confers its differential functions during the haemostatic processes. Full-
length TFPI, TFPIα, is released from activated platelets and endothelial cells, and is predicted 
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to mediate the physiologically recognised anticoagulant function of TFPI during the initiation 
of coagulation.27 This form of TFPI is effectively enhanced by protein S. On the other hand, 
TFPIβ located on endothelial cells surrounding the tissue damage, is likely to specifically 
regulate inhibition of FXa that escapes the site of vascular injury. The inhibitory efficiency of 
this latter TFPI pool, due to its location and truncations, will rely only upon direct actions of 
TFPI itself, as it is not enhanced by protein S.75 Furthermore, a large proportion of plasma 
TFPI is bound to lipoproteins and truncated. Although the role of this TFPI pool in the 
anticoagulant processes is uncertain, mainly because it is not enhanced by protein S,229 it 
still may provide relevant functions due to its relatively high concentrations in plasma.388 
For a long time, TFPI has been considered to influence only the initiation of coagulation,31 
whereas efficient downregulation of the propagation step of coagulation has been mostly 
attributed to the APC/protein S pathway.192 However, recently, synergistic activity of the 
TFPI/protein S and APC/protein S systems during the propagation stage was suggested.224,228 
Moreover, TFPI has also been shown to inhibit prothrombinase activity through an 
interaction with a partially-activated FV.106 Potentially, these three anticoagulant systems 
cooperate to effectively reduce thrombin generation during the propagation phase of 
coagulation. In the first instance, APC/protein S and TFPI/FVa* could reduce the 
procoagulant response and diminish the augmented generation of thrombin, which would 
then allow TFPI/protein S to mediate the slow binding and inhibition of FXa, all leading to 
the efficient control of thrombin formation. Nevertheless, this role of the TFPI/protein S 
complex in the propagation phase has not been fully verified and, at this time, the weight of 
evidence favours it acting predominantly during the initial stage of coagulation. 
4.1.1 TFPI cofactor function of protein S: interaction sites and mechanism 
During the work for my thesis, I identified the importance of the SHBG-like domain in the 
TFPI binding and enhancement during inhibition of FXa. As the SHBG-like domain comprises 
a large proportion of the protein S molecule, further research is needed to identify the 
specific interaction site for TFPI. It is interesting that protein S has been shown to also affect 
the inhibition of TF/FVIIa complex activity by TFPI.31,77 Such dual facilitating effect upon the 
TFPI actions, in inhibiting FXa as well as TF/FVIIa, indicates the possible physiological 
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importance of protein S in the TFPI pathway. The role of the SHBG-like domain in the 
protein S cofactor function upon the inhibition of TF/FVIIa-mediated generation of FXa by 
TFPI is highly likely, but requires formal verification. 
Another aspect of the TFPI/protein S complex activities that has not been fully explored is 
the role of C4BP in this pathway. Even though C4BP does not directly affects the coagulation 
system, it greatly influences the regulation of coagulation through its interaction with 
protein S, creating a link between coagulation and complement pathways. Despite several 
reports on C4BP negatively affecting the APC and TFPI anticoagulant systems,31,202,389 and its 
association with a risk of venous thrombosis,390 the exact mechanisms through which C4BP 
regulates coagulation are yet to be elucidated. Because I found that the SHBG-like domain 
of protein S binds to TFPI, I became interested in this matter. Since protein S preferentially 
binds to C4BP in a 1:1 ratio with a very high affinity,391 approximately 95nM of plasma 
protein S should remain392 available to interact with APC or TFPI and function as their 
cofactor. While APC has been suggested to bind to the protein S Gla domain161,207 and to the 
EGF1 domain,175,393 the interactions with C4BP and TFPI are both mediated through the 
SHBG-like domain.178,179,381 According to my results, C4BP-bound protein S is a poor cofactor 
for TFPI, and these findings fully support a previous observation by Hackeng et al.31 While 
this reduction in C4BP-bound protein S cofactor function towards TFPI complements results 
from my studies showing the importance of the SHBG-like domain in the TFPI enhancement, 
additional research is needed to evaluate the nature of the competition between C4BP and 
TFPI to interact with protein S. Either this reduction in the TFPI enhancement occurs due to 
TFPI and C4BP binding to the same residues within the protein S SHBG-like domain, or it is 
caused by steric hindrance mediated by C4BP, thereby blocking TFPI from accessing the 
reactive site on the protein S SHBG-like domain. Several clusters within both LG subunits 
have been proposed to comprise the interaction site for C4BP,262-267,394 whereas the point of 
interaction with TFPI is likely within the LG1 subunit381 (Figure 4.1). Determing which 
residue(s), are particularly important for TFPI binding and enhancement, would clarify 
further the mechanisms behind the competition between TFPI and C4BP. 
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Figure 4.1 Residues within the protein S SHBG-like domain interacting with C4BP and TFPI. 
Residues essential for binding to C4BP are coloured blue and the proposed binding area within LG1 for TFPI is 
shown in purple. The SHGB-like domain model is adapted from Villoutreix et al.
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Like many other haemostatic processes, inhibition of FXa by TFPI occurs on the activated 
surfaces on which FXa is localised. However, the binding affinity of TFPI for phospholipid 
membranes is very weak. Many have hypothesised that protein S, through its high affinity 
for negatively-charged membranes, brings TFPI closer to the membrane-bound FXa, 
resulting in improved FXa inhibition.31,229,230,381 This was indirectly shown by Wood et al.75 
According to their findings, the TFPI cofactor function of protein S is conferred only by 
TFPIα, as TFPIβ is already associated with the membranes, and therefore does not require 
protein S to potentiate its phospholipid binding for efficient inhibition of FXa. Interestingly, 
TFPI binding to phospholipids has been suggested to be mediated through its C-terminus.111 
On the other hand, in the presence of FXa, TFPI lacking the C-terminal tail can still localise to 
phospholipid membranes.112 Also, although the inhibitory function of TFPI upon FXa appears 
to be dependent on its C-terminus,229,379 it is dispensable for the facilitating effects of 
protein S,121 indicating that a direct binding of TFPI to phospholipids through its C-terminus 
might not be relevant in a physiological environment (when protein S is present). I believe 
that in plasma, protein S binds TFPI and, through its high affinity for phospholipids, it 
efficiently facilitates interaction with TFPI and therefore inhibition of FXa located on the 
negatively-charged surfaces (most likely provided by the activated platelets). My results 
indicate that protein S and TFPI associate through a direct interaction between the LG1 
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subunit in the SHBG-like domain of protein S and the TFPI Kunitz 3 domain,229 most likely 
with Glu226.230 
4.1.2 TFPI/protein S cofactor function of FV: possible interaction sites and a suggested 
mechanism 
In the final part of the work I carried out, I demonstrated a new cofactor function of FV 
upon the inhibitory activities of the TFPI in the presence of protein S, mediated by direct 
interactions between the three molecules. I believe that this novel anticoagulant function of 
FV is attributed to full-length FV. My results demonstrated that FV is efficient in enhancing 
inhibition of FXa mediated by TFPI at concentrations below its free full-length levels in 
plasma, in the presence of physiological concentrations of free protein S. For these reasons, 
I hypothesise that during the initial stage of coagulation, before the activation of FV and 
efficient formation of the prothrombinase complex, sufficient amounts of full-length FV will 
be available to contribute to the enhancement of the TFPI/protein S complex in inhibiting 
FXa. Potentially, TFPI enhanced by bound protein S and FV, will efficiently inhibit FXa 
thereby limiting assembly or activity of prothrombinase. Since TFPI is already in complex 
with protein S and full-length FV which contains an intact B domain, direct binding of the 
TFPI/protein S/FV complex to FVa is unlikely.  
As mentioned previously, the TFPI/protein S anticoagulant system is limited to free full-
length plasma TFPI that has been released from platelets or endothelial cells.75 TFPI inhibits 
FXa inefficiently in the absence of cofactors. Protein S has been kinetically shown to 
enhance mainly the initial inhibition of FXa by facilitating the initial interaction between TFPI 
and FXa, with a less apparent effect upon the isomerisation step.31,381 I propose a similar 
mechanism of TFPI cofactor function exerted by FV. Importantly, the enhancement of TFPI 
by protein S is phospholipid-dependent.31 Also, no FV enhancement takes place in the 
absence of phospholipids. Furthermore, antibodies directed against the C2 domain of FV, 
previously shown to mediate its binding to phospholipids,385 abolished the entire FV 
cofactor function. Taken together, the finding that FV cofactor activity is phospholipid-
dependent mirrors that of the enhancement exerted by protein S. I have demonstrated that 
FV acts synergistically with protein S to facilitate TFPI association with FXa without affecting 
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the isomerisation step. Since the initial formation of the complex between TFPI and FXa is a 
rate limiting step,31 the enhancement of this stage by the two cofactors, likely accounts for 
their most significant roles in the control of the initiation of coagulation.  
While my research has revealed a novel role of FV, the specific interaction sites important 
for its enhancement of TFPI and protein S in inhibiting FXa are yet to be defined. Within FV, 
the integrity of its B domain appears to have a significant role in cofactor function towards 
TFPI and protein S. Whether the B domain actually comprises the interaction site with TFPI 
or protein S, remains to be evaluated. The A2 domain in FVa is known to bind to FXa,395 but 
it is not known whether this is also the case for FV. Regarding TFPI, although its C-terminus 
has been suggested to mediate TFPI binding to FV,121 it is not essential for the FV 
enhancement of the initial inhibition of FXa in the presence of protein S. Also, the role of the 
protein S SHBG-like LG subunits in the FV enhancement should be characterised in greater 
detail. While a cluster of residues within LG2 has been proposed to mediate interaction with 
FVa180 (Figure 4.2), my results suggested that either of the LG subunits can be sufficient to 
provide interaction site for binding to FV. To verify this, further kinetic evaluation together 
with binding studies, most likely using single or small composite substitutions, are needed. 
Figure 4.2 Residues within the protein S SHBG-like domain suggested to interact with FVa. 
Residues that may be important for interaction with FVa
180
 are highlighted in green. The SHGB-like domain 
model is adapted from Villoutreix et al.
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I hypothesise that FV and its isoforms have potentially important roles in supporting the 
anticoagulant pathways. On one hand, TFPI bound to FVshort increases inhibition of 
coagulation.307 On the other hand, since in normal plasma very low concentrations of this 
form of FV can be detected, the magnitude and the physiological relevance of this 
interaction may be questioned. At the same time, during the propagation of coagulation, 
TFPI binds to partially-activated FV, leading to downregulation of the prothrombinase 
activity.106 Also, binding of FV have been suggested to increase TFPI half-life in plasma by 
protecting from is truncation and/or clearance.342 Now, my research indicates an additional 
function of FV in cooperation with protein S in enhancing TFPI to inhibit FXa, most likely 
occurring during the initial stages, before FV becomes activated. The fact that FV exerts any 
anticoagulant functions is rather surprising due to its well established procoagulant role in 
circulation. All actions of FV appear to be highly dependent on its proteolysis. I believe that 
differential cleavage of FV, together with local availability of the associated procoagulants or 
anticoagulants, define whether FV will exert its pro- or anticoagulant properties. 
To conclude, TFPI plays an important role in regulating haemostasis through inhibition of 
FXa and TF/FVIIa. The activity of TFPI in inhibition of the membrane-bound FXa is 
substantially enhanced by its cofactors protein S and FV, leading to efficient downregulation 
of FXa activity. I propose a model in which these three anticoagulant proteins jointly 
promote inhibition of FXa on an activated surface (Figure 4.3). 
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Figure 4.3 Proposed model of the mechanism of protein S and FV cofactor functions in the enhancement of 
TFPI in inhibiting FXa. 
My results suggest the mechanism by which TFPI inhibition of FXa is enhanced by protein S and FV by forming 
a TFPI/protein S/FV complex through direct interactions mediated by the protein S SHBG-like domain. Protein 
S and FV cooperatively bring TFPI in proximity to a membrane-bound FXa, thereby increasing efficiency of its 
inhibition. 
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APPENDIX 
Figure 1. Enhancement of TFPI in the inhibition of FXa by WT protein S, Face1 and GLA2.  
FXa activity (0.5nM) was followed in real-time through cleavage of S-2765 (200µM) at 405nm in the presence 
of 25μM phospholipids, presence or absence of TFPI (1.5nM) and 10 or 40nM WT protein S, Face1 (A) and 
GLA2 (B). Results from representative experiments are shown (n=2). 
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Key Points
• The protein S SHBG-like
domain and, more
specifically, its LG1 subunit
are important for binding and
enhancement of TFPI.
• TFPI binding to the protein S
SHBG-like domain likely
positions TFPI Kunitz domain
2 for optimal interaction with
the active site of FXa.
Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the
inhibition of activated factor X (FXa). TFPI Kunitz domain 3 residueGlu226 is essential
for enhancement of TFPI by protein S. To investigate the complementary functional
interaction site on protein S, we screened 44 protein S point, composite or domain
swap variants spanning the whole protein S molecule for their TFPI cofactor function
using a thrombin generation assay. Of these variants, two protein S/growth arrest–
specific 6 chimeras, with either the whole sex hormone–binding globulin (SHBG)-like
domain (Val243-Ser635; chimera III) or the SHBG laminin G-type 1 subunit (Ser283-
Val459; chimera I), respectively, substituted by the corresponding domain in growth
arrest–specific 6, were unable to enhance TFPI. The importance of the protein S
SHBG-like domain (and its laminin G-type 1 subunit) for binding and enhancement of
TFPI was confirmed in FXa inhibition assays and using surface plasmon resonance.
In addition, protein S bound to C4b binding protein showed greatly reduced en-
hancement of TFPI-mediated inhibition of FXa compared with free protein S.We show
that binding of TFPI to the protein S SHBG-like domain enables TFPI to interact optimally with FXa on a phospholipidmembrane.
(Blood. 2014;123(25):3979-3987)
Introduction
Tissue factor pathway inhibitor (TFPI) is a ;41 kDa Kunitz-type
protease inhibitor that consists of an acidic amino-terminal poly-
peptide, followed by 3 tandemKunitz-type domains (Kunitz domains
1, 2, and 3) and a basic carboxy (C)-terminal tail.1 It circulates in
plasma at a concentration of ;1.6 nM.2,3 The majority (;80%) of
plasmaTFPI is truncated and bound to lipoproteins,;5% is localized
in storage granules within platelets,;5% circulates as free truncated
variants, and only around 10% is considered to be free full-length
TFPI,4 with this having the greatest anticoagulant activity.5-7
TFPI and its cofactor protein S downregulate tissue factor
(TF)-induced thrombin generation, and a deﬁciency of either
protein has been linked to an increased risk of venous thrombosis.8-10
TFPI speciﬁcally inhibits the initiation of coagulation through direct
binding and inhibition of factor Xa (FXa) and, in a FXa-dependent
manner, inhibition of the TF/factor VIIa (FVIIa) complex by
forming a quarternary TF/FVIIa/FXa/TFPI complex.11,12 The P1
residue in the Kunitz domain 2 of TFPI is required for binding to
FXa, whereas the P1 residue in Kunitz domain 1 is required for
binding and inhibition of TF/FVIIa.13 The kinetic mechanism of
FXa inhibition by TFPI is described as a 2-step process where TFPI
ﬁrst forms an immediate encounter complex with FXa (FXa/TFPI),
followed by a slow isomerization into a ﬁnal tight complex
(FXa/TFPI*).14
Protein S, as well as being a well-established cofactor for ac-
tivated protein C (APC), is a cofactor for TFPI and reduces the Ki for
FXa inhibition by TFPI approximately tenfold.15 It thereby reduces
the dissociation constant of the TFPI/FXa complex to close to the
plasma concentration of free full-length TFPI (0.25 nM).15 The
protein S enhancement of TFPI is dependent on the TFPI Kunitz
domain 3, particularly TFPI Kunitz domain 3 residues Glu226 and
Arg199.16,17 The complementary interaction site on protein S for
TFPI has to date not been the subject of any report, and the mech-
anism behind this enhancement has yet to be fully deﬁned.
Protein S is a 73-kDa, vitamin K–dependent, multidomain
protein.9 It comprises an N-terminal g-carboxylated glutamic acid
(Gla) domain, a thrombin-sensitive region (TSR), 4 epidermal growth
factor–like (EGF) domains and a C-terminal sex hormone–binding
globulin (SHBG)-like domain.18 The SHBG-like domain is composed
of 2 lamininG-type subunits, LG1andLG2.19,20 ProteinS circulates in
plasma at concentrations of 20 to 25mg/mL, with approximately 60%
bound to C4b-binding protein (C4BP).21-23 The protein S/C4BP in-
teraction is of high afﬁnity (0.1 nM), and the binding site for C4BP
is located in the protein S SHBG-like domain.24,25
In the present study, we investigated the functional interaction
site of protein S for TFPI usinga library of 44protein Svariants.Using
single-point and composite variants, we examined the importance of
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solvent-exposed amino acid residues spanning the Gla-TSR-EGF1-
EGF2-EGF3-EGF4 domains. The role of the protein S SHBG-like
domainwas investigatedusing3previously describedproteinS/growth
arrest–speciﬁc 6 (Gas6) domain swap chimeras.24,25 Using thrombin
generation and FXa inhibition assays, as well as a direct binding
method,wedemonstrate that theSHBG-like domainmediates theTFPI
cofactor function of protein S.
Materials and methods
Generation and expression of protein S variants
Wild-type (WT) protein S and a panel of 34 protein S variants containing
composite or single amino-acid substitutions spanning the Gla-TSR-EGF1-
EGF2domainshave beengenerated anddescribedpreviously.26,27Only protein
S Gla variants previously shown to bind normally to phospholipid membranes
were evaluated for their TFPI cofactor function.27,28 In addition, the cDNA for
3 previously described protein S/Gas6 chimeras were available.24,25 In
these, either the whole SHBG-like domain (Val243-Ser635; chimera III),
or its individual LG1 (Ser283-Val459; chimera I) or LG2 (Ser460-Ser635;
chimera II) subunits, were replaced by the corresponding domains of the
homologous Gas6. Additional protein S mutants spanning the EGF1 and 3-4
domains were constructed through site-directed mutagenesis (KOD Hot Start
DNA polymerase kit; Novagen) using the pcDNA/WT protein S vector as a
template andmutagenic oligonucleotide primers (Thermo Scientiﬁc).Muta-
tions were veriﬁed by DNA sequencing. The following mutations were intro-
duced: N86A/E87Q/D88A/M91A (termed NEDM), K94A/T103A/K105A
(termed KTK), D182N/E184Q/E186Q/E189Q (termed DEEE), R192Q/
E201Q/D202N/D204N (termed REDD), D227N/K233Q (termed DK),
K229Q/K230Q (termed KK), and D237N/K239Q/E242Q (termed DKE); see
supplemental Table 1 on theBloodWeb site for full details on substitutions in all
44 protein S variants.
The vectors containing WT or mutant protein S were either transiently or
stably transfected into HEK293T or HEK293 cells (ATCC), respectively, fol-
lowed by expression in the presence of vitamin K as previously described.26,27
Protein S purification and quantification
WT protein S and protein S variants were either concentrated in conditioned
medium or puriﬁed using barium citrate precipitation29 followed by anion-
exchange chromatography as previously described.27 Protein S concentra-
tions of WT protein S and protein S single or composite variants (spanning
Gla-TSR-EGF1-EGF2-EGF3-EGF4) were determined by a previously de-
scribed in-house enzyme-linked immunosorbent assay (ELISA).26,27 The
concentrations of puriﬁed WT protein S and protein S/Gas6 chimeras were
determined by absorption at 280 nmusing extinction coefﬁcients (E1%, 1 cm)
of 9.8, 10, 9.5, and 9.9 for WT protein S and chimeras I, II, and III, respec-
tively. The extinction coefﬁcients were predicted through the ProtParamTool
(ExPasy). Semiquantitative western blotting using a monoclonal antibody
conﬁrmed the validity of this approach (results not shown).
TFPI expression, purification, and quantification
TFPI was expressed, puriﬁed, and quantiﬁed as previously described.17 Brieﬂy,
the TFPI expression vector was transiently transfected into HEK293T cells.
After a 3-day expression, full-length TFPI was puriﬁed in 2 steps; heparin
Sepharose FF chromatography followed by afﬁnity puriﬁcation using an
anti-TFPI Kunitz domain 1 antibody (Sanquin). The pure TFPI was quantiﬁed
using an in-house ELISA. As described previously, TFPI expressed and puri-
ﬁed according to this protocol is full-length and fully active andmigrates as one
band on a sodium dodecyl sulfate–polyacrylamide gel electrophoresis with an
apparent molecular weight of 41 kDa.
Phospholipid vesicle preparation
Synthetic phospholipids (Avanti Polar Lipids) 1,2-Dioleoyl-sn-glycero-3-
phosphoserine, 1,2-Dioleoyl-sn-glycero-3-phosphocholine, and1,2-Dioleoyl-
sn-glycero-3-phosphoethanolamine were mixed in a molar ratio of 20:60:20
and extruded as previously described.26
Thrombin generation assay by CAT
The TFPI cofactor function of protein Swas assessed by calibrated automated
thrombography (CAT) using a Fluoroscan Ascent FL plate reader (Thermo
Labsystem) and Thrombinoscope software (Synapse BV), as described
previously.26,27 Thrombin generationwas initiated in 80mLprotein S–depleted
plasma (EnzymeResearch Laboratories) with 1 pMTF (Dade Innovin), 50mM
phospholipid vesicles, and 16.6 mM CaCl2 in a total volume of 120 mL. The
amount of thrombin formed was monitored using 0.42 mM of a thrombin-
sensitiveﬂuorogenic substrate, Z-Gly-Gly-Arg-AMC(Bachem) in the presence
or absence of TFPI (0-2 nM) and protein S (0-100 nM). Protein S was added
either as concentrated and dialyzed conditioned media or as puriﬁed protein.
The addition of concentrated conditioned media from mock-transfected
HEK293 cells did not affect thrombin generation. To inhibit contact activation,
corn trypsin inhibitor (Enzyme Research Laboratories) was added (30 mg/mL
plasma in the screening experiments and 65 mg/mL plasma in protein
S titrations). A polyclonal antibody against protein S (DAKO) and mixture
of monoclonal antibodies against Kunitz domain 1, Kunitz domain 2, and
C-terminus of TFPI (Sanquin) were used to show that any effects from the
addition of protein S and TFPI were speciﬁc.
The TFPI cofactor function of protein S was initially assessed in 3 dif-
ferent protein S–depleted plasmas. One of the plasmas (frozen protein
S–depleted plasma; Enzyme Research Laboratories) showed more reproduc-
ible results and was more sensitive to the addition of TFPI and protein S than
the other two (lyophilized protein S–depleted plasma from Hyphen and
Afﬁnity Biologicals; results not shown) and was consequently used for all
experiments reported in this study.
Binding of protein S to domain-specific monoclonal antibodies
Domain-speciﬁc monoclonal antibodies MK21 (Gla), MK41 (EGF3/EGF4),
MK54 (EGF1), and MK67 (TSR),30 all at 1 mg/mL, were immobilized in
a 96-well Maxisorp microplate in 50 mM sodium carbonate buffer, pH 9.6, at
4°C overnight. All subsequent incubations were carried out at room tempera-
ture, and wells were washed 3 times with 250mL of 20mMTris-HCl pH 7.4,
150 mM NaCl, 3 mM CaCl2 (TBSCa
21), and 0.1% Tween 20 between each
step. Wells were blocked with 200 mL 3% bovine serum antigen (BSA) in
TBSCa21 for 2 hours. Titrated protein S variants (0-10nMforMK21, 0-15 nM
forMK41 andMK54, and 0-1.5 nM forMK67) were incubated in the plate for
1 hour. Bound protein S was detected with a biotinylated monoclonal anti-
protein S antibody (HTI), followed by a high sensitivity streptavidin-
horseradish peroxidase diluted 1:10000 (Pierce).
Protein S-dependent APC-mediated FVa inactivation assay
Protein S enhancement of APC-mediated inactivation of a previously
prepared and reported double mutant of FV, FV R506Q/R679Q,31 was
assessed by determining the loss of FVa activity as described previously.26,27
Brieﬂy, FVR506Q/R679Qwas activated by human thrombin followed by the
addition of hirudin. The activated FVa variantwas used as a substrate for APC
to determine the ability of protein S variants (0-100 nM) to enhance cleavage
of Arg306 of FVa by 0.25 nM APC in the presence of phospholipids. After
stopping the reaction by a dilution in ice-cold TBSCa21 supplemented with
0.5% BSA, the remaining FVa activity was measured in a prothrombinase
assay, as described previously.26
C4BP purification and characterization
Plasma-puriﬁed C4BP (Complement Technologies, Inc.), was further puri-
ﬁed to remove bound protein S, essentially as previously described.32 Brieﬂy,
C4BP was incubated in 3 M guanidine and 20 mM Tris, pH 7.4, for 1 hour
at room temperature and separated from protein S using a HiPrep 16/60
Sephacryl S-300 column (GE Healthcare). C4BP and protein S eluted in
separate fractions, as expected. The C4BP pool was concentrated and the
protein concentration was determined by absorption at 280 nm using an
extinction coefﬁcient (E1%, 1 cm) of 13.32.33 To assess the optimal
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C4BP/protein S ratio resulting in complete binding of protein S, different
molar concentrations of C4BP and WT protein S were mixed in TBSCa21
supplemented with 0.1% BSA and incubated for 1 hour at room temperature.
The presence of free protein S was investigated using size-exclusion
chromatography (Superose 12; GE Healthcare) followed by ELISA and
western blotting. We found that when a molar ratio of 1.8:1 of C4BP and
protein S were mixed, no free protein S was detected (results not shown).
FXa inhibition assay
FXa (0.5 nM; Enzyme Research Laboratories) activity was monitored by the
cleavage of the chromogenic substrate S-2765 (Chromogenix), in the pres-
ence or absence of 2 nM TFPI and protein S variants (0-160 nM), in the
presenceof 25mMphospohlipids and5mMCaCl2, as describedpreviously.
16,17
To study the enhancement of TFPI-mediated FXa inhibition by C4BP-bound
protein S,WT protein S was preincubated with a twofoldmolar excess of C4BP
in assay buffer for 1 hour at room temperature. TFPI cofactor function of C4BP-
bound protein S was studied as described here previously. To derive the
concentration of protein S required to reach 50% of the maximal enhancement
of TFPI-mediated inhibition of FXa (EC50), the initial velocity (V0) of the
S-2765 cleavage was plotted against the protein S concentration. The V0
was determined using nonlinear regression as previously described.15,16
The EC50 was determined by a one-phase exponential decay nonlinear
curve ﬁt.16,17
Binding of protein S to TFPI investigated by surface
plasmon resonance
Puriﬁed recombinant TFPI was immobilized on a CM5 chip (GEHealthcare)
using amine coupling according to the manufacturer’s instructions. The ﬂow
cells were perfused with protein S (0-1000 nM) and measurements were
carried out by surface plasmon resonance (SPR) as described previously.16,17
Results
Screening of protein S variants for the TFPI cofactor function
in plasma
Thrombin generation wasmeasured in protein S–depleted plasma. A
dose-dependent decrease in thrombin generation was observed after
the addition of increasing concentrations of TFPI (0-2 nM) in the
absence of protein S. As expected, dose-dependent effects were
detected by reduction of the peak and endogenous thrombin potential
values, as well as an increase in lag time (Figure 1A). Inhibitory
antibodies againstTFPIdidnot have any effect on thrombingeneration
in the absence of added TFPI, suggesting that the anticoagulant pool
of TFPI in the plasmawas co-depletedwith proteinS (Figure 1B). This
is consistent with the ﬁndings previously reported by Castoldi
et al.34 The addition ofWT protein S in the absence of TFPI had no
Table 1. Binding of protein S to domain-specific monoclonal
antibodies and enhancement of APC-mediated cleavage of FVa at
Arg306 by protein S
WT PS Chimera I Chimera II Chimera III
MK 21 (Gla) 1.93 6 0.78 1.67 6 0.33 1.62 6 0.78 1.92 6 0.83
MK 41 (EGF3-EGF4) 0.76 6 0.18 1.00 6 0.32 0.50 6 0.26 0.75 6 0.46
MK 54 (EGF1) 0.25 6 0.13 0.21 6 0.12 0.17 6 0.06 0.20 6 0.07
MK 67 (TSR) 0.22 6 0.09 0.18 6 0.03 0.13 6 0.06 0.15 6 0.09
EC50 for FVa
R506Q/R679Q
inactivation
5.18 6 0.36 5.20 6 1.19 6.31 6 0.53 4.92 6 0.95
PS, protein S.
Kd app/EC50 values obtained from 3 independent experiments are given in
nanomolars and are expressed as mean 6 SD.
Figure 1. Protein S enhancement of the TFPI-mediated inhibition of thrombin
generation in protein S–depleted plasma. Thrombin generation was measured in
protein S–depleted plasma supplemented with 50 mM phospholipids and 1 pM TF
in the presence or absence of 0 to 2 nM (A) or 1 nM TFPI (B-C) and in the
presence or absence of 50 nM WT PS (B-C). (A) A dose-dependent decrease in
thrombin generation could be seen after the addition of increasing concentrations
of TFPI. (B) Inhibitory antibodies against TFPI (a mix of 120 nM anti-TFPI Kunitz
domain 1, 120 nM anti-TFPI Kunitz domain 2, and 120 nM anti-TFPI C-terminus)
did not affect thrombin generation in protein S–depleted plasma, whereas they
successfully repressed all inhibition of thrombin generation by TFPI in the
presence or absence of protein S. In addition, inhibitory antibodies against protein
S (2.8 mM; Dako) inhibited the enhancement of TFPI seen in the presence of
protein S but had no effect on the absence of protein S. (C) The TFPI cofactor
function of WT protein S and protein S variants was evaluated at 1 nM TFPI and 50
nM protein S. Pure WT protein S and WT protein S in concentrated conditioned
media gave identical results. Protein S variants with amino acid substitutions in the
Gla-TSR-EGF1-EGF2-EGF3-EGF4 domains (see supplemental Table 1 for full
details of amino acid substitutions in the protein S variants used in this study) were
screened in concentrated conditioned media. Protein S/Gas6 chimeras were
purified before all experiments. All protein S variants were compared with WT
protein S in concentrated conditioned media or were purified, as suitable. The
relative protein S enhancement was determined as the decrease in peak height
compared with WT protein S. The decrease in peak height in the presence of WT
protein S compared with TFPI alone was set as 100% (n 5 2). Results are
expressed as mean 6 standard deviation (SD). (A-B) Representative experiments
are shown (n 5 3). PS, protein S.
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effect on the thrombin generation, whereas it efﬁciently enhanced
TFPI-mediated inhibition of thrombin generation, as reported
previously.15,17,34 Inhibitory antibodies against TFPI and protein
Swere used to verify that inhibitory effects were a direct consequence
of TFPI and TFPI cofactor function of protein S (Figure 1B).
The functional interaction site of protein S for TFPI was in-
vestigated using the library of 44 protein S variants. The screening of
WT protein S and the protein S variants for their TFPI cofactor
functionwasperformedat 1nMTFPI and50nMproteinS (Figure 1C).
The protein S Gla-TSR-EGF1-EGF2-EGF3-EGF4 variants were
added as concentrated, conditioned media, whereas protein S/Gas6
chimeras were added as pure protein. WT protein S was studied
both as concentrated conditioned media and pure protein; both
enhanced TFPI equally well (results not shown). TFPI was efﬁciently
enhanced by recombinant WT protein S. The great majority of pro-
tein S variants exhibited similar or only moderately decreased en-
hancement of TFPI compared with WT protein S (Figure 1C). Protein
S enhancement of TFPI is known to be phospholipid dependent. To
ensure that any decrease in TFPI cofactor function was not caused by
a lack of binding to phospholipid membranes, we only studied protein
S Gla variants already known to bind phospholipid membranes with
the same afﬁnity as WT protein S.27,28 All protein S Gla variants
enhanced TFPI to a similar or moderately decreased level as WT
protein S, suggesting that the protein S Gla domain has no other
function in the enhancement of TFPI than binding to phospholipids.
For 2 compositeGla-variants, Face1 andGLA2, covering themajority
of Gla substitutions, this was also conﬁrmed in FXa inhibition assays
(results not shown). In contrast, we identiﬁed 2 variants with severely
impaired TFPI cofactor function in these experiments (Figure 1C),
protein S/Gas6 chimeras III and I, in which the whole SHBG-like
domain (Val243-Ser635) or the LG1 subunit (Ser283-Val459),
respectively, had been replaced by the corresponding domain inGas6.
Protein S binding to domain-specific monoclonal antibodies
and protein S enhancement of APC-mediated cleavage of FVa
at Arg306
Binding of protein S/Gas6 chimeras I to III to domain-speciﬁc
monoclonal antibodies was evaluated to assess the integrity of their
Figure 2. Enhancement of the TFPI-mediated in-
hibition of thrombin generation by WT protein S
and protein S/Gas6 chimeras I to III. Thrombin
generation was measured in protein S–depleted plasma
supplemented with 50 mM phospholipids and 1 pM TF,
in the presence or absence of 1 nM TFPI, and in the
presence or absence of titrated (0-100 nM) WT protein
S (A), chimera I (B), chimera II (C), or chimera III (D).
Representative experiments are shown (n5 3). (E) Peak
thrombin was plotted against protein S concentrations.
The peak height in the presence of TFPI alone represents
100%. Results are expressed as mean6 SD (n5 3). PS,
protein S.
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domain structure. WT protein S and the protein S/Gas6 chimeras
were titrated in a plate coated with monoclonal antibodies recog-
nizing theGla (MK21), TSR (MK67), EGF1 (MK54), or EGF3-EGF4
(MK41) domains. Bound protein was detected using a monoclonal
antibody. Kd app values were obtained by ﬁtting the binding curves to
a one-site binding equation (Table 1). There was no signiﬁcant dif-
ference (P. .05) in binding between the chimeras and WT protein S
for any of the antibodies tested. The results suggest that replacement of
the SHBG-like domain or its individual subunits did not lead to any
major conformational changes within the remaining domains.
Furthermore, the ability of the protein S/Gas6 chimeras to en-
hance the APC-mediated cleavage of FVa at Arg306 was deter-
mined. For this, a FVa inactivation assay with R506Q/R679Q FVa
was used. The FVa inactivation was performed in the presence of
0.25 nM APC and titrated (0-100 nM) WT protein S or protein
S/Gas6 chimeras. After a 10-minute inactivation, the remaining FVa
activity was measured in a prothrombinase assay. All chimeras efﬁ-
ciently enhanced the APC-mediated cleavage of Arg306 to the same
extent as WT protein S (Table 1). The results suggest that the sub-
stitution of the SHBG-like domain or its individual subunits did
not affect the enhancement of APC-mediated FVa cleavage at the
Arg306 position. Importantly, these results also demonstrate that the
chimeras bind phospholipids, because this is required for efﬁcient
enhancement of FVa inactivation in this assay.
Evaluation of the importance of the SHBG-like domain for the
TFPI cofactor function of protein S in plasma
To further evaluate the importance of the SHBG-like domain in the
TFPI cofactor function of protein S in plasma, pureWTprotein S and
protein S/Gas6 chimeras were titrated (0-100 nM) in the presence of
1 nMTFPI (Figure 2). Chimeras I and III both hadminimal inhibitory
effect on thrombin generation (Figure 2B,D), whereas chimera II
enhancedTFPI to a similar extent as that ofWTproteinS (Figure2A,C).
When peak thrombin generation of each variant was compared
(Figure 2E), chimera III was essentially unable to enhance TFPI.
Chimera I reduced the peak height by only 45% at a concentration
of 100 nM, whereas only 25 nMWT protein S and chimera II were
needed for the same decrease in thrombin generation (Figure 2E).
Under our experimental conditions, protein S had no effect on
thrombin generation in the absence of TFPI (results not shown).
These results suggest that the SHBG-like domain, and speciﬁcally
the LG1 subunit of protein S (swapped in chimera I), is essential for
TFPI cofactor function in plasma.
Protein S enhancement of TFPI-mediated FXa inhibition
FXa inhibition assays with puriﬁed reagents were used to kinetically
evaluate the enhancement of TFPI in its inhibition of FXa by WT
protein S and protein S/Gas6 chimeras. Progress curves of FXa
inhibition by TFPI and increasing concentrations of protein S are
presented in Figure 3A-D. The initial rates of S-2765 hydrolysis by
FXa in the presence of TFPI and increasing concentrations of protein
S are plotted in Figure 3E, and the EC50 values have been derived. In
agreement with the plasma-based assays, limited enhancement of
TFPI was detected after the addition of chimera III (Figure 3D). A
major decrease in the enhancement of TFPI by chimera I (Figure 3B)
was also detected, whereas chimera II (Figure 3C) behaved similarly
to WT protein S (Figure 3A) with only an approximately 2.7-fold
increase in EC50 (39.6 6 22.2 vs 14.6 6 8.2 nM; presented as
mean6 SD) (Figure 3E). These results conﬁrm the importance of
the protein S SHBG-like domain, and more speciﬁcally the LG1
subunit, in the TFPI cofactor function.
Figure 3. Enhancement of TFPI in the inhibition of FXa by WT protein S and
protein S/Gas6 chimeras I to III. FXa activity (0.5 nM) was followed in real time
through cleavage of S-2765 (200 mM) at 405 mm in the presence of 25 mM
phospholipids, the presence or absence of TFPI (2 nM), and in increasing concen-
trations (0-160 nM) of WT protein S (A), chimera I (B), chimera II (C), or chimera III
(D). Results from representative experiments are shown (n 5 3). (E) The initial
velocity (V0) was calculated and plotted against protein S concentration. Results are
given as mean 6 SD and are expressed as percentage of the V0 in the presence of
TFPI alone (n 5 3). PS, protein S.
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C4BP-bound protein S enhancement of TFPI-mediated
FXa inhibition
To further assess the role of the protein S SHBG-like domain in the
TFPI cofactor function, the enhancement of TFPI-mediated inhibi-
tion of FXa byC4BP-boundWTprotein Swas studied and compared
with the TFPI enhancement by free WT protein S using FXa in-
hibition assays (Figure 4). Although free WT protein S effectively
enhanced TFPI-mediated inhibition of FXa in a dose-dependent
manner (Figure 4A), a minimal enhancement by C4BP-bound WT
protein S was detected (Figure 4C). These results support those of
the protein S/Gas6 chimeras and strongly indicate the importance of
protein S SHBG-like domain in its TFPI cofactor function.
Evaluation of binding of protein S to TFPI by SPR
Our functional assays have shown that the protein S SHBG-like
domain is essential for protein S to function as a cofactor for TFPI.
SPR was performed to investigate the role of the protein S SHBG-
like domain in the direct interaction with TFPI. Puriﬁed protein
S (0-1000 nM) was perfused over immobilized TFPI. As previously
shown, WT protein S bound to TFPI in a dose-dependent manner
(Figure 5A).16,17,34 In agreement with previously published studies,
no afﬁnity for the TFPI/protein S interaction could be derived be-
cause a 2-phase association phase was observed and the binding
curves did not reach equilibrium. Nevertheless, the results from the
binding experiments correspond well with the results from the FXa
inhibition assays. The substitution of the whole SHGB domain in
chimera III resulted in an almost complete lack of binding interaction
with TFPI (Figure 5D). Chimera I exhibited severely decreased bind-
ing toTFPI (Figure 5B), whereas chimera II interactionwithTFPIwas
moderately decreased (Figure 5C). These results suggest that there is
a direct interaction between the protein S SHBG-like domain and
TFPI. Both LG subunits appear to be required for this interaction, but
there is a more dominant role of LG1.
Discussion
The TFPI cofactor function of protein S plays an important role in the
regulation of the initiation of coagulation. However, despite its
importance, the molecular mechanism underlying the TFPI cofactor
function of protein S has yet to be fully deﬁned. In 2010,Ndonwi et al
demonstrated the importance of the TFPI Kunitz domain 3 in the
protein S cofactor function.16 We subsequently identiﬁed a func-
tional interaction site for protein S at Glu226 within the TFPI Kunitz
domain 3.17 In a recent study, Wood et al showed that the enhance-
ment by protein S is limited to free full-length TFPI, either circulating
in plasma or released from endothelial cells or platelets. In contrast,
protein S does not enhance the activity ofmembrane-associated TFPI
(TFPIb).35 Because membrane-bound TFPI does not have a Kunitz
domain 3, their study conﬁrmed the importance of this domain for
the protein S enhancement.Wood et al also created a TFPIb variant
containing a Kunitz domain 3 but, for reasons that are not clear,
protein S was unable to enhance this TFPI variant.35
Although the protein S interaction site of TFPI is well character-
ized, the TFPI interaction site of protein S has not been determined. To
explore this, we assessed the importance of solvent-exposed amino
acid residues within the Gla-TSR-EGF1-EGF2-EGF3-EGF4 domains
and the protein S SHBG-like domain, in the protein S enhancement of
TFPI activity in thrombin generation assays. We identiﬁed 2 protein
S/Gas6 chimeric variants showing substantial reductions in their TFPI
cofactor function in plasma, a result that was conﬁrmed in FXa in-
hibition assays. These ﬁndings suggest that the protein S SHBG-like
domain (evaluated with chimera III) and mainly its LG1 subunit
(evaluated with chimera I) are important for the TFPI cofactor
function. The protein S/Gas6 chimeras have been characterized
previously for their APC cofactor function and ability to bind
C4BP.24,25,39Aspreviously reported, thewholeSHBGswap, chimera III,
Figure 4. Enhancement of TFPI inhibition of FXa by protein S–, C4BP-, and
C4BP-bound protein S. FXa activity (0.5 nM) was followed in real time through
cleavage of S-2765 (200 mM) at 405 mm in the presence of 25 mM phospholipids, the
presence or absence of TFPI (2 nM), and in increasing concentrations (0-160 nM) of
protein S (A), 0 to 320 nM C4BP (B), and C4BP-bound protein S in a 2:1 ratio (C).
Representative experiments are shown (n 5 3). (D) V0 was calculated and plotted
against protein S concentration. Results are given as mean6 SD and are expressed
as percentage of the V0 in the presence of TFPI alone (n 5 3). PS, protein S.
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has normal cofactor function for APC in its inactivation of FVa at
residue Arg306, a result conﬁrmed in our present study.24 This
result is in agreement with results published by van Wijnen et al,
who used a domain depletion approach and concluded that the
SHBG-like domain is not important for the APC-mediated FVa
cleavage.36 The 3 protein S/Gas6 chimeras also bind to domain-
speciﬁc monoclonal antibodies with the same afﬁnity as WT pro-
tein S. These results suggest that these domain swaps do not lead to
any major conformational changes in Gla-TSR-EGF1-EGF2-EGF3-
EGF4 domains.
That protein S can bind directly to TFPI has been established by
SPR.16,17,34 In fact, the mechanism of protein S enhancement of
TFPI depends on this direct interaction.17 Castoldi et al used immu-
noprecipitation experiments and suggested that free protein S and
full-length TFPI form a complex in circulation.34 In the present
study, we show that the protein S SHBG-like domain is directly
involved in the protein S/TFPI interaction. The results obtained
with the LG subunit chimeras suggest that both LG domains may
contribute to the interaction. However, LG1 seems to be of greatest
importance, because chimera II binds appreciablymore than chimera I.
The protein S SHBG-like domain is known to contain the inter-
action site for C4BP. Both LG subunits are believed to be involved in
the interaction with this protein, but despite numerous attempts, the
interaction site has not been precisely identiﬁed.37-39 Hackeng et al
have previously shown that the addition of amolar excess of C4BP to
free protein S in normal plasma resulted in a 40% decrease of the
TFPI enhancement by protein S in thrombin-generation assays.15 In
addition, immunodepletion experiments showed that protein S
Figure 5. Binding of WT protein S and protein
S/Gas6 chimeras I to III to TFPI studied with SPR. A
CM5 chip was coupled with TFPI immobilized to 2500
response units. The flow cell was perfused with in-
creasing concentrations (0-1000 nM) of WT protein S
(A), protein S chimera I (B), protein S chimera II (C), or
protein S chimera III (D). Results from a representative
experiment are shown (n 5 2). PS, protein S; RU,
response units.
Figure 6. Proposed mechanism of the protein
S/TFPI/FXa complex assembly on a phospholipid
surface. Our results suggest that the mechanism of
protein S cofactor enhancement of TFPI involves for-
mation of a complex between the SHBG-like domain of
protein S and the Kunitz domain 3 (K3) of TFPI (partic-
ularly Glu226). Protein S helps localize TFPI onto an
activated membrane surface in a position favorable for
the interaction of Kunitz domain 2 (K2) with the serine
protease domain (SP) of FXa. The boxes show the
respective models of the protein S SHBG-like domain
and the TFPI Kunitz domain 3. TFPI Glu226 and the
residues substituted in protein S/Gas6 chimera I are
highlighted in black. The TFPI Kunitz domain 3 and the
protein S SHGB -domain models are adapted from
Mine et al and Villoutreix et al, respectively.37,42
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bound to C4BP does not interact with TFPI.34 In the present study,
we have compared the enhancement of TFPI-mediated FXa
inhibition by C4BP-bound WT protein S to free protein S and
demonstrated a dramatic decrease in the TFPI cofactor function.
These results support a role of the protein S SHBG-like domain
for the TFPI cofactor function as well as the direct interaction
between protein S and TFPI. Interestingly, whereas both LG subunits
have been shown to be important for the interaction with C4BP,37-39
our results suggests that the LG1 subunit of the SHBG-like domain
may be of greater importance than the LG2 subunit for binding TFPI.
The afﬁnity of TFPI for phospholipid membranes is very weak
and is known to be dependent on the presence of the TFPI
C-terminus.40,41 In contrast, it has also been shown that TFPI lacking
the C-terminal tail can localize to phospholipid membranes in the
presence of FXa, suggesting that direct binding of TFPI to phos-
pholipids may only be important in limited physiologic contexts.40
In addition, protein S has been shown kinetically to enhance the
initial interaction between TFPI and FXa. It has previously been
hypothesized that protein S, through its high afﬁnity for negatively
charged phospholipids, brings TFPI in close proximity to FXa on
an activated membrane and thereby increases the TFPI/FXa asso-
ciation rate.15-17,35 We propose that protein S and TFPI can asso-
ciate in plasma through a direct interaction between the protein S
SHBG-like domain and the TFPI Kunitz 3 domain, particularly
with Glu226. Upon initiation of coagulation on phospholipid
surfaces, protein S brings TFPI Kunitz domain 2 into proximity of
the active site of the protease domain of FXa, thereby decreasing
the concentration of TFPI needed for efﬁcient inhibition of FXa
(Figure 6).
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